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Extracellular Matrix Mediated Cartilage Regeneration: 
A Novel Three-Dimensional In Vitro Microenvironment to Facilitate Cell 




Joint articular cartilage is vulnerable for degenerative disease after trauma due to the limited 
self-healing ability. Mesenchymal stem cells (MSCs) are considered a promising source for 
cartilage repair and regenerative medicine because of their excellent capacities of 
self-renewal and multipotent differentiation. Conventional in vitro expansion system, however, 
limits the utilization of MSCs for cartilage regeneration because in monolayer culture MSCs 
rapidly lose their self-renewal ability and differentiation potential. The lack of proper 
microenvironment in the current two-dimensional expansion system is attributed to the loss of 
self-renewal and multipotent differentiation in MSCs. Three-dimensional (3D) cell-deposited 
extracellular matrix (ECM) provides a novel strategy for in vitro MSC expansion, not only 
promoting cell proliferative rate but also improving chondrogenic potential. We generated 3D 
ECM deposited by synovium-derived stem cells (SDSCs) to reconstruct an in vitro 3D stem 
cell niche. First, MSCs were expanded on 3D ECM including SDSCs, adipose-derived stem 
cells (ADSCs) and bone marrow stem cells (BMSCs). The cell morphology of MSCs cultured 
on ECM changed to a thin and spindle-like shape and cell migration was directional along the 
fibrils of ECM. A dramatic increase in cell number and a greatly enhanced chondrogenic 
potential were observed, though surprisingly the ECM-treated MSCs did not display 
concomitantly improved adipogenic or osteogenic potentials. 3D ECM was also adopted to 
expand terminally differentiated cells including articular chondrocytes and nucleus pulposus 
(NP) cells, in order to improve the technique of autologous cell transplantation for cartilage 
repair and intervertebral disc regeneration. We found that ECM not only improved 
chondrocyte or NP cell expansion but also delayed dedifferentiation. Chondrocytes or NP 
cells expanded on ECM also acquired a strong redifferentiation capacity, particularly when 
treated with TGF-β1 in a pellet culture system. Further, we compared the activity of several 
key signaling kinases and integrin expression in BMSCs cultured on ECM and conventional 
plastic flasks. 3D ECM increased the expression of SSEA-4, integrin α2, α4 and β5, and 
induced sustained activation of Src kinase, ERK1/2 and cyclin D1. Not only the expression 
but also the responsiveness of TGF-β type II receptor was enhanced by 3D ECM in BMSCs. 
These observations suggested that 3D cell-deposited ECM promoted BMSC proliferative 
capacity through integrin/Src/ERK1/2 signaling pathway and enhanced chondrogenic 
potential by improving the responsiveness of TGF-β receptors. Finally we generated two 
distinct types of ECM separately deposited by SDSCs and articular chondrocytes. 
SDSC-deposited ECM (S-ECM) contained fibrillar type I collagen, whereas 
chondrocyte-deposited ECM (C-ECM) is composed of fibrillar type I and II collagen with 
proteoglycans. S-ECM showed a superior influence on SDSCs to C-ECM in cell self-renewal 
and chondrogenic potential. The proliferative and chondrogenic abilities of chondrocytes 
were comparable on S-ECM and C-ECM. SDSC-deposited ECM was superior to 
chondrocyte-deposited ECM and functioned as a universal expansion system in vitro for 
MSCs and terminally differentiated cells to promote cell proliferative and chondrogenic 
potentials. In conclusion, we demonstrated that 3D cell-deposited ECM provides a proper 
microenvironment for in vitro expansion of MSCs and terminally differentiated cells, not only 
promoting self-renewal ability but also improving chondrogenic potential, and the novel 3D 
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Articular cartilage is a unique, hypocellular and avascular tissue, mostly made of extracellular 
collagens and proteoglycans (PGs), supporting frictionless movements and loading-bearing 
capacity of articulation.1 Articular cartilage has a limited ability to heal after trauma and 
cartilage lesions often progress to cartilage degeneration if untreated. Mesenchymal stem 
cells (MSCs) are considered an attractive source for cell therapy and regenerative medicine 
because of their excellent self-renewal and differentiation potentials to multiply lineages.2 
Conventional monolayer expansion system in vitro limits the utilization of MSCs for 
regeneration of cartilage defects and intervertebral disc, because MSCs rapidly lose their 
self-renewal ability and multipotent differentiation capacity.3;4 The lack of a proper 
microenvironment in current two-dimensional (2D) expansion system is proposed to be 
responsible for the loss of multipotential differentiation in MSCs.5
 
 We hypothesize that a 
nature three-dimensional (3D) cell-deposited extracellular matrix (ECM) can provide a 
proper microenvironment to improve MSC self-renewal and multipotent differentiation. 
Natural ECM provides a structural scaffold to resist tensile and compressive stress and 
functions as a tight connection to cytoskeleton of cells through cell-surface receptors, 
enabling cells to sense and respond to mechanical and chemical signals.6 Compared to 
traditional 2D ECM, this natural 3D ECM is composed of multiple matrix proteins such as 
collagens, fibronectin and proteoglycans.7 In the structure, 3D ECM is more pliable than 2D 
ECM, has more fibrillar matrix and contains the space originally occupied by the cells 
generating matrix. The native cell-deposited ECM not only provides a proper niche to 
maintain MSC self-renewal and differentiation potential but also establishes a model to mimic 
the interaction in vivo between cells and ECM.8
 
 
Our long term goal is to develop a strategy that can maintain MSCs self-renewal and 
promote the chondrogenic potential in the in vitro culture system, to improve the current 
therapy of autologous cell transplantation and to investigate the interaction between cells and 
ECM. The objectives of this dissertation are: (1) compare the effects of 3D ECM and 2D 
xvii 
 
conventional plastic culture on MSCs; (2) improve the culture conditions of terminally 
differentiated cells by adopting 3D ECM; (3) investigate the interaction between MSCs and 
ECM; (4) compared extracellular matrices deposited by two distinct types of cells. 
The central hypothesis
 
 is that natural cell-deposited ECM serves as an in vitro 3D stem cell 




Specific aim 1: Compare the proliferative rate and chondrogenic potential of MSCs on 
3D cell-deposited ECM and the conventional plastic culture. 
1.1 Generate and characterize 3D ECM deposited by synovium-derived stem cells (SDSCs). 
 
1.2 Expand SDSCs on 3D ECM and conventional plastic culture and compare the 
chondrogenic potentials. 
 
1.3 Expand and compare adipose-derived stem cells (ADSCs) on SDSC-deposited ECM, 




 We hypothesize that 3D ECM will improve SDSCs and ADSCs self-renewal 
ability and enhance chondrogenic potential. More specifically, we believe that SDSCs and 
ADSCs expanded on ECM will show a higher proliferative rate than the cells cultured on 
conventional plastic surface. In a pellet culture system, SDSCs and ADSCs will exhibited a 
higher chondrogenic gene expression and cartilage-specific proteins and matrix. 
 
Specific aim 2: Use SDSC-deposited ECM to improve in vitro culture of terminally 
differentiated cells such as articular chondrocytes and nucleus pulposus cells. 
2.1 Expand articular chondrocytes on 3D SDSC-deposited ECM and conventional plastic 
flasks and investigate the changes of cell proliferative rate, immunophenotype profile and the 
xviii 
 
level of dedifferentiation. 
 
2.2 Induce articular chondrocytes expanded on ECM and plastic flasks toward 
redifferentiation by incubation of TGF-β-containing medium or serum-containing medium. 
 
2.3 Expand and compare cell proliferative and redifferentiation potentials of nucleus pulposus 




 We hypothesize that 3D SDSC-deposited ECM will promote the proliferation 
of articular chondrocytes and nucleus pulposus cells, delay the process of dedifferentiation 
and enhance the effect of redifferentiation. 
 
Specific aim 3: Investigate the interaction between ECM and bone marrow stem cells 
(BMSCs) and the potential mechanism of the enhanced chondrogenic differentiation 
after expansion on ECM. 
3.1 Investigate BMSCs expanded on ECM including proliferative rate, immunophenotype 
profile, intracellular oxygen reactive species and apoptotic response. 
 
3.2 Explore integrin system and intracellular signaling pathways that affect BMSC 
self-renewal. 
 
3.3 Induce BMSCs toward chondrogenic differentiation and elucidate the mechanism for the 
improved chondrogenic potential. 
 
Hypothesis 3: We hypothesize that 3D ECM interacts cells through integrin system to 
activate Src/ERK signaling pathway. Phosphorylated ERK1/2 will increase the expression 
and activation of cyclin D1 to promote cell cycle from G1 to S phase. The elevated cyclin D1 
will be responsible for the improved cell self-renewal. Meanwhile, 3D ECM will increase the 





Specific aim 4: Compare two different extracellular matrices separately deposited by 
SDSCs and articular chondrocytes on the effects of cell proliferation and 
chondrogenic potential. 
4.1 Obtain ECMs from SDSCs and chondrocytes and compare the components in the two 
types of ECM. 
 
4.2 Expand SDSCs and chondrocytes separately on conventional plastic flaks, 
SDSC-deposited ECM and chondrocyte-deposited ECM. 
 
4.3 Compare chondrogenic differentiation of SDSCs and chondrocytes expanded under the 




 We hypothesized that ECM from tissue-specific sources will improve the 
proliferation and chondrogenic potential differently. More specifically, we believe that SDSCs 
cultured on SDSC-deposited ECM will have a superior effect on self-renewal and 
chondrogenesis to those on chondrocyte-deposited ECM. We also believe that chondrocyte 
cultured on chondrocyte-deposited ECM will have a better result in cell proliferation and 
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1.1 Articular Cartilage Biology 
 
Cartilage is a unique tissue in articulated joints covering long bones and provides frictionless 
movement and a mechanical loading-bearing surface. Cartilage transfers the force generated 
by underlying bones and supports a large range of joint motion with lubrication and stability.1-3 
The structure of cartilage can be divided into four zones: superficial zone, middle zone, deep 
zone and calcified cartilage zone shown in Table 1.1 and Figure 1.1.2-5
 
  
Zones Thickness Composition 
Superficial zone 
200 μm 
10-20% of the cartilage thickness 
Tangentially oriented collagen fibers 
Middle zone 
1 mm 
60% of the cartilage thickness 
Randomly oriented collagen fibers 
Deep zone 
600 μm 
30% of the cartilage thickness 
Perpendicularly oriented collagen 
fibers 
Calcified zone Interface with the bone 
Large bundled collagen fibers 
anchored within subchondral bone 
Table 1.1 Four zones in articular cartilage 
 
Cartilage is composed of 1% chondrocytes and 99% the matrix.4;6 There are two major 
functions of chondrocytes: 1) to produce sufficient collagens and proteoglycans to form 
mature cartilage tissue in the developmental stage; and 2) to release enzymes to break down 
aging components and replace with newly generated matrix.4;6;7 The size, morphology and 
arrangement of chondrocytes vary with the depth of cartilage. From the surface of cartilage to 
the deeper level, chondrocytes change from flatter to rounder and from a scattered to an 
organized arrangement. The major compositions of cartilage include water (70%), type II 
collagen (15%) and proteoglycans (15%). The function of each component in cartilage is 








Produce extracellular matrix and enzymes 
to break down aging contents 
Collagen (major Type II) 15% 
Provides cartilage with its tensile strength 
and stiffness 
Proteoglycans 15% 
Provide resiliency to compression and 
elasticity 
Water 70% 
Provides suitable environment for 
chondrocyte survival and matrix function 
Table 1.2 Major components in articular cartilage 
 
Cartilage functions to transfer force and bear loads, and the biomechanical properties of 
human articular cartilage have been extensively studied. Cartilage provides resiliency not 
only to tensile loads but also to compressive forces depending on different matrix 
compositions. Cartilage has a relatively low compressive stiffness (E = 0.1 - 2.0 MPa), 
Poisson’s ratio (ν = 0.2) and permeability.10;11 Table 1.3 shows other biomechanical properties 




Mechanical Parameter Normal Cartilage Aged Cartilage 
Young’s modulus (MPa) 122 76 
Elastic energy (kJ/m3 141 ) 83 
Viscoelastic energy (kJ/m3 42.5 ) 22.9 
Table 1.3 Biomechanical properties of normal and aged human cartilage 
 
1.2 Cartilage defects and degenerative diseases 
 
1.2.1 Three cartilage defects 
Three typical cartilage defects occur in clinical practice, including subchondral, full-thickness 
and osteochondral defects (Figure 1.3).14 Subchondral defect is typically a focal lesion limited 
to the superficial or middle zone of cartilage. Full-thickness defect extends to subchondral 
4 
 





Young patients usually suffer cartilage-related diseases caused by trauma. Clinical focal 
lesions after trauma are usually very small (< 1 cm2) and happen only on the articular 
cartilage surface.14-17 Due to the limited self-healing ability of articular cartilage, focal lesions if 




Osteoarthritis (OA) is one of the oldest and most common diseases in human history; it is 
defined as a degenerative disease of joints affecting not only articular cartilage but also 
menisci and bone tissue. The symptoms of OA include steady or intermittent pain in joints, 
stiffness after a period of inactivity such as sleeping and sitting, swelling or tenderness in one 
or more joints, reduced range of motion and cracking in joints.3
 
  
Besides trauma, several risk factors may lead to OA. Age is a main risk; it is reported that 
most people over the age of 60 have OA of some severity and 72% of OA patients are over 
40-years old.3 Gender is another factor related to OA; women are more likely to be affected 
than men. OA is more common in men before age 45 and in women after age 45.17;19 
Hereditary gene defects result in damaged collagen components in cartilage and obesity 




Four grades of macroscopic changes in osteoarthritic articular cartilage were proposed by 
Outerbridge. In grade 1, cartilage becomes soften in some areas. In grade 2, there is 
fragmentation a half inch or less in diameter. In grade 3, the fragmented area enlarges to 
more than half an inch, and in grade 4, the injuries develop to full-thickness defects or to 





Articular cartilage becomes soften, fibrillated, and eroded down to the subchondral bone in 
OA. At the microscopic level, OA results in chondrocyte cell death and the degradation of 
cartilage matrix.21;22 Since chondrocytes are the only cellular components in articular cartilage, 
they are able to respond to cartilage damage caused by OA, firstly by clustering and 
proliferating. Moreover, OA increases the production and activity of cytokines, chemokines 
and other inflammatory mediators from immune cells, synovial cells and chondrocytes. 
Inflammatory mediators include interleukins such as IL-1, IL-6, IL-7, IL-17 and IL-18; reactive 
oxygen species such as hydrogen peroxide, superoxide and nitric oxide; and lipid-derived 
mediators such as prostaglandins.23-25 The mediators induce chondrocyte apoptosis, 
proteolysis and cell death. In OA, proteolytic enzymes destroy cartilage matrix by cleaving 
type II collagen without degrading type IX or type XI collagen.21;24
 
 
Recently the Centers for Disease Control and Prevention (CDC) reported that 27 million 
Americans suffered from OA and that females were more likely to be affected than males. By 
the year 2030, 25% of adult U.S. citizens, nearly 67 million people, will have arthritis and 
other cartilage degenerative diseases. A study conducted by the researchers in Stony Brook 
(NY) showed that about 0.8% of women and 0.3% of men nationwide had OA. The annual 
medical care expended on OA is about $185.5 billion and work absence due to OA costs 
employers over $10 billion per year in U.S.26;27
 
 
1.3 Intervertebral disc degeneration 
Intervertebral discs (IVD) are between two vertebrae in human spine. The total number of 
discs in spine is twenty-three. IVD composes 20% to 30% of the length of spine and the size 
of discs increases from cervical to lumbar regions. IVD degeneration is the primary cause of 
low back pain. It is reported that, in US, approximately 5.7 million people suffer with IVD 
degeneration and most of them are in the 45 to 64 year old range.28-30
 
 
Intervertebral discs have the following functions: 1) manage the movement of fluid within the 
nucleus that allows vertebrae to rock back and forth and increases flexibility; 2) serve as 
shock absorbers; 3) act as pads to maintain the space between the 24 movable vertebrae; 4) 
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allow extension and flexion.31;32
 
  
The structure of IVD contains three avascular tissues: annulus fibrosus (AF), nucleus 
pulposus (NP) and cartilage endplates (Figure 1.5A).33 NP, located at the center of IVD, acts 
as a spongy tissue and is composed of a large amount of water, proteoglycans and collagens 
to resist compression. Chondrocyte-like cells are found in NP tissue; the cell density is 4 × 
106 cells/cm3 at maturity.28;31;32 Outside NP is annulus fibrosus that is made of a series of 
lamellae. The concentric collagen fibers that compose AF tissue orient at various angles and 
bear the upper body weight due to the swelling effect of NP. Fibroblast-like cells are found in 
AF with a relatively higher cell density of 9 × 106 cells/cm3. The cell density in NP and AF is 
much less compared to that in articular cartilage of 1.4 × 107 cells/cm3. Cartilage endplates, a 




In normal IVD, the compositions of AF and NP include a network of collagens including type I, 
II, III, V, VI, IX, XI, XII, and XIV, a variety of proteoglycans that mainly contains aggrecan, 
versican, decorin, biglycan and fibromodulin, and other matrix proteins such as fibronectin 
and elastin.28-30 However, the proportion of matrix components varies from NP to AF and the 
inner to the outer part of AF. The outermost layers of AF are composed of mostly type I 
collagen and NP contains type II collagen. From the outer to the inner AF, type I collagen 
decreases and type II collagen increases.Type X collagen is also found in NP and inner AF 
layers. Aggrecan is a major component of matrix proteoglycans in AF and NP. In NP the 
proportion of aggrecan and water content is about 50% to 80% of the wet weight but, in AF, it 
only holds 20% to 70% from the outer to inner part.29-31;34
 
 
IVD degeneration progresses with age or after trauma due to the poor self-repair mechanism 
similar to articular cartilage. Loss of proteoglycans is the most significant change in IVD 
degeneration and aggrecan degrades from large molecules to small fragments (Figure 
1.5B).30 The degeneration progresses steadily in NP since aggrecan composes most of the 
matrix and the loss of aggrecan results in dysfunction in loading-bearing and back pain.29-31 
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The network of collagen matrix also undergoes degeneration but not as obvious as that of 
proteoglycans. The types and distribution of collagens alter in NP during IVD degeneration; 
type II collagen becomes denatured and more type I collagen is synthesized. Except the 
significant decrease in matrix components, some enzyme production and activity increases, 
such as matrix metalloproteinases (MMPs), cathepsins and aggrecanases.28-32 The activity of 




During the process of IVD degeneration, NP cells are stimulated to proliferate and the cell 
density increases.36;37 However, the level of cell death and cell senescence increases 
simultaneously. Shortening telomeres when cells undergo repeated division and an increased 
generation of reactive oxygen species and cytokines would be the reason for cell death and 
senescence.38-40 The phenotype of NP cells in IVD degeneration also changes caused by 
synthesizing different matrix proteins from NP cells, secretion of growth factors, an increase 
in the level of inflammatory factors and enhanced enzymatic activity.35;41
 
 
1.4 Current therapy tragedies for articular cartilage repair and IVD degeneration 
 
1.4.1 Intrinsic self-repair of articular cartilage 
Articular cartilage has very limited self-healing ability once trauma or degeneration occurs 
because the avascular structure prevents mesenchymal stem cells in bone marrow or 
chondrocyte progenitors from migrating to damaged areas. Some animal studies showed that 
spontaneous healing was observed when minor lesions were on the surface of cartilage or 
subchondral defects were less than 3 mm in diameter.17;19 However, articular cartilage fails to 
repair the large defects that extend to osteochondral tissue and the damages ultimately lead 
to cartilage degeneration. The most important issue in cartilage self-repair is that the repaired 
chondral tissue is fibrocartilagenous in which the ratio of type I collagen is much higher than 
type II collagen with fewer proteoglycans. This fibrocartilagenous tissue fails to have normal 
biomechanical functions or withstand load-bearing like hyaline cartilage tissue. Eventually the 




1.4.2 Conservative treatments and surgical procedures 
Steroidal and non-steroid anti-inflammatory drugs are commonly used to treat cartilage 
defects but those medicines are mainly for pain relief. Hyaluronic acid can be injected into the 
joints to reduce pain. At present D-glucosaminesulphate and chondroitinsulphate are proven 
to improve articular cartilage healing. Overall, the effectiveness of drug treatments is minor 
and none of them can fully heal cartilage defects.19;42
 
 
Surgical procedures are used to stimulate the intrinsic repair in articular cartilage by drilling or 
microfracturing subchondral bones. The purpose of these procedures is to release the 
mesenchymal stem cells in blood and bone marrow to recruit into the defects. However, 
fibrocartilagenous or scar tissue is formed and therefore is susceptible to degradation.14;19;42;44
 
 
Transplantation of periosteum and perichondrium was used in cartilage repair; the tissue 
covered articular cartilage defects. The procedure provided a fast reconstruction of the 
cartilage surface but resulted in calcification and eventually degeneration in the defect area. 




Osteochondral transplantation is the procedure in which osteochondral plugs are harvested 
from less used load-bearing areas in joints and transferred into cartilage defects. The 
technique can be used to repair large defects and provides rapid bone healing to fix the 
osteochondral plugs into the implant site. The disadvantages of the procedure include donor 
site morbidity, increased cell death of chondrocytes and formation of fibrocartilagenous tissue 
which leads to further cartilage degeneration.8;14;46-49
 
 
1.4.3 Autologous chondrocyte transplantation 
Autologous chondrocyte transplantation (ACT) has been used in clinical practice since 1994 
and has been proven more effective than other surgical procedures.50 In the first step of ACT, 
a small amount of cartilage tissue is taken by arthroscopy from a non-weight bearing area 
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(150 - 300 mg). In the second step, chondrocytes are released from biopsy by enzymatic 
digestion and expanded in vitro to reach an adequate cell number for intra-articular injections. 
In the third step, cultivated chondrocytes are injected into articular cartilage damage sites, 
covered with a periosteal graft and sutured to prevent water leak (Figure 1.6).43;43;50;51
 
 
The first generation of ACT relied on cultured chondrocytes and injecting cells beneath a 
periosteal graft. It has several disadvantages including surgical damage in cartilage biopsy, 
cell-phenotype change in the process of chondrocyte expansion in vitro (also called 
dedifferentiation), leakage of chondrocytes from the defects and periosteal complications 
such as hypertrophy and detachment from the injection site.8;42;43;51
 
  
The second generation of ACT uses a bi-layer collagen membrane instead of periosteal graft. 
The collagen membrane is sutured onto the cartilage defects and expanded chondrocytes 
are injected underneath. The replacement of collagen membrane to periosteal graft simplifies 




The third generation of ACT is also called the “all-in-one” procedure; it uses 
three-dimensional biocompatible scaffolds where chondrocytes are seeded and differentiate 
to generate cartilage-specific matrix. The newly generated cartilage repair graft is designed to 
fit the size of defects and fibrin glue is used as sealant to fix the graft.8;42;43;51
 
 
The clinical outcomes of ACT are successful because hyaline-like cartilage tissues are 
observed and reach 90% of native cartilage stiffness. Different from fibrocartilagenous tissues, 




However, the disadvantages of ACT are obvious including the limited expandability of 
chondrocytes and the rapid dedifferentiation in the process of in vitro expansion over several 
passages. In dedifferentiation, chondrocytes lose their round morphology and change to a 
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spindle-shaped, fibroblast-like phenotype. Type I collagen is synthesized in dedifferentiated 
chondrocytes instead of type II collagen and aggrecan. Another common complication of ACT 
is periosteal hypertrophy that results in pain in the repaired joints and detachment of 
periosteal graft leading to the failure of ACT. The ACT procedure includes cartilage biopsy 




1.4.4 Autologous or allogeneic cell transplantation for nucleus pulposus repair 
Mature nucleus pulposus (NP) contains chondrocyte-like cells with a low cell density and 
limited self-healing. The NP environment is harsh because of high stress, low oxygen tension, 
low pH and limited nutrients due to an avascular structure. Intervertebral discs (IVD) face the 




Similar to autologous chondrocyte transplantation (ACT), autologous or allogeneic NP cell 
transplantation has been used in animal studies. NP cells are first obtained from a healthy 
IVD and expanded in vitro to reach an adequate cell number, then injected into the 
degenerated IVD. The injected NP cells are able to synthesize new matrix contents such as 
aggrecan and type II collagen. The implanted NP cells effectively improve disc conditions 
without a major immune response.58
 
 
Worse than articular cartilage, the cell density is much lower in NP and NP cells have less 
expandability than chondrocytes. It is reported that the cell viability was improved when NP 
cells were co-cultured with AF cells.59 A new co-culture system with MSCs was adopted to 
increase NP cells’ proliferative ability.60 Growth factors, such as transforming growth factor β 
and insulin-like growth factor, were supplemented to stimulate NP cell proliferation.60
 
 
However, the poor expandability of NP cells limits the application of autologous or allogeneic 
cell transplantation to repair IVD degeneration. 
Because the matrix components in articular cartilage are similar to those in IVD, 
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transplantation of articular chondrocytes into degenerative IVD was tested and this method 
effectively reduced the loss of proteoglycans in the injured IVD.57;61 Even though aggrecan 
and type II collagen are found both in articular cartilage and NP tissue, the ratio of aggrecan 
to collagen is different. In NP, the ratio of aggrecan to collagen is significantly higher 
(approximately 27:1) than that in articular cartilage (2:1),62
 
 indicating that chondrocyte 
transplantation for IVD is still risky. 
1.5 Adult mesenchymal stem cells 
 
1.5.1 Embryonic stem cells and induced pluripotent stem cells 
Embryonic stem cells (ESCs) are identified by the properties of unlimited self-renewal, 
immortality and pluripotent differentiation to multiple tissues and organs. The study of ESCs 
began in the 1950s and the culturing system was adopted in 1981 using a fibroblast feeder 
layer and serum.63;64 Thomson et al. in 1998 first created several human embryonic stem cell 
lines (hESCs).65 Human embryonic stem cells are typically isolated from the inner cell mass 
of the blastocytes and expanded on a feeder cell layer to maintain hESC in an 
undifferentiated state. After removing hESCs from the feeder cell layer, they are cultured in 
suspension where embryoid bodies containing differentiated and undifferentiated cell 
aggregate. Embryoid bodies can be cultured on monolayer later and spontaneously 
differentiate to three germ lineages. Theoretically, ESCs can differentiate into any desired 
lineage through stimulation of specific growth factors or under proper protocols.66-69
 
 
Levenberg et al.70 cultured hESCs on a three-dimensional (3D) scaffold to promote cell 
proliferation and differentiation. A 3D vessel-like structure was observed, characterized by 
neural tissue, cartilage and liver.70 ESCs are a potential candidate for cartilage and bone 
tissue repair. Jukes et al. developed cartilage tissue-engineered constructs using mouse 
ESCs on a 3D scaffold in vitro and, after transplantation in vivo, the cartilage construct was 
ossificated and ultimately replaced by bone tissue.71 However, the disadvantages of using 
hESCs are obvious. The use of hESCs involves the destruction of in vitro human fertilized 
eggs to obtain blastocytes, which is unacceptable by some people in certain religions and 
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countries. A major immune rejection or response can occur when hESCs are implanted into 
patients. The risk of hESCs forming tumor tissue in vivo is still large.72-76
 
 
Recently the generation of induced pluripotent stem (iPS) cells provides a novel method and 
potentially exciting approach for stem cell research, drug testing and tissue engineering. iPS 
cells are the pluripotent stem cells transferred from terminally differentiated adult somatic 
cells by induction of several key transcription factors. Takahashi et al. in 2006 successfully 
developed the first iPS mouse cells by inserting four transcription factors [Sox2, Oct-3, c-Myc 
and Klf4 (Krueppel-like factor 4)] to reprogram fibroblasts to ES-like cells.77 Yu et al. also 
reprogrammed iPS cells using Oct3-4, Sox2, Nanog and Lin28 by lentivirus transfection78. In 
2008 iPS cells were generated by using adenovirus79;80 and, in 2009, the first iPS cells were 
reported using only recombinant proteins.81-83 The use of adenovirus and recombinant 
proteins can significantly reduce the risk of tumor formation since they do not affect the 
targeted host genes. Although iPS cells overcome some disadvantages of hESCs, there are 
still some drawbacks to limit their use. The reprogramming of iPS cells involves viral 
integration, even though recombinant proteins are in use but with low efficiency. The 
generation of iPS cells faces the disadvantages of low efficiency and high cost, because the 
typical efficiency of iPS cell generation is less than 1%; the efficiency can increase to 28% if 
using hematopoietic stem cells or mesenchymal stem cells.66;82;84
 
 
1.5.2 Adult stem cells 
A well-known adult stem cell is hematopoietic stem cell (HSC) that can be collected from 
bone marrow and umbilical cord blood. Hematopoietic stem cells (HSCs) are characterized 
by cell surface markers, which are positive for CD34, CD133, CD177, CD59 and CXCR4, but 
negative for lineage-specific antigen, CD38, and CD73 etc. The ability of HSC differentiation 
into non-hematopoietic lineage tissues is possibly artifact, because mesenchymal stem cells 
locate or migrate into hematopoietic organs.85-89
 
 
Mesenchymal stem cells (MSCs) are another type of adult stem cells, characterized by a 
strong self-renewal ability and multipotent capacity to differentiate into multiple lineages, 
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including bone, cartilage, adipose tissue, muscle, tendon, stromal cells and connective tissue. 
MSCs are characterized by surface markers positive for CD73, CD90 and CD105, but 
negative for CD45, DC34, CD14, CD11b, CD79a, CD19 or HLA-DR. Three typical MSCs, 
which are frequently studied in stem cell research and cartilage tissue engineering, will be 




Ideal MSCs for regenerative medicine include the following criteria: 1) they should have a 
large cell number for clinical therapy; 2) they should have a minimally invasive procedure to 
collect or harvest tissue for MSCs; 3) they should have multiple differentiation potentials; 4) 




MSCs provide a great potential for regenerative medicine and cartilage tissue engineering. 
MSCs have several advantages over ESCs and iPS cells. Even though MSCs have a weaker 
proliferative rate than ESCs, they can be collected from various tissue sources and still 
provide adequate cells for therapy if culture conditions and protocols are improved94;95. The 
multipotential differentiation to multiple lineage tissues of MSCs can benefit bone and 
cartilage tissue regeneration, tendon and skeletal muscle repair and cardiac tissue 
engineering.19;96;97 MSCs can be collected directly from patients to avoid any immune 
rejection. Meanwhile, the results of various immunoassays on MSCs suggest that MSCs 
have a strong immunosuppressive effect by inhibiting T-cell recognition and suppressing the 
production of TNF-α or INF-γ. The immunosuppressive effect enables the use of allogeneic 
MSCs with minimal immune reaction.91;98-100 MSCs are not subject to the ethical dilemmas 
and forming teratocarcinoma that are associated with ESCs.101-104
 
 
1.5.3 Bone marrow stem cells 
Bone marrow stem cells (BMSCs) were first reported by Friedenstein et al.91;105-107 The 
fibroblast-like cells in bone marrow were found through attachment to tissue culture plates 
and the cells exhibited osteogenic differentiation ability. Since their discovery, BMSCs have 
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been studied in depth and found to differentiate into not only osteoblasts108 but also 
chondrocytes,109 adipocytes,110 myoblasts111 and early progenitors of neural cells.112
 
 
The BMSC population in bone marrow is scant and represents 0.001% to 0.01% of the 
nucleated cells, which is only 1/10 of the proportion of HSCs. BMSCs, however, show a 
strong proliferation ability in monolayer expansion in vitro.91;107;113 The expansion conditions 
were improved to increase BMSC cell yield and to maintain their differentiation potentials. In 
the process of in vitro expansion, BMSCs with different cell morphologies are harvested, 
including thin and spindle-shaped cells and wider cells. It was found that small, thin BMSCs 
self-renewed rapidly and had a greater potential for multipotential differentiation. In repeated 




The immunophenotype profile of BMSCs is similar to other mesenchymal stem cells. BMSCs 
are positive for CD105, CD73 and CD90 but negative for CD34, CD 45 CD11a CD19 and 




Positive markers Negative markers 
CD9. CD10. CD13, CD29, CD44, CD49a, 
CD49c, CD49e, CD51, CD54, CD58, CD61, 
CD71, CD73, CD90, CD102, CD104, CD105, 
CD106, CD119, CD120a, CD120b, CD121, 
CD127, CD140a,, CD166, CCR1, CCR4, 
CCR7, CXCR5, CCR10, VCAM-1, CD166, 
AL-CAM, ICAM-1, STRO-1, CD340, SSEA-4. 
W8B2, W3D5, W4A5, W5C4, W5C5, W7C6, 
9A3, 58B1, HEK-3D6 
CD45, CD34, CD14, CD11A, CD19, CD86; 
CD80/CD40, CD15, CD18, CD25, CD31, 
CD50, CD62E, CD62P, CD117 
Table 1.4 Cell surface markers to characterize BMSCs 
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BMSCs have been successfully used in animal studies and clinical practices. The injection of 
BMSCs was used to repair fresh bone fractures and osteochondral defects. The injected cells 
shortened healing period, enhanced the repair effect in bone fracture treatment, and reduced 
the chance of future bone fracture.119;120 BMSCs were used to repair full-thickness defects in 
articular cartilage using various scaffolds. The repair effectiveness of BMSC transplantation 
was better than those not treated with BMSCs.102;121;122 However, BMSC injection therapy 
failed to significantly improve osteoarthritis possibly due to the serious inflammatory reaction 
caused by arthritis.123 Since BMSCs can differentiate to skeletal, smooth and cardiac muscle 
cells, cardiac regeneration is the focus of current research. In animal studies, autologous 
BMSCs were used to treat myocardial infarction and improved cardiac function and 
angiogenesis,96;124;125
 
 indicating that BMSC can be useful in cardiomyocyte regeneration. 
1.5.4 Adipose-derived stem cells 
Adipose-derived stem cells (ADSCs), termed “pre-adipocytes” historically, are another 
promising candidate for regenerative medicine.126;127 ADSCs can be digested enzymatically 
from adipose tissue and separated from adipocytes by centrifugation. ADSCs share 
similarities with BMSCs such as an extensive proliferative ability and multipotential 
differentiation capacity to osteoblasts, adipocytes, chondrocytes, myoblasts and neural 
cells.128-132 Compared to BMSCs, ADSCs have several advantages including easy 
accessibility, abundant adipose tissue source, higher yield of cell numbers and superior 
proliferative rate. It is reported that approximately 400,000 liposuction surgeries are 
preformed in U.S. every year and yield about 100 mL to 3 L of lipoaspirate tissue that is 
discarded. ADSCs can be collected safely and conveniently from those abundant lipoaspirate 
tissues.132-134 Surgery risk is reduced by using autologous ADSCs because fat tissue is more 
easily accessible than bone marrow. Furthermore, 5 × 103 cells can be collected from 1 g of 
adipose tissue; that is 500-fold greater than the number of BMSCs from the same weight of 
bone marrow.135-137
 
 Adipose tissue is considered a rich and safe source for ADSCs. 
The cell surface marker expression of ADSCs is similar to that of BMSCs, positive for MSC 
markers and negative for HSC markers.138 Particularly, CD49d is positive and CD106 is 
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negative in ADSCs. ADSCs also show increased expression of CD54 (ICAM-1) compared to 
BMSCs.138-140 The proliferative rate of ADSCs in vitro expansion is not different from that of 




It is not surprising that ADSCs exhibit excellent adipogenic potential when induced in 
adipogenic differentiation medium.128;138;142 Under osteogenic stimulation, ADSCs are able to 
express osteoblast-specific genes and bone tissue matrix that are compatible with 
BMSCs.138;142-144 In a murine calvarial defect model, ADSCs were transplanted to repair bone 
defects and the newly generated bone tissue had biological and biomechanical functions.145 
In chondrogenic differentiation, ADSCs are able to express chondrogenic-specific genes 
such as Sox9, aggrecan and type II collagen and generate cartilage-related extracellular 
matrix of sulfated glycosaminoglycans and type I and II collagens.138;142;146 However, 
compared to BMSCs, ADSCs showed no difference in chondrogenic ability in 
two-dimensional culture but were much weaker in a three-dimensional system.147
 
 
1.5.5 Synovium-derived stem cells 
Synovium-derived stem cells (SDSCs) are from “synovial fibroblasts” that are considered 
tissue-specific cells for regeneration medicine and cartilage repair.92;148;149
 
 Compared to 
BMSCs, ADSCs and other MSCs, synovial membrane is located near articular cartilage and 
provides suitable MSCs to migrate into subchondral defects. SDSCs have several 
advantages over BMSCs and ADSCs including higher proliferative rate, regardless of donor 
age, and a stronger chondrogenic potential with minimal hypertrophy risk. 
Synovial membrane can be harvested by arthroscopy with minimal invasiveness and less risk 
to donors because of its strong regenerative capacity. SDSCs can be released by enzyme 
digestion. Approximately 21,000 cells can be harvested from 1 mg of synovium tissue which 
provides a sufficient cell number for animal studies and clinical practices.92 The expandability 
of SDSCs is identical to BMSCs and superior to ADSCs; SDSCs can be expanded over 10 
passages without cell senescence (cell morphology changes to flattened and larger and then 
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the cells stop proliferating). When seeding at a low cell density, SDSCs show a more rapid 
proliferative rate than other MSCs.150;151 The colony forming ability of SDSC is about 100-fold 
greater than that of BMSCs and comparable to ADSCs.141 With regard to adipogenesis and 
osteogenesis, SDSCs are identical to BMSCs and ADSCs.140;141;152 SDSCs exhibited superior 
chondrogenic potential compared to BMSCs and ADSCs. With the induction of transforming 
growth factor-β1 (TGF-β1), both BMSCs and SDSCs generated cartilage-specific genes and 
matrix that were stronger than ADSCs.152 Using the combination of transforming growth 
factor-β3 (TGF-β3) and bone morphogenic protein - 2 (BMP-2), SDSCs produced 2.5-fold 
more sulfated glycosaminoglycans and 50% more collagen than BMSCs.150 The superior 
chondrogenic capacity of SDSCs was also confirmed by other studies.153;154
 
 
There are two major cell types in synovial tissue, where the round nucleated cells are called 
“macrophage-like” or “type A” cells and the spindle type cells are named “fibroblast-like” or 
“type B” cells. Our laboratory developed a “negative isolation” procedure to improve SDSCs’ 
proliferative and chondrogenic capacities. Cells from digested synovial tissue are suspended 
and incubated with Dynabeads® M-450 conjugated with CD14 antibody specific for 
macrophages; then the conjugated cells are removed by using the Dynal Magnetic Particle 
Concentrator® and unconjugated cells are presumed “type B” cells (SDSCs). Figure 1.7 
shows the negative isolation procedure in synovial cells.155 The negatively isolated SDSCs 




1.6 Chondrogenesis of mesenchymal stem cells 
MSC chondrogenesis is the process where multipotent MSCs differentiate into articular 
chondrocytes and generate cartilage-specific extracellular matrix, induced by growth factors 
and nonproteinaceous chemical molecules, in a serum-free medium and under optimal 
culture conditions such as hypoxia. In the process of chondrogenesis, MSCs continue to 
express type I and II collagen and aggrecan (chondrogenic markers), and type X collagen 
(hypertrophic marker) in the late stage.109;149;156-158 The first chondrogenesis of MSCs was 
reported by Ashton et al.156 and a pellet culture system was developed by Johnstone et al. to 
18 
 
enhance chondrogenic effect.109 The pellet culture system is widely used to evaluate 
chondrogenic potential of MSCs in vitro.109;149;157;159
 
 The following introduction will focus on 
growth factors, optimal chondrogenic media and culture conditions and the hypertrophic 
markers of chondrogenesis. Chondrogenic differentiation signaling pathways and 
transcription factors induced by TGF-β growth factor will be discussed. 
1.6.1 Growth factors in chondrogenesis 
The transforming growth factor-β (TGF-β) superfamily is the most commonly used to induce 




TGF-β1, 2, and 3 promote the synthesis of proteoglycans and type II collagen in MSCs in 
vitro.159;161 TGF-β1 in vivo stimulates skeletal tissue development and induces MSC 
chondrogenic differentiation to repair cartilage defects.19;159;162
 
 TGF-β3 is proposed to have a 
stronger effect in MSC chondrogenesis than TGF-β1, but our study using SDSCs suggested 
that there was no difference in chondrogenic effect between these two TGF-β factors. From 
histology and immunohistochemistry, both TGF-β1 and TGF-β3 can induce SDSCs to 
generate a large amount of sulfated GAGs and type II collagen. The quantification of 
chondrogenic index induced by TGF-β1 and TGF-β3 shows no statistical difference. (Figure 
1.8) 
Bone morphogenetic proteins (BMPs) are important members of the TGF-β superfamily that 
contain a sub-class of 20 polypeptides. Several BMPs can promote MSC chondrogenesis 
and cartilage formation by increasing the expression of aggrecan and collagens, such as 
BMP-2, -4, -6, -7, -13 and -14. Interestingly, BMP-3 inhibits MSC chondrogenesis and 
osteogenesis by inhibiting BMP-2 activity.163;164 The combination of TGF-β and BMPs can 
enhance MSC chondrogenic differentiation, proven by previous studies165
 
 and our research 
on ADSCs (Chapter 3). 
The insulin-like growth factor (IGF) family including IGF-I and IGF-II is also investigated in 
19 
 
MSC chondrogenic differentiation. The binding of IGF to receptors induces activation of 
different intracellular downstreams and subcutaneously enhances the expression of 
chondrogenic genes and proteins.159;166 In articular cartilage, IGF-I is produced to maintain 
chondrocyte morphology and induce cell migration to repair defects. It has been proven that 
IGF-I plays an important role in embryonic development and that the mutation of IGF-I results 
in serious developmental defects in various musculoskeletal tissues.159;166;167
 
 
The fibroblast growth factor (FGF) family is also used to improve MSC chondrogenesis and 
includes 22 sub-class proteins binding to receptors.168 The intracellular signaling pathway of 
FGF is characterized to Ras–MAPK (mitogen activated protein kinase) pathway.169 The most 
well-known member of the FGF family is FGF-2, which functions to promote the proliferation 
of MSCs and chondrocytes and to enhance chondrogenic differentiation with other TGF-β 
factors.170 The knock-out FGF-/- mice had serious issues in cartilage and bone 




1.6.2 Optimal chondrogenic conditions 
In addition to protein-based growth factors, several nonproteinaceous chemical compounds 
are used as supplements in the induction of MSC in vitro chondrogenesis. Dexamethasone is 
a synthetic glucocorticoid that can enhance MSC chondrogenesis. The normal concentration 
of dexamethasone is 10-7 M and the combination with TGF-β can induce a greater generation 
of aggrecan and type II collagen.109;172 Ascorbic acid (vitamin C) is demonstrated to have a 
stimulatory effect on chondrogenic differentiation in adult MSCs and in embryonic limb 
development.173;174 Insulin is also added to promote in vitro chondrogenesis of MSCs and 
chondrocytes and is used at a higher level than that in normal human serum.175;176
 
 
Hypoxia, a low oxygen tension (1% - 5%), can improve MSC chondrogenesis demonstrated 
by several studies. The improvement of chondrogenic differentiation in hypoxia is related to 
an elevated expression of hypoxia-inducible factors (HIFs), specifically HIF-1α, and 
chondrogenic transcription factor Sox-9. Thus, protein downstream affects MSCs to generate 
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an increased level of cartilage-specific matrix.177-180 Hypoxia is also demonstrated to inhibit 
the formation of fibrous cartilage by decreasing the marker genes of type I and III collagen,181 




Hypertrophy is the terminal stage in chondrogenesis where ossification occurs in cartilage 
matrix and chondrocytes change their morphology to fibroblast-like cells and eventually 
differentiate into osteoblasts and form endochondral bone tissue. Typical hypertrophic 
markers include type X collagen, matrix metalloproteinase 13 (MMP13), alkaline 
phosphatase (ALP), bone sialoprotein type II (IBSP), secreted phosphoprotein type 1 (SPP1, 
or osteopontin) and Runt domain transcription factor (Runx2).184;185 The fate of hypertrophic 
chondrocytes is either to differentiate to osteoblasts or to undergo apoptosis, and this will 
jeopardize the effect of MSC-generated cartilage tissue.186;187
 
 
BMP-2 and BMP-4 not only stimulate MSCs toward chondrogenesis but also induce the 
expression of hypertrophic marker genes.188 However, TGF-β can suppress hypertrophy in 
chondrocytes.189 Intracellular reactive oxygen species (ROS) play an important role in 
chondrogenesis and hypertrophy. An elevated level of ROS is found in hypertrophic 
chondrocytes and antioxidant treatment can reverse the excessive hypertrophy. Morita et al. 
demonstrated that increased ROS can inhibit proliferation and initiate hypertrophic changes 
in chondrocytes.187 Type X collagen is the only well-accepted marker for chondrocyte 
hypertrophy that is regulated by Runx2, a transcription factor in osteogenesis, and the 




Hypertrophy is one of the major concerns in MSC-derived cartilage tissue engineering, not 
only ossification but also vascularization. Articular chondrocytes show no signs of 
hypertrophy including negative expression of type X collagen and resistance to calcification, 
but MSC-derived chondrocytes have the potential to mineralize and develop vascular 
invasion after transplantation in vivo.184;185 Parathyroid hormone-like peptide (PTHrP) is 
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proposed as an inhibitor to hypertrophy in in vitro MSC chondrogenesis.191 A recent study 
showed that the coculture of articular chondrocytes and MSCs can significantly suppress 
MSC hypertrophy during chondrogenesis because of PTHrP secreted by articular 
chondrocytes.192
 
 In future, the mechanism of hypertrophy in MSC chondrogenesis needs to 
be studied to improve cartilage tissue engineering. 
1.6.4 Chondrogenesis of SDSC induced by the combination of TGF-β1, IGF-I and FGF-2 
Our previous study investigated SDSC chondrogenesis and improved chondrogenic 
differentiation by growth factor cocktail: TGF-β1, IGF-I and FGF-2.149
 
  
Following negative isolation, SDSCs were centrifuged into pellets and cultured in serum-free 
chondrogenic medium. The SDSC pellets were divided into five groups. All five groups were 
treated with 50 ng/mL of FGF-2 for three days and then induced to chondrogenesis by the 
growth factor cocktail (10 ng/mL of TGF-β1 and 500 ng/mL of IGF-I) for 15 days. The detail 
experiment schedule is shown in Figure 1.9A. Group D1 was treated only with 10 ng/mL of 
TGF-β1. Group D2 was treated with 10 ng/mL of TGF-β1 for 11 days and switched to the 
cocktail for 4 days. Group D3 was treated with TGF-β1 for 7 days and the cocktail for 8 days. 
Group D4 was treated with TGF-β1 for 4 days and the cocktail for 11 days. Group D5 was 
treated with the cocktail for 15 days (Figure 1.9A). 
 
Histology and immunohistochemistry showed that, with the cocktail treatment of TGF-β1 and 
IGF-I, SDSC pellets had the strongest potential of chondrogenesis. Group D5 had the 
extensive expression of sulfated GAGs and type II collagen. Type I collagen was positive in 
all the groups but type X collagen was negative (Figure 1.9B). Biochemistry and real-time 
PCR also showed that the combination of TGF-β1 and IGF-I can maximally induce the 
expression of chondrogenic matrix and genes. This study suggested a new strategy to induce 
chondrogenesis of MSCs by the sequential combination of growth factors.  
 
1.6.5 Intracellular signaling pathways of TGF-β induced chondrogenesis 
Members of the TGF-β superfamily bind to type II and type I TGF-β receptors. Both type II 
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and type I receptors contain serine/threonine kinase domains in the intracellular parts. In the 
process of binding TGF-β to type II receptor, type I receptor is recruited and phosphorylated. 
Following the phosphorylation, type I receptor phosphorylates and activates intracellular 
signaling pathways, including Smad, mitogen-activated protein kinase (MAPK)/extracellular 
signal regulated kinase (ERK), JNK/p38 signaling, Wnt and Noggle. Therefore, type I 
receptor functions as a downstream of type II receptor.193-197
 
 
Smad proteins, named from mothers against DPP homologs, are the major signaling 
mediators in the TGF-β superfamily induced chondrogenesis. There are three types of Smad 
proteins: receptor-regulated Smads (R-Smads), common-partner Smads (Co-Smads) and 
inhibitory Smads (I-Smads). In the TGF-β induced signaling pathway, phosphorylated type I 
receptor activates R-Smads, Smad2 and Smad3 specifically. Samd2/3 associate with 
Co-Smad (Smad4) and the complex transfers to the nucleus to regulate the expression of 
target genes in cooperation with transcription factors. In BMP signaling pathway, type I 
receptor activates Smad1/5/8 and links to Smad4. The compound of Samd1/5/8/4 moves to 
the nucleus and starts the target gene expression (Figure 1.10).193-195;198-200
 
 
TGF-β also induces the MAPK/ERK signaling pathway. In this pathway, binding of TGF-β to 
type II receptor induces the activation of type I receptor. This results in phosphorylation of 
numerous kinases, such as Src (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene 
homolog) and Grb2 (growth factor receptor binding protein 2). The phosphorylation of Src or 
Grb2 activates Ras by catalyzing the exchange of GDP to GTP. Ras then binds to Raf and 
activates the MAPK cascade including MEK and ERK1/2 (Figure 1.11).201-204 However, the 
function of ERK1/2 in chondrogenesis is controversial. Yamada et al. demonstrated that 
activation of ERK1/2 was crucial in regulation of aggrecan gene expression induced by 
TGF-β,205 but recent studies suggested that inhibition of ERK1/2 can improve the MSC 
chondrogenic differentiation.206-208 One possible explanation is that activation of ERK1/2 is 
essential to chondrogenesis induced by TGF-β in the early stage up to 120 minutes, but in a 





TGF-β can induce JNK and p38 MAPK signaling cascades. TGF-β activates JNK through 
MKK4 (MAP kinase kinase 4) and p38 MAPK through MKK3/6. Activated JNK and p38 MAPK 
move to the nucleus and initiate the expression of target genes with transcription factors 
(Figure 1.12).204;209-213 More importantly, the signaling pathway of JNK and p38 is independent 




TGF-β can induce the PI3K/Akt signaling pathway. PI3K is activated by TGF-β and then 
phosphorylates the downstream Akt that is independent of Smad activation216. PI3K plays an 
important role in cell adhesion, migration and TGF-β-induced actin filament reorganization 
(Figure 1.13).204;217 However, the PI3K/Akt signaling was reported to antagonize 
Smad-mediated effects. The activated Akt can interact with Smad3 and hence prevent the 
translocation of Smad2/3 to the nucleus. The interaction of Akt and Smad3 can delay 
chondrogenic differentiation induced by TGF-β.218-221
 
 
TGF-β can activate Rho-like GTPase, including RhoA, Rac and Cdc42 to modulate cell 
adhesion, proliferation and survival.204;222;223 The activation of RhoA and Cdc42 by TGF-β is 
independent of the Smads signaling pathway, indicated by the unaffected activation of 
p21-activated kinase (PAK) in the inhibition of Smad2/3 phosphorylation.224;225 However, 
Smad7 is associated with the activation of Cdc42 (Figure 1.14).226;227
 
 
In MSC chondrogenic differentiation, Sox9 (Sry-related high-mobility-group box 9) is the key 
transcriptional factor to initiate the expression of chondrogenic-specific genes and inhibits 
chondrocyte hypertrophy. After the activation of Smad2/3 by TGF-β, the Sox9 and Smad2/3/4 
complex translocate to the nucleus. Cooperating with other transcription factors, such as 
Barx2 and c-Maf, chondrogenic genes like type II collagen and aggrecan are activated to 
express.228-230 In vivo Sox9 plays an important role in the development of musculoskeletal 





1.7 MSC-based cartilage tissue engineering 
 
1.7.1 Definition of cartilage tissue engineering 
Tissue engineering (TE) is defined as the utilization of biomaterials, cells, factors and other 
biochemical and biophysical stimulations to regenerate, repair or restore live tissues that 
have not only physiological but also biomechanical functions.237 Cells used in TE can be 
autologous, allogeneic and xenogeneic. Biochemical factors, such as signaling molecules 
and biophysical stimulation like compression or shear force, induce cells toward desired 
lineage tissues. Biomaterials like scaffolds function to provide support for cells and 
mechanical properties such as suitable stiffness and elasticity. The general procedure of TE 
includes the following steps. MSCs or autologous cells are harvested from patients and 
expanded in vitro to acquire adequate cell numbers. The expanded cells are seeded into 
biocompatible scaffolds and cultured in the presence of growth factor combination to induce 
cell proliferation and differentiation. The immature constructs containing the scaffolds and 
cells are cultured in a bioreactor that mimics the in vivo condition or presses suitable physical 
stimulations. The mature constructs (also called engineered tissue) are transplanted into 
patients to repair catilage defects or damaged tissues.237;238
 
 The cells used in cartilage tissue 
engineering include chondrocytes, ESCs and adult MSCs that were discussed previously. 
The growth factors in TE are the same as those used to induce chondrogenesis. Next we will 
focus on biocompatible scaffolds and bioreactors. 
1.7.2 Biocompatible scaffolds 
The primary function of scaffolds is to provide a temporary structure for implanted cells until 
new extracellular matrix is generated. The criteria for scaffolds include biocompatibility, 
biodegradability, mechanical stability and a porous structure that is three-dimensional and 
permissive for biological growth factors. 
 
Fibrous scaffolds are the most commonly used in cartilage tissue engineering including poly 
glycolic acid (PGA), poly lactic acid (PLA) and the copolymer poly lactic-co-glycolic acid 
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(PLGA). They have been approved by US Food and Drug Administration (FDA) for clinical 
use. The fibrous scaffolds have a three-dimensional structure for cell attachment, migration 
and proliferation. They can be degraded by hydrolysis and the degradation time is 
controllable. Several in vitro and in vivo studies showed that MSCs or chondrocytes seeded 
in scaffolds generated extracellular matrix that is identical to native hyaline cartilage. Those 
constructs were implanted to repair partial-thickness or full-thickness defects in articular 
cartilage and achieved better results than control groups.155;239-244 Fibrous scaffolds are 
modified and improved by using nano-technology. Due to the morphological similarities of 
nanofibers to natural extracellular matrix, MSCs and chondrocytes can be improved to higher 
proliferative rate and better generation of matrix.245-247 Composite scaffolds are developed to 




Hydrogel scaffolds are also commonly used in cartilage tissue engineering that can absorb 
water and signaling factors, keep cell morphology and be injected into defect areas. The 
types of hydrogels include type I and III collagen, hyaluronan, chondroitin sulfate and poly 
ethylene glycol (PEG).251-254 MSCs and chondrocytes are seeded in hydrogels and 
successfully generate cartilage-specific matrix. The hydrogels are improved to incorporate 
signaling molecules such as growth factors that can spontaneously deliver TGF-β1 to induce 




Hydrodynamic bioreactor is the most commonly used equipment in tissue engineering and is 
also called a rotating wall vessel (RWV). Cell-scaffold constructs are placed in the 
hydrodynamic bioreactor filled with medium and growth factor supplements, and gas 
exchange occurs through a permeable core. With rotation, constructs can be cultured with 
sufficient nutrients and subjected to a low-level shear force.257-259 Our laboratory used the 
hydrodynamic bioreactor to induce SDSCs into hyaline cartilage-like tissue.155 Dynamic 
compression bioreactor is designed to increase construct mechanical properties by 
enhancing cartilage-specific matrix generation. It is reported that chondrocytes seeded in 
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hydrogel increased matrix synthesis though daily compressive stimulation.260;261 The 
hydrostatic pressure bioreactor is made to mimic the contact stress in joints and increase the 
generation of cartilage-like matrix.262
 
 
1.7.4 Cartilage tissue engineering using synovium-derived stem cells 
Our laboratory successfully generated tissue constructs identical to native hyaline cartilage 
using porcine SDSCs.155 SDSCs were collected from two young pigs and negative isolation 
was undertaken using CD14 specific antibody conjugated Dynabeads®
 
 or conventional 
expansion. SDSCs were seeded in PGA scaffold with fibrin glue and cultured in a cocktail of 
10 ng/mL TGF-β1, 50 ng/mL FGF-2 and 500 ng/mL IGF-I for 3 days. After that, the constructs 
containing SDSCs and PGA were transferred to a hydrodynamic bioreactor filled with 
chondrogenic medium supplemented with 10 ng/mL TGF-β1 and 500 ng/mL IGF-I for one 
month. 
Histology and immunohistochemistry showed that the SDSC constructs strongly expressed 
sulfated glycosaminoglycans and type II collagen. The hypertrophic marker, type X collagen 
was negative. Mechanical analysis suggested that the SDSC constructs had similar 
equilibrium modulus to natural hyaline cartilage. SDSC constructs with negative isolation 
generated 50% more GAG and had two-fold equilibrium modulus than the constructs with 
conventional expansion. Immunohistochemistry confirmed that macrophage cells existed in 
the conventionally expanded synovial cells, but were completely removed after negative 
isolation (Figure 1.15). 
 
Rabbit SDSC constructs were engineered following the same protocol above and 
transplanted into full-thickness femoral condyle cartilage defects in New Zealand white 
rabbits. After six months, cartilage morphology and histology analysis showed that the 
cartilage defects were filled with newly generated constructs, strongly expressing 
proteoglycans and type II collagen but had negative expression of type I collagen. In the 
control group, fibrocartilagenous tissues were found in the defects that were positive for type I 
collagen. Mechanical analysis showed that the defect areas repaired with SDSC constructs 
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had an equilibrium modulus that was identical to the surrounding undamaged cartilage tissue 
and were higher than that in the control group (Figure 1.16). The engineered constructs using 
SDSCs successfully repaired full-thickness defects in articular cartilage.263
 
 
1.8 Extracellular matrix 
Extracellular matrix (ECM) provides an essential microenvironment for mesenchymal stem 
cells and plays an important role in cell adhesion, survival, migration, proliferation, 
differentiation and matrix remodeling.174;264;265 Natural ECM provides a structural scaffold to 
resist tensile and compressive stress, and functions as a tight connection to the cytoskeleton 
of cells through cell-surface receptors to enable cells to sense and respond to mechanical 
and chemical signals. Stromal cells and MSCs usually reside within a specific extracellular 
regulatory microenvironment containing a complex mixture of ECM signals to direct cell 
self-renewal or differentiation. The extracellular signaling includes soluble cytokines and 
growth factors, components of ECM such as collagen and mineralized materials and the 
interaction between neighboring cells through cell surface receptors.266-268
 
  
Bone marrow, the microenvironment for osteoblasts, BMSCs and HSCs, is composed of 
calcified bone matrix, type I, III, IV, V and VI collagen, fibronectin, laminin, connecting 
proteins and large molecular weight proteoglycans.265;269-271 Growth factors reside in bone 
marrow (such as TGF-β, IGF, BMPs) and ECM acts as a reservoir to pass signals to cells 
through interaction with cell surface receptors.272-275 In bone marrow, the sustainability of 
BMSC self-renewal and the induction of differentiation are supported by the influence of 
factors secreted by osteoblasts, the adhesion to ECM and the connections between MSCs 
and osteoblasts, HSCs and stromal cells.276;277
 
 
In articular cartilage ECM not only provides structural integrity but also has physiological 
functions to maintain chondrocyte morphology, direct chondrocyte migration and influence 
immune cytokines.8;21;45;159 The components of articular cartilage include type II collagen, 
proteoglycans (primarily aggrecan), hyaluronan and other matrix proteins. Cartilage ECM 






1.8.1 Integrin system and signaling mechanism 
Extracellular matrix has a profound influence on cell adhesion, survival, proliferation and 
differentiation. The interaction between cells and ECM are mainly dependent on integrins and 
other surface receptors.280-282
 
 Here we focus on the integrins of mesenchymal stem cells and 
the integrin-dependent intracellular signaling mechanism. 
Integrin receptors have a transmembrane structure and are composed of heterodimeric 
molecules including α and β subunits. The extracellular domains have contact with ECM and 
the cytoplasmic domains associate with cell actin cytoskeleton and protein kinases. Currently 
at least 16 α and 8 β subunits of integrins have been identified that can generate 22 distinct 
αβ heterodimeric receptors.280;281;283;284 Table 1.5 shows the major integrin heterodimeric 
receptors and their protein ligands.281
 
 
Integrin subunits ligands 
β1 α1 Collagens, Laminins 
 α2 Collagens, Laminins 
 α3 Collagens, Laminins, Fibronectin, Entacin 
 α4 Fibronectin, VCAM-1 
 α5 Fibronectin 
 α6 Laminins 
 α7 Laminins 
 α8 Vitronectin, Fibronectin, Tenascin 
 α9 Vitronectin, Fibronectin, Tenascin 
 α10 Collagens 
 α11 Collagens 
 αV Vitronectin, Fibronectin 
β2 αL ICAM-1. ICAM-2, ICAM-3 
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 αM IC3b, Fibronectin, ICAM-1 
 αX IC3b, Fibronectin 
 αD ICAM-3 
β3 αIIβ Fibronectin, Fibrinogen, von Willebrand factor, 
Vitroectin, Thrombospondin, Tenasin 
 αV Fibronectin, Fibrinogen, von Willebrand factor, 
Vitroectin, Thrombospondin, Osteopontin, Collagens 
β4 α6 Laminins 
β5 αV Vitronectin, Fibronectin 
β6 αV Tenasin, Fibronectin 
β7 α4 Fibronectin, VCAM-1 
 αE E-cadherin 
β8 αV Vitroectin 
Table 1.5 Integrin receptors and the protein ligands281
 
 
Due to the short structure and lack of enzymatic function of the cytoplasmic domains of 
integrins, extracellular signaling transduction must be accompanied by cytoskeletal actins, 
cytoplasmic kinases and transmembrane growth factor receptors. After contacting with ECM, 
integrins cluster in cell membrane, become a signaling complex and associate with 
cytoskeletal actin filaments. The reorganized actin filaments in turn accelerate the clustering 
of integrin with a positive feedback mechanism. Finally, ECM, integrins and the cytoskeletal 




Integrins activate several tyrosine kinase; one of those, focal adhesion kinase (FAK), has 
been studied in depth. After integrin clustering, the β subunit activated FAK directly or through 
cytoskeletal proteins such as talin and paxillin. FAK autophosphorylates Tyr397 and creates a 
binding site for Src homology 2 (SH2) domain of Src or Fyn. Src then phosphorylates FAK at 
Tyr925 and activates Grb2 and Ras. Phosphorylated FAK eventually activates MAPK 
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cascades and modifies cytoskeletal actin filaments.281;282;286 Activation of MAPK cascades 
can also be FAK-independent, in which the activation is initiated by integrin α5β1, αVβ3, α2β1, 
αVβ6 and α6β4 respectively, when cells adhere to ECM proteins such as fibronectin, collagens, 
laminins, virtonectin and tenascin. It is believed that FAK-related proteins such as CAKβ and 
PYK2/RAFTK may compensate for FAK to activate the MAPK signaling pathway.280;282;287;288
 
 
1.8.2 Typical ECM proteins and their integrin receptors 
Fibronectin is one of the major ECM proteins in bone marrow and articular cartilage, and it is 
most commonly used as a substrate in MSC expansion in vitro.289-291 Two different integrins, 
α5β1 and αVβ3, are identified as the receptors to fibronectin, which recognize a short motif 
composed by three amino acid residues (RGD: arginine, glysine and aspartic acid) in 
fibronectin.292-295 In addition, integrins of αIIbβ3, αVβ5, αVβ8, αVβ6 and αVβ1 are shown to contact 
fibronectin by binding to the RGD motif. α4β1 and α4β7 integrins recognize fibronectin through 
an RGD-independent motif but LDV or REDV motif.296-298 The binding of integrins to 
fibronectin induces FAK phosphorylation and activation of the MAPK cascade.292;293 
Interestingly many proteoglycans and glycosaminoglycans bind to fibronectin and the 
interaction between integrins and proteoglycans are associated with syndecans. Syndecans 
1, 2 and 3 are only found in specific tissues whereas syndencan 4 is ubiquitous. Integrin 
heterodimers bind to proteoglycans with the cooperation of syndecans and syndecans 
activate intracellular signaling transduction and induce focal adhesion.292;299-303
 
 
Collagen is a main component in bone and cartilage that is recognized by several receptors. 
Four collagen receptors of integrin heterodimers are identified including α1β1, α2β1, α10β1 and 
α11β1.293;299;300;304 Integrin α1β1, expressed in MSCs, is considered the receptor to type IV 
collagen and has a high affinity to non-fibrillar collagens.305-307 Integrin α2β1 is widely 
expressed and binds to collagen fibrils and fibrillar collagens.308-310 Integrin α10β1 is found in 
cartilage chondrocytes311 and integrin α11β1 plays an important role in tooth development.312 
Integrin collagen receptors can recognize proteoglycans with an association with syndecans 
that is similar to fibronectin receptors.313;314 In addition to integrin collagen receptors, discoidin 






Laminins are important components of the basement membrane together with type IV 
collagen. Four integrin heterodimers are the receptors including α3β1, α6β1, α6β4 and α7β1.293 
Integrin α3β1 is essential in the development of kidneys, lungs and skin.318;319 Integrin α7β1 is 
found in muscle tissue and is important to muscle development320. Integrin α6β4 is found in 
epithelial cells and binds to the basement membranes.321;322 Besides integrin receptors, 
α-dystroglycan functions as a laminin receptor that is also known as 67kD laminin receptor 
due to its molecular weight.292;323;324
 
 
1.8.3 3D vs. 2D ECM and distinct cellular response 
The current understanding of interaction between cells and ECM is based on studies of focal 
and fibrillar adhesions. Research on cell adhesion, migration, proliferation and differentiation 
is primarily derived from in vitro two-dimensional (2D) tissue culture substrate. However, in 
vivo three-dimensional (3D) ECM provides a different support to cells and induces distinct 
intracellular signaling transductions to influence cell adhesion, motility and proliferation. The 
studies of 3D ECM and the induced cell response can improve MSC-based tissue 




A novel cell-deposited 3D ECM provides a new approach to study the interaction between 
cells and ECM.94;95;325 Traditional 2D ECM involves the deposition of soluble matrix proteins 
such as fibronectin, collagen and laminins on culture surface. Compared to traditional 2D 
ECM, this natural 3D ECM composes multiple matrix proteins such as type I and III collagen, 
fibronectin, heparin sulfate proteoglycans, elastin, laminins and decorin etc. In the structure, 
3D ECM is more pliable than 2D ECM, has higher fibrillar matrix and contains the space 
originally occupied by the feeder cells generating matrix.325;327;328
 
 
An assay using human fibroblasts grown on 3D and 2D ECM showed that the cells attached 
to 3D ECM six-fold faster compared to the substrates of fibronectin, collagen, laminin or 3D 
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collagen gel.264 In 2D culture, cells adhere to ECM primarily on focal adhesion involving 
integrin αVβ3 and fibrillar adhesion depending on integrin α5β1. On 3D ECM, cells adhesion 
involves integrin α5β1 and α2β1 and the absence of integrin αVβ3. The focal adhesion is 
completely associated with fibronectin-containing fibrils that can be independent of fibronectin 
in 2D culture.264;325;326 Meanwhile, phosphorylation of FAK decreases when cells are cultured 
on 3D ECM but the activity of Src and ERK1/2 increases, indicating that cell adhesion and 
protein kinase activity are different between the 3D and 2D environments.329
 
 
The cell proliferation rate on 3D ECM increases at least two-fold in human fibroblasts325 and 
12-fold in porcine SDSCs95 compared to cells in 2D culture. The cell migration on 3D ECM is 
directional rather than the random migration on 2D culture. Rac is considered to control cell 
migration and Rac activity was proven to decrease on 3D ECM. The lower activity of Rac 
induced more directional migration.264;325;326 Another reason for the directional movement is 
that 3D ECM is more pliable and contains more space than 2D ECM; cells can sense the 
rigidity of ECM and move to areas with higher rigidity.264;325;330;331
 
 However, the work on 3D 
ECM and cell response is just beginning. Using 3D ECM is a new approach to study cell 
behavior, cancer mechanisms, drug delivery and to improve MSC-based tissue regeneration. 
1.9 Challenges in cartilage tissue regeneration 
Mesenchymal stem cells provide a promising cell source for cartilage tissue regeneration due 
to their self-renewal ability and multipotential differentiation capacity. However, there are 
several challenges facing the current application of MSC-based cartilage regeneration. 
 
The lack of a unique MSC surface marker makes it difficult to identify and isolate MSCs from 
cell pools. Even though it is reported that MSCs must show positive for CD90, CD105 and 
CD73 but negative for CD45, CD11b, CD14 or HLA-DR, the percentage of positive surface 
markers changes in different MSCs from different tissue sources.332 SSEA-4 is demonstrated 
as a positive surface marker in MSCs and the sorting of SSEA-4+ cells indeed enhanced 
differentiation including osteogenesis, adipogenesis and chondrogenesis.333 The SSEA-4 
positive isolation method is mainly limited to BMSCs, so future work will concentrate on 
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testing different tissue-source MSCs. Our negative isolation method using Dynabeads 
conjugated with CD14 antibody is an indirect way to purify SDSCs.148;155
 
 This negative 
isolation has some drawbacks including the removal of excessive cells up to 50% of the total 
population and unbound cells that are a mixed population of SDSCs and synovial fibroblasts. 
In future, it is important to identify unique cell surface markers for MSCs and develop a new 
isolation method to purify MSCs from other fibroblasts and immune cells. 
Self-renewal, the process by which MSCs proliferate and create more cells, is one of the 
important properties of MSCs. Maintaining self-renewal ability in vitro is crucial to MSCs as 
that it provides sufficient cells for tissue regeneration in vivo. Conventional MSC in vitro 
culture requires weekly passaging to retain proliferation rate and preserve future 
differentiation potential. However, the late passages of MSCs not only fail to 
proliferate140;152;154 but also lose multipotency except for differentiation into adipocytes.334
 
 
Another important property of MSCs is the stemness that is defined by the potentials of MSCs 
to differentiate into multiple tissues. The loss of multipotency in late-passage MSCs is 
possibly due to exposure to enzymes such as trypsin that damages cell surface 
proteins.335-338 Another explanation is spontaneous differentiation in the expansion period 
affected by serum and the 2D culture environment. Spontaneous differentiation is different 
from induced differentiation which is controlled by growth factors. Cells express multiple 
differentiation growth factors and cytokines in spontaneous differentiation that significantly 
reduce the sensitivity and effectiveness of cells in the future induced differentiation.94;271;339 
Tuan and colleagues tried to identify the signature genes that maintain MSC self-renewal and 
multipotency. Five specific genes were found expressed in undifferentiated MSCs but absent 
in differentiated cells, including actin filament associated protein, frizzled 7, dickkopf 3, 
protein tyrosine phosphatase receptor F and RAB3B. The interference of these genes by 
siRNA could affect MSC proliferative rate and multipotency.340 However, our understanding of 
the stemness of MSCs is poor and it is important to improve the in vitro culture of MSCs to 
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Figure 1.1 The structure of articular cartilage is composed by four zones: the superficial zone, 
the middle zone, the deep zone and the calcified cartilage zone. Figures are from Nelson L, 








Figure 1.2 Histology and immunohistochemistry of hyaline cartilage tissue. Images are from 
joint U-diet (A&C) and O-diet (B&D). Safranin O were used to stain sulfated GAGs (A-B) and 
immunohistochemistry were probed for type II collagen (C-D). Figures are from Matthew 
J.Ravosa, Elisabeth K.Lopez, Rachel A.Menegaz et al. Using ''Mighty Mouse'' to understand 
masticatory plasticity: myostatin-deficient mice and musculoskeletal function. Integrative and 





Figure 1.3 Three typical cartilage defects were met and studied in clinics, including 
subchondral defect, full-thickness defect and osteochondral defect. Figures are from Khan IM, 
Gilbert SJ, Singhrao SK et al. Cartilage integration: evaluation of the reasons for failure of 

















Figure 1.4 Articular cartilage is the main tissue affected by OA, which becomes softening, 
fibrillation, and erosion down to the subchondral bone. In the microscopic level OA results in 









Figure 1.5 (A) The structure of intervertebral disc contains three avascular tissues: annulus 
fibrosus (AF), nucleus pulposus (NP) and the cartilage endplates; (B) the degenerative 
disease of intervertebral disc changes the normal organized annulus and soften nucleus 
pulposus (left) to desiccated and disorganized tissues (right). Figure 1.5(A) from Smith LJ, 
Fazzalari NL. The elastic fibre network of the human lumbar anulus fibrosus: architecture, 
mechanical function and potential role in the progression of intervertebral disc degeneration. 
Eur.Spine J. 2009;18:439-48. Figure 1.5B from Urban JP, Roberts S. Degeneration of the 





Figure 1.6 The autologous chondrocyte transplantation (ACT) technique biopsy of cartilage 
tissue, release of chondrocytes and expansion in vitro, and the intraarticular injection into the 
articular cartilage defect. Figure 1.6 from Marlovits S, Zeller P, Singer P et al. Cartilage repair: 





Figure 1.7 The procedure of negative isolation method. Cell from the digested synovial tissue 
(A) are suspended and incubated with Dynabeads® M-450 CD14 conjugated with a 
monoclonal antibody specific for macrophages; then the conjugated cells are removed by 
using the Dynal Magnetic Particle Concentrator® and unconjugated cells are supposed “type 





Figure 1.8 Chondrogenesis of SDSC separately induced by TGF-β1 or TGF-β3. (A) Alcian 
blue staining and immunohistochemistry of type II collagen for SDSC pellets after 14-day 
induction; (B) Quantification of chondrogenesis index (GAG/DNA) of SDSC pellets induced 








Figure 1.9 Chondrogenesis of SDSC induced by the combination of TGF-β1, IGF-I and 
FGF-2. (A) the detail schedule of adoption TGF-β1, IGF-I and FGF-2; (B) the treatment of the 
cocktail of TGF-β1 and IGF-I, SDSC pellets had the strongest potential for chondrogenesis. 






Figure 1.10 In the TGF-β induced signaling pathway, the phosphorylated type I receptor 
actives R-Smads, Smad2 and Smad3 specifically. Samd2/3 associates with Co-Smad 
(Smad4) and the complex transfers to the nucleus to regulate the expression of target genes 
in cooperation with transcription factors. Figure 1.10 from Miyazawa K, Shinozaki M, Hara T 






Figure 1.11 TGF-β can induce the activation of MAPK/ERK signaling pathway. In this pathway, 
binding of TGF-β to type II receptor induces the activation of type I receptor. The 
phosphorylation of Src or Grb2 activates Ras by catalyzing the exchange of GDP to GTP. Ras 
then binds to Raf and activates MAPK cascade including MEK and ERK1/2. Figure 1.11 from 





Figure 1.12 TGF-β can induce JNK and p38 MAPK signaling cascades. TGF-β activate JNK 
through MKK4 (MAP kinase kinase 4) and p38 MAPK through MKK3/6. The activated JNK 
and p38 MAPK move to the nucleus and initiate the expression of target genes with 
transcription factors Figure 1.12 from Zhang YE. Non-Smad pathways in TGF-beta signaling. 





Figure 1.13 TGF-β can induce PI3K/Akt signaling pathway. PI3K is activated by TGF-β and 
then phosphorylate the downstream Akt that is independent of Smads activation. PI3K plays 
an important role in cell adhesion, migration and TGF-β-induced actin filament reorganization. 






Figure 1.14 TGF-β can activate Rho-like GTPase, including RhoA, Rac and Cdc42 to 
modulate the cell adhesion, proliferation and survival. The activation of RhoA and Cdc42 by 
TGF-β is independent of Smads signaling pathway, indicated by the unaffected activation of 
p21-activated kinase (PAK) in the inhibition of Smad2/3 phosphorylation Figure 1.14 from 





Figure 1.15 The engineered SDSC constructs were strongly positive for sulfated 
glycosaminoglycans and type II collagen. Hypertrophic marker, type X collagen was negative. 
The mechanical analysis suggested that the SDSC constructs had the similar equilibrium 





Figure 1.16 The engineered constructs using SDSCs successfully repaired the full-thickness 
defects in articular cartilage. Group A was repaired with SDSC constructs; Group B was 
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Joint injury results in cartilage lesions that are characterized by a poor repair response. Adult 
stem cells are immensely appealing for biological joint repair, such as cartilage tissue 
engineering and regeneration. However, adult stem cells gradually lose their stemness once 
they are removed from their in vivo niche for plating in plastic flasks. We utilized a 
tissue-specific stem cell, synovium-derived stem cell (SDSC), as a model to reconstruct an in 
vitro three dimensional (3D) stem cell niche. After seeding on SDSC-derived extracellular 
matrix (ECM), the initially wide and flat SDSCs became thin and spindle-shaped and were 
arranged in a 3D configuration with typical stem cell phenotypes. A dramatic increase in cell 
number and a greatly enhanced chondrogenic capacity were observed, though surprisingly 
the ECM-treated SDSCs did not display concomitantly improved adipogenic or osteogenic 
potentials. Thus, we conclude that a tissue-specific stem cell can be used to prepare its own 
in vitro niche for stem cell proliferation while maintaining and enhancing its lineage-specific 
stemness. The ability to reconstitute the in vitro stem cell niche will greatly benefit 






Adult stem cells are immensely appealing for tissue engineering and therapeutic applications 
because of their general multipotentiality and relative ease of isolation from numerous tissues; 
they are currently a leading candidate for a renewable source of transplantable cells. The 
effectiveness of stem cell therapy is facilitated by the ability to manipulate the signals that 
determine stem cell behavior in a temporal and spatially appropriate fashion, both at the 
treatment target site as well as during in vitro processing prior to transplantation. In vitro 
expansion represents a formidable challenge since stem cells are thought to exist in niches 
where extrinsic signals modulate the intrinsic signals that drive self-renewal and cell fate 
determination.1,2 However, outside of their niche, adult stem cells lose their developmental 
potential quickly3 and tend to either randomly differentiate or undergo apoptosis over time4
 
. 
Though a cocktail of growth factors can be used to increase the number of cells dramatically, 
the cells do not maintain stem cell characteristics. Instead, they become more mature, 
differentiated progenitor cells which eventually exhaust themselves after having divided a 
specific number of times. Therefore, one of the major challenges is controlling the fate of 
stem cells outside their natural environment. 
In order to successfully translate human adult stem cell biology into applications in 
regenerative medicine, it is important to recreate a functional stem cell niche in vitro that 
consists entirely of known, xeno-free, and chemically defined factors and molecules.5 Studies 
on Drosophila indicate that when germ stem cell (GSC) niches are experimentally “emptied” 
of their GSCs, the remaining niches can signal incoming somatic stem cells to take up foreign 
residence and at least transiently maintain some of their stem cell features6 and even reverse 
the fate of already differentiating cells.7 Here we hypothesized that synovium-derived stem 
cell (SDSC)-derived extracellular matrix (ECM) can serve as an in vitro three dimensional (3D) 
niche, facilitating SDSC propagation and allowing restoration of stem cell stemness toward 
chondrogenesis. In our previous studies, we negatively isolated SDSCs from harvested 
synovial tissue8 for in vitro cartilage tissue engineering9 and in vivo tissue transplantation.10 
SDSCs are reported as a tissue-specific stem cell for chondrogenesis.11-14 Using minimally 
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invasive arthroscopic techniques, it is possible to harvest synovial tissue from patients from 
which SDSCs can be isolated. This brings up the intriguing possibility of autologous 
transplantation therapy, whereby these isolated SDSCs can be modified and retransplanted.    
 
To date, we know of no studies that present a stem cell-derived ECM exhibiting a ‘niche 
effect’ on stem cell proliferation while maintaining stemness for a tissue-specific lineage 
except one study that demonstrated that ECM induced differentiation.15 Here we negatively 
purified SDSCs from pig synovial cells and engineered SDSC-derived 3D ECM. Partially 
differentiated SDSCs (Passage 3) were plated in plastic flasks either with or without ECM 
coating for two consecutive passages. The SDSCs grown on 3D ECM exhibited more of the 
properties typical of native stem cells compared with those plated on plastic flasks. 
ECM-treated SDSCs also displayed a remarkably enhanced chondrogenic capacity but not 
adipogenic or osteogenic potential.  
83 
 
MATERIALS AND METHODS 
 
Isolation and culture of SDSCs 
Two 3-month-old pigs were collected from a local slaughterhouse and harvested to provide 
synovial tissue from both knees. The synovial tissue was finely minced and digested at 37ºC 
for 30 min in 0.1% trypsin (Roche) and then for 2 h in 0.1% collagenase P (Roche) to release 
SDSCs. SDSCs were collected from the filtrate by centrifugation and plated in complete 
medium [αMEM containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL 
streptomycin and 0.25 μg/ml fungizone (Invitrogen)]. Nonadherent cells were removed by 
medium change every two days. For negative isolation of synovial fibroblasts from primary 
cultures, cell suspension (107 cells/mL) was incubated with 5 × 107/mL Dynabeads® M-450 
CD14 containing a monoclonal antibody specific for macrophages (Dynal Biotech) at 4ºC for 1 
h. The conjugated cells and the unbound Dynabeads® were collected using the Dynal 
Magnetic Particle Concentrator® (Dynal Biotech), and the depleted supernatant with synovial 
fibroblasts (referred to as SDSCs8
 
) was saved for further passaging. 
Preparation of SDSC-derived ECM 
Fibronectin (1 µg/cm2, BD Bioscience) was pre-coated on plastic flasks at 37oC for 1 h. 
Passage 2 SDSCs were plated in 175-cm2 flasks at a density of 6 × 103 cells/cm2
 
 in complete 
medium for 7 days. After SDSCs reached 90% confluence, 50 µM L-ascorbic acid phosphate 
(Wako) was added for an additional 8 days. To obtain cell-free ECM, ECM was incubated with 
0.5% Triton X-100 (Sigma) containing 20 mM ammonium hydroxide (Sargent-Welch) in PBS 
for 5 min at 37ºC. ECM was stored in D-PBS containing 100 U/mL penicillin, 100 μg/mL 
streptomycin and 0.25 μg/mL fungizone at 4 ºC. 
SDSCs grown on SDSC-derived ECM 
Passage 3 SDSCs were plated at 3,000 cells/cm2 in plastic flasks for two passages in two 
groups: ECM-coated flasks (ECM) or plain plastic flasks (Plastic). The medium was replaced 
every three days. The cell number from both treatments at P4 and P5 was counted using a 
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counting hemocytometer for cell proliferation rate. 
 
Scanning Electron Microscope 
Representative samples (n=2) were primarily fixed for 2 h at room temperature in 2.5% 
glutaraldehyde (Sigma). Secondary fixation was completed for another 2 h in 2% osmium 
tetroxide (Sigma). The samples were then dehydrated consecutively in 25%, 50%, 75%, 95%, 
and 100% (twice) ethanol for 10 min each, in hexamethyldisilazane (HMDS, Sigma) at a ratio 
of 1:1 with ethanol twice for one hour each time, in HMDS at a ratio of 1:2 with ethanol 
overnight, and in HMDS 3 times for 4 h each time. The samples were freeze-dried for 24 h 
and added with gold sputter. The images were recorded by a scanning electron microscope 





 SDSCs were incubated for 30 min on ice in PBS containing 5% FBS and 1% NaN3 
(Sigma), and then for 30 min on ice with appropriately diluted mouse monoclonal antibodies 
to CD29 (Abcam), CD44 (Abcam), CD45 (Abcam), CD68 (BD Pharmingen), CD90 (BD 
Pharmingen), and CD105 (GeneTex Inc.) or isotype-matched IgGs [IgG1 and IgG2a 
(Beckman Coulter)]. After washing with cold PBS, SDSCs were incubated with the secondary 
antibody [FITC-conjugated goat anti-mouse Ig (Abcam)] for 30 min in the dark followed by 
fixation in 400µL of 1% paraformaldehyde. Negative control samples received equivalent 
amounts of isotype-matched pre-immune antibodies. The cells were analyzed on a BD dual 
laser FACSCalibur (BD Biosciences) using the FCS Express 3 software package. 
Chondrogenic differentiation of SDSCs 
0.3 × 106 of SDSCs, either with or without ECM treatment, from P3 and P5 were placed in 
15-ml polypropylene tubes and centrifuged at 500 g for 5 min to form pellets. The pellets were 
cultured in chondrogenic medium consisting of high-glucose DMEM, 40 µg/mL proline, 100 
nM dexamethasone, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.1 mM ascorbic 
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acid-2-phosphate and 1 × ITS™ Premix (BD Biosciences) with the supplementation of 10 
ng/mL TGF-β1 (R&D) for 14 days.  
 
Adipogenic differentiation of SDSCs 
After 95% cell confluence, the culture medium was switched to adipogenic medium consisting 
of growth medium (low glucose DMEM, 10% FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin) supplemented with 10-6 M dexamethasone, 0.5 mM isobutyl-1-methy xanthine, 
100 µM indomethacin and 10 µg/mL insulin for an additional 21 days. Adipogenic 
differentiation was assessed using Oil Red O stain for adipose oil and TaqMan® real time 
PCR for quantification expression of adipogenic marker genes.  
 
Osteogenic differentiation of SDSCs 
After 95% cell confluence, the culture medium was switched to calcification medium 
consisting of growth medium supplemented with 10-7 M dexamethasone, 10 mM β-glycerol 
phosphate, 0.2 mM ascorbate-2-phosphate, and L-glutamine for an additional 21 days. 
Osteogenic differentiation was assessed using alizarin red stain for ECM calcification. 
TaqMan® real time PCR was used to semi-quantitatively evaluate osteogenic marker gene 
expression.  
 
Histochemistry and immunohistochemistry 
The pellets (n=3) were fixed overnight at 4ºC in 4% paraformaldehyde, followed by 
dehydrating in a gradient ethanol series, clearing with xylene, and embedding in paraffin 
blocks. 5-μm sections were histochemically stained with alcian blue (Sigma) and Safranin O 
(Sigma). For immunohistochemical analysis, the sections were immunolabeled with primary 
antibodies against collagen II (II-II6B3), collagen I (Abcam), and collagen X (Sigma), followed 
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by the secondary antibody of biotinylated horse anti-mouse IgG (Vector). Immunoactivity was 
detected using Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a 
substrate.   
 
Biochemical analysis for DNA and GAG content 
For biochemical analysis, the pellets (n=6) were digested for 4 h at 60ºC with 125 μg/mL 
papain in PBE buffer (100 mmol/L phosphate, 10 mmol/L EDTA, pH 6.5) containing 10 
mmol/L cysteine, by using 100 μL enzyme per sample. To quantify cell density, the amount of 
DNA in the papain digestion was measured using the QuantiTTM PicoGreen® dsDNA assay kit 
(Invitrogen) with a CytoFluor® Series 4000 (Applied Biosystems). GAG was measured using 
dimethylmethylene blue dye and a SpectronicTM BioMateTM 3 Spectrophotometer (Thermo 
Scientific) with bovine chondroitin sulfate as a standard. 
 
Western blot 
To assess non-dissolvable collagen II expression in extracellular matrix, SDSC pellets (n = 3) 
were lyophilized and incubated in 4 M guanidine hydrochloride (GuHCl, Sigma) for 20 h at 
4ºC, then digested with 0.6 mg/ml of pepsin (Sigma) in 0.5 M acetic acid at 4ºC for 48 h at a 
ratio of 10:1 (mg/mg) dry sample to pepsin. The samples were centrifuged at 48,000 g for 1 h, 
and the supernatant was lyophilized and dissolved in radioimmunoprecipitation assay (RIPA) 
buffer with protease inhibitors (Pierce). To assess dissolvable collagen II expression in 
cytoplasm, the pellets were homogenized and dissolved in RIPA buffer with protease 
inhibitors. Total proteins were quantified using BCATM Protein Assay Kit (Pierce). 40 μg 
protein from each sample was denatured and separated using NuPAGE® Novex® Bis-Tris 
Mini Gels (Invitrogen) in the XCell SureLockTM Mini-Cell (Invitrogen) at 120 volts for 3 h at 4°C. 
Bands were transferred onto a nitrocellulose membrane (Invitrogen) using an XCell ΙΙTM Blot 
module (Invitrogen) at 15 volts overnight at 4°C. The membrane was incubated with a primary 
monoclonal antibody against collagen II (II-II6B3) in 1% non-fat milk in TBST for 1 h at room 
temperature (β-actin served as an internal control), followed by the secondary antibody of 
HRP-conjugated goat anti-mouse (Pierce) for 40 min at room temperature and exposure 
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using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) and CL-XPosure 
Film (Pierce).  
 
TaqMan® Quantitative PCR 
The total RNA was extracted from samples (n=4) using an RNase-free pestle in TRIzol® 
(Invitrogen). 1 µg of mRNA was used for reverse transcriptase (RT) with High-Capacity cDNA 
Archive Kit at 37ºC for 120 min as recommended by the manufacturer (Applied Biosystems). 
Chondrogenic marker genes (types I, II, X collagen, Sox 9, and aggrecan), adipogenic 
marker genes (LPL, PPARγ, and C/EBPα), and osteogenic marker genes (OCN, SPP1, and 
type I collagen) were customized by Applied Biosystems as part of the Custom Taqman® 
Gene Expression Assays (Table 1). Eukaryotic 18S rRNA (Assay ID HS99999901_s1 ABI) 
was carried out as the endogenous control gene. Real-time PCR was performed with the 
iCycler iQTM Multi Color RT-PCR Detection and calculated by computer software 
(Perkin-Elmer). Relative transcript levels were calculated as χ=2-ΔΔCt, in which ΔΔCt=ΔE-ΔC, 
ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s. 
 
Statistics 
The Mann-Whitney U test was used for pairwise comparison in biochemistry analysis and 
real-time PCR data. All the statistical analysis was performed with SPSS 13.0 statistical 







SDSC-derived ECM serves as an in vitro 3D stem cell niche 
After using SDSCs to prepare 3D ECM substrate, Passage 3 (P3) SDSCs were plated in 
plastic flasks with (Figure 2.1A) or without (Figure 2.1B) ECM coating at the same initial cell 
density for 10 days. At day 2, SDSCs grown on ECM were thinner and more spindle-shaped 
though both groups exhibited similar cell distribution. After 4 days, SDSCs plated on plastic 
flasks proliferated slowly; in contrast, SDSCs grown on ECM increased their cell number 
dramatically and reached confluence at day 5 [shown by phase contrast microscope (PCM)] 
and were arranged in order [shown by scanning electron microscope (SEM)]. At day 9, 
SDSCs plated on plastic flasks became wider and flattened (shown by PCM and SEM); in 
contrast, ECM-treated SDSCs overlapped in 3D format (shown by PCM) with tightly 
organized cell distribution (shown by SEM).  
 
To assess SDSC proliferation efficiency, P3 SDSCs were plated in plastic flasks either with 
(red line) or without (blue line) ECM coating for two continuing passages (Figure 2.1C). In the 
first passage (Passage 4, P4), ECM-treated SDSCs increased in cell number 17.5-fold 
compared with 6.5-fold for SDSCs plated on plastic flasks. For the last passage (Passage 5, 
P5), ECM-treated SDSCs increased in cell number 37.9-fold compared with 2.6-fold for 
SDSCs plated on plastic flasks. In total, SDSCs grown on ECM yielded a total cell number 
39.2-fold more than those incubated on plastic flasks after two-passage expansion. 
 
The SDSC-derived cell-free ECM exhibited a nanosized 3D fibrillar structure (the diameter for 
nanofibers was approximately 45.09 ± 8.83 nm) as revealed by SEM (Figure 2.1D). Once the 
ECM was detached from the flasks, ECM tension switched from “stressed” to “relaxed”, which 
is similar to a natural scaffold. Cartilage associated structural matrix proteins were assessed 
in SDSC-derived ECM by safranin O staining for sulfated glycosaminoglycans (GAGs) and 
immunostaining for collagens I, II, and X (Figure 2.1E), suggesting that the ECM was 




SDSCs grown on SDSC-derived ECM regain stem cell phenotypes 
We assessed the phenotype expression profiles from SDSCs with or without ECM treatment, 
including mesenchymal stem cell (MSC) surface markers (CD29, CD44, CD90, and CD105, 
Figure 2.2A) and a hematopoietic stem cell (HSC) marker (CD45) as well as a 
monocyte/macrophage marker (CD68) (Figure 2.2B). There was no CD45 or CD68 
detectable in SDSCs (Figure 2.2B), probably due to monocytes and macrophages having 
been removed by negative selection (8, 9). The percentage of CD90-positive-SDSCs at P3 
was 13.32% and increased dramatically to 66.15% at P4 and 79.87% at P5 when SDSCs 
were propagated on SDSC-derived ECM. When SDSCs were incubated on plastic flasks, 
however, only a small increase was observed (13.32% at P3 versus 18.03% at P4 versus 
28.15% at P5) (Figure 2.2C). CD90 percentage data were also consistent with CD90 mean 
fluorescent intensity (MFI) data, which was more intense in ECM-treated SDSCs than SDSCs 
plated on plastic flasks (30.46 versus 15.47 at P5) (Figure 2.2D). An important indicator of 
chondrogenic potential16, the CD90 data suggested that ECM-treated SDSCs may regain 
their capacity for differentiating toward chondrogenesis. Surprisingly, the percentage of 
CD29-positive-SDSCs was lower in treatment with ECM than that plated on plastic flasks 
(81.89% versus 96.52%) at P5 (Figure 2.2C), which was consistent with CD29 MFI tendency 
(29.48 versus 57.13) (Figure 2.2D). There was no obvious difference between the two 
treatments in CD105-positive-SDSCs (18.78% for ECM versus 19.71% for Plastic) and 
CD44-positive-SDSCs (99.31% for ECM versus 99.19% for Plastic) at P5 (Figure 2.2C). 
 
SDSCs propagated on ECM enhance their capacity toward chondrogenesis 
To define the potentially protective effects of SDSC-derived ECM on SDSC determination, 
pellets from passage 3 SDSCs grown on plastic flasks (P3.Plastic), passage 5 SDSCs grown 
on plastic flasks (P5.Plastic), or passage 5 SDSCs grown on ECM (P5.ECM) were incubated 
in chondrogenic medium for 14 days. Histochemical and immunohistochemical staining 
showed that SDSCs propagated on ECM displayed greatly enhanced chondrogenic potential 
(Figure 2.3A). At day 0, there was no detectable positive staining in pellets from all three 
groups. At day 7, sulfated GAGs were intensely stained in P5.ECM pellets compared with 
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much less staining in P3.Plastic pellets and were almost non-detectable in P5.Plastic pellets. 
At day 14, the staining trend for sulfated GAGs became more obvious with the most intense 
expression in P5.ECM pellets and the least expression in P5.Plastic pellets. Another key 
marker, collagen II, displayed a similar staining profile as sulfated GAGs. As an early marker 
of chondrogenesis, collagen I expression became weaker at days 7 and 14 in P5.ECM pellets 
in contrast with being more intense at day 14 in pellets from SDSCs plated on plastic flasks, 
suggesting that P5.ECM pellets undergo chondrogenic differentiation much earlier than those 
from either P5.Plastic or P3.Plastic. Interestingly, compared with SDSCs plated on plastic 
flasks, at day 14, ECM-treated SDSCs formed pellets surrounded with a unique “false 
membrane”, which stained positively for collagen II instead of sulfated GAGs and collagen I. 
There was no type X collagen detectable in pellets from any of the three groups. 
 
To quantify stem cell proliferation and chondrogenic differentiation at the protein level in a 
pellet culture system, we performed biochemical analyses for DNA content per pellet and 
ratio of GAG to DNA (chondrogenic index) as well as western blot for collagen II expression in 
cytoplasm (immature type) and extracellular matrix (mature type). After incubation in 
chondrogenic medium, DNA contents (Figure 2.3C) from both SDSC pellets at P5 were 
shown to decrease with time. However, after day 14, DNA content in pellets from SDSCs 
grown on ECM was maintained until day 14 (1.31 ± 0.07 µg per pellet) compared with a 
continuing drop in pellets from SDSCs plated on plastic flasks (1.03 ± 0.06 µg per pellet). The 
chondrogenic index (Figure 2.3D) increased in pellets from all three groups with time, except 
for P5.Plastic pellets between day 0 and day 7. At day 14, P5.ECM SDSCs yielded pellets 
with the highest chondrogenic index (39.37 ± 3.05) compared with P3.Plastic SDSCs (12.77 ± 
1.21), and P5.Plastic SDSCs yielded pellets that had the lowest chondrogenic index (5.19 ± 
1.11). At day 0, however, P5.Plastic SDSCs formed pellets with the highest chondrogenic 
index (1.05 ± 0.29) compared with P3.Plastic SDSCs (0.47 ± 0.11), while P5.ECM SDSCs 
formed pellets with the lowest chondrogenic index (0.21 ± 0.39), suggesting that SDSCs 
grown on ECM displayed not only less differentiation and highly proliferative stem cells but 
also tremendously enhanced chondrogenic potential. Our western blot data (Figure 2.3B) 
showed that collagen II protein was detectable in both cytoplasm and extracellular matrix of 
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P5.ECM pellets at days 7 and 14; however, collagen II was detectable only in the cytoplasm 
of P5.Plastic pellets at day 14, which is consistent with our above histology and biochemical 
data.  
 
We also quantitatively assessed chondrogenic marker gene expression in SDSC pellets. The 
mRNA profiles for collagen II (Figure 2.3E) and aggrecan (Figure 2.3F) were similar to the 
chondrogenic index at the protein level (Figure 2.3D). At day 7, collagen II mRNA in P5.ECM 
pellets was 160-fold higher than those from P3.Plastic, and 330-fold higher than those from 
P5.Plastic. At day 14, collagen II mRNA in P5.ECM pellets was 6-fold higher than those from 
P3.Plastic, and 95-fold higher than those from P5.Plastic. Sox 9 mRNA (Figure 2.3G) in 
P5.ECM pellets increased dramatically at day 7 and remained stable until day 14 compared 
with that at a low level in P5.Plastic pellets, probably accounting for the high expression of 
collagen II at day 7. In SDSC pellets from P5.ECM, collagen I mRNA (Figure 2.3H) transiently 
increased in the early phase and dropped to the lowest expression at day 14 compared with 
that in pellets of SDSCs plated on plastic flasks, indicating the maturity of ECM-treated SDSC 
pellets. In the meantime, the low level of collagen X mRNA (Figure 2.3I) suggested that ECM 
treatment could prevent SDSCs from hypertrophic differentiation.  
 
ECM does not retain SDSCs’ potential for adipogenic and osteogenic differentiation 
Under stimulation by the cocktail for adipogenic differentiation, P3.Plastic SDSCs exhibited 
more lipid vacuoles than those from either P5.Plastic or P5.ECM (Figure 2.4A). 
Adipose-specific genes, such as lipoprotein lipase (LPL, Figure 2.4B), peroxisome 
proliferator-activated receptor gamma (PPARγ, Figure 2.4C), and CCAAT/enhancer binding 
protein alpha (C/EBPα, Figure 2.4D) were quantified to assess their relative mRNA level. 
P3.Plastic SDSCs had the highest expression in all three adipogenic marker genes. P5.ECM 
SDSCs displayed higher (LPL mRNA and C/EBPα mRNA) or similar (PPARγ mRNA) 
expression of adipogenic marker genes compared with P5.Plastic SDSCs. Our quantitative 





Under stimulation by the cocktail for osteogenic differentiation, SDSCs underwent a change 
in morphology from spindle-shaped to cuboidal, and formed large nodules, which were 
observed with a PCM and were positive for Alizarin Red staining compared with negative 
controls (Figure 2.5A). This process was demonstrated by a significant increase in the 
expression of osteogenesis specific genes, including osteocalcin (OCN, Figure 2.5B), 
secreted phosphoprotein 1 (SPP1/osteopontin, Figure 2.5C) and collagen α1 (Col I, Figure 
2.5D). In all three osteogenic marker genes, P3.Plastic SDSCs had the highest expression 
while SDSCs from P5.ECM SDSCs had the lowest expression, indicating SDSCs grown on 






As a tissue-specific stem cell, SDSCs are promising MSCs for cartilage tissue engineering 
and regeneration. However, like other MSCs, SDSCs exhibit diminished proliferation and 
differentiation capacity when they are expanded on standard plastic flasks, which presents a 
number of problems in the clinical setting. In this study, we successfully engineered an in vitro 
3D stem cell niche using SDSC-derived ECM for improving SDSC proliferation while 
enhancing SDSC stemness toward chondrogenesis. In contrast, SDSCs grown on plastic 
flasks displayed diminished replicative capacity and increased random multi-differentiation 
properties. We also demonstrated that ECM-treated SDSCs do not regain their adipogenic 
and osteogenic potential, suggesting that an in vitro 3D stem cell niche facilitates SDSC 
propagation while allowing SDSCs to retain or even reinforce stemness for chondrogenic 
differentiation.  
 
The stem cell niche is a specialized microenvironment that helps sustain the stem cell pool 
within each tissue or organ system4. Typically, even with considerable variation in niche 
design, there are three key components in the niche concept: supporting niche cells, 
supporting ECM with growth-modulating factors, and the physical characteristics of the 
surrounding 3D structures.17,18 Of them, niche cells are normally a heterogeneous cell 
population and act to limit or control stem cell division. For instance, osteoblasts, the HSC 
niche cells, maintain HSC quiescence19 by producing osteopontin, which suppresses stem cell 
expansion20. Thus, in native tissue, a loss of niche cells may result in overproliferation of stem 
cells. Recently, growing evidence suggests that some stem cells can create their own 
microenvironments.21-23 Stem cells may play an important role in organizing and specifying 
their niche, and conversely the architectural design of a niche appears to be specifically 
tailored to suit the particular needs of its resident stem cells.24 Tissue-specific matrices clearly 
influence developmental lineage choices, and thus whole tissue and organ formation.25 In 
such a microenvironment, adult stem cells are expected to expand greatly while retaining their 
stemness for a tissue-specific lineage. In our study, SDSCs were used to create their own 
microenvironments without supporting niche cells. When partially differentiated SDSCs were 
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seeded in such a niche, the morphological transformation accelerated from wider, flattened 
cells to thinner, spindle-shaped cells, demonstrating that SDSC-derived ECM can restore 
SDSCs back to the original size and shape observed in their natural niche. After the initial lag, 
the cell numbers were dramatically expanded with cells growing in a 3D format. Phenotypic 
characterization demonstrated that SDSCs grown on ECM retained and possibly enhanced 
stem cell stemness. Differentiation data clearly indicated that SDSCs grown on SDSC-derived 
ECM regained stemness specifically toward the chondrogenic lineage but not toward 
adipogenic or osteogenic lineages, supporting reports that stem cell niches act to protect the 
self-renewing, undifferentiated state of the cells within and regulate the rate of production of 
committed, tissue-specific progenitors.26 Although the presence of niche cells in an in vivo 
niche act to limit or inhibit stem cell proliferation and maintain its multi-differentiation potential, 
our findings indicate that in an in vitro niche, the absence of niche cells may be associated with 
restoring stem cell proliferation and enhancing tissue-specific lineage differentiation capacity. 
The underlying mechanisms need further elucidation. 
 
The geometry, composition, and stiffness of the ECM surrounding cells residing in their niche 
also have major effects on cell signaling and behavior.27-29 While ECM is known to serve as a 
reservoir for growth factors and cytokines,25 our study demonstrated that SDSC-derived ECM 
is a 3D matrix consisting of nanostructured fibers with collagen I as one of the major structural 
proteins. ECM adhering on plastic flasks through fibronectin exhibited substrate tension, 
reported to up-regulate type I collagen polymerization.30 The presence of greater amounts of 
type I collagen may contribute to a physical architecture that transmits different mechanical 
cues to their resident cells.31 Because there is a growing body of evidence that cell 
attachment, proliferation, and migration will be enhanced when cells grow in a more 
physiologically similar environment as opposed to standard 2D tissue culture substrates,27,31,32 
creating such an in vitro functional niche becomes a vital step to restoring the full potential of 
stem cells for therapeutic applications and may also have important implications for research 
regarding niche-related signal transduction. For example, signaling by morphogens, 
particularly through the Wnt, Notch and Hedgehog pathways, is known to be important for the 
self-renewal of many adult stem cell types.33-35 With further study in the context of stem 
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cell-derived ECM, functional in vitro niches, may implicate these signals in even more 
complex roles. Although most proliferative signals seem to concurrently stimulate the 
commitment to differentiation,36 our study suggests that an in vitro stem cell niche can 
encourage stem cell self-renewal and prevent both undesired differentiations and exhaustion, 
consequently improving the potential of the cell population as a whole. Communication within 
the niche is essential for the maintenance of proper stem cell function and for determining the 
rate of stem cell self-renewal. Further studies are needed to determine which of these ECM 
molecules are crucial for the maintenance of the undifferentiated stem cell phenotype, the 
underlying tissue-specific stem cell signalling pathways, and the mechanical interactions 
between the ECM and seeded cells. This in vitro stem cell niche provides a promising and 
reliable approach in re-programming stem cells for either investigational or therapeutic 
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Figure 2.1. Effect of SDSC-derived ECM on SDSC morphology and proliferation. (A) 
Passage 4 SDSCs grown on SDSC-derived ECM at days 2, 5, and 9.  (B) Passage 4 
SDSCs grown on plastic flasks at days 2, 5, and 9. Phase contrast microscope (PCM) and 
scanning electron microscope (SEM) were used to evaluate SDSC morphology properties. (C) 
Cell proliferation from Passage 3 SDSCs grown in plastic flasks either with or without ECM 
coating for two consecutive passages. (D) SDSC-derived ECM attaching on plastic flasks 
(“stressed” ECM) or detaching from plastic flasks (“relaxed” ECM). (E) SDSC-derived ECM 
was stained with Safranin O for sulfated GAGs, and immunostained for chondrogenic matrix 
(collagens I, II, and X). All scale bars are 200 μm. 
 
Figure 2.2. Quantitative flow cytometry analysis of typical cell surface antigens (red color) 
from MSC (CD29, CD44, CD90, CD105) (A) and HSC (CD45) as well as 
monocyte/macrophage (CD68) (B) with isotype-specific control. The percentage of positive 
cells (C) and mean fluorescent intensity (MFI) (D) were also shown for MSC phenotype 
changes in SDSCs grown in plastic flasks with or without ECM coating for two consecutive 
passages.    
 
Figure 2.3. Distinctively chondrogenic capacity from SDSCs grown on SDSC-derived ECM. 
The pellets from P3 and P5 SDSCs were incubated in chondrogenic medium for 14 days. (A) 
Alcian blue and Safranin O staining were used to detect sulfated GAGs, and immunostaining 
was used to detect collagens I, II, and X. The scale bar is 800 µm. (B) Western blot was used 
to detect collagen II protein either in the pellet matrix (mature type) or in cytoplasm (immature 
type) of differentiated SDSCs. Three independent experiments were performed. Biochemical 
analyses were used to detect DNA content per pellet (C) and ratio of GAG to DNA (D). 
TaqMan real time PCR was used to quantitatively assess chondrogenic markers [collagen II 
(E), aggrecan (F), Sox 9 (G), collagen I (H), and collagen X (I)] at the mRNA level. Significant 
differences are indicated as follows: * = p < 0.05; ** = p < 0.01; and *** = p < 0.001. Data are 




Figure 2.4. Adipogenic differentiation of SDSCs. The SDSCs from P3.Plastic, P5.Plastic or 
P5.ECM were incubated in adipogenic induction medium for 14 days. PCM was used to 
detect adipose vacuoles, which was also confirmed by Oil Red O staining (A). The SDSCs 
incubated in DMEM with 10% FBS served as a control and are referred to as either a control 
for PCM (“P”-Control) or a control for Oil Red O (“O”-Control). All scale bars are 200 μm. 
TaqMan real time PCR was also used to quantitatively assess relative gene expression of 
adipogenic markers [LPL (B), PPARγ (C), and C/EBPα (D)]. Significant differences are 
indicated as follows: * = p < 0.05 and ** = p < 0.01. Data are shown as average ± SD for n = 5 
in real time PCR. 
 
Figure 2.5. Osteogenic differentiation of SDSCs. The SDSCs from P3.Plastic, P5.Plastic or 
P5.ECM were incubated in osteogenic induction medium for 14 days. PCM was used to 
detect bone nodules, which was also confirmed by Alizarin Red staining (A). The SDSCs 
incubated in DMEM with 10% FBS served as a control and are referred to as either a control 
for PCM (“P”-Control) or a control for Alizarin Red (“A”-Control). All scale bars are 200 μm. 
TaqMan real time PCR was also used to quantitatively assess relative gene expression of 
osteogenic markers [OCN (B), SPP1 (C), and Collagen I (D)]. Significant differences are 
indicated as follows: * = p < 0.05; ** = p < 0.01; and *** = p < 0.001. Data are shown as average 




Table 2.1. TaqMan® Customized Porcine Marker Gene Primers and Probes 
 






X60107 Reverse CACTGGCTCTCTGCATCCA 
Probe CTGACCGGGCGACCTG 
Col I α1 
Forward CCGTGCCCTGCCAGATC 
AF201723 Reverse CAGTTCTTGATTTCGTCGCAGATC 
Probe TCGCACAACACATTGC 
Col II α1 
Forward TCCTGGCCTCGTGGGT 
AF201724 Reverse GGGATCCGGGAGAGCCA 
Probe CTCCCCTGGGAAACC 
Col X α1 
Forward GGCCCGGCAGGTCATC 





























X16575 Reverse GTCTCCTGACTGTCCTTCTCTTG 
Probe CCCAGCGCCTGCACG 
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Objective.   To improve the proliferative capacity and chondrogenic differentiation potential 
of adipose stem cells (ASCs) by large-scale ex vivo expansion on either ASC- or 
synovium-derived stem cell (SDSC)-derived extracellular matrix (ECM) followed by 
differentiation in a serum-free chondrogenic medium.  
Methods.   ASCs isolated from porcine infrapatellar fat pad were expanded in plastic flasks 
coated with ECM deposited by either ASCs or SDSCs for two passages. ASCs grown in 
non-coated flasks served as a control. The expanded ASCs were evaluated for cell 
proliferation and intracellular reactive oxygen species (ROS). The cells were centrifuged to 
form pellets and cultured in a serum-free chondrogenic medium with either 10 ng/mL 
transforming growth factor beta 3 (TGF-β3) or 10 ng/mL TGF-β3 combined with 10 ng/mL 
bone morphogenetic protein 6 (BMP-6) for 14 days. The expanded ASCs were also 
evaluated for their chondrogenic differentiation capacity using histology, 
immunohistochemistry, biochemistry, and real-time PCR. 
Results. The cell number yielded on ECM expansion did not show significant difference in 
deposition between ASCs and SDSCs and was 6 to 10 times that grown on conventional 
plastic flasks. ECM-expanded ASCs exhibited a lower ROS level compared to those grown 
on non-coated flasks. Our histology data showed that typical chondrogenic markers, 
including type II collagen and glycosaminoglycans, were intensively distributed in the pellets 
from ECM-expanded ASCs instead of those from flask-grown cells. Our biochemical analysis 
data indicated that ASCs expanded on ECM, either from ASCs or SDSCs, exhibited a similar 
chondrogenic index (GAG/DNA), which was significantly higher than that from ASCs grown 
on plastic flasks. The combination of TGF-β3 and BMP-6 increased 36% more in ASC 
chondrogenic index than the treatment with TGF-β3 alone. Real-time PCR was consistent 
with the above data. Interestingly, ECM pretreatment also decreased expanded ASC 
hypertrophy (ALP and MMP13). ECM deposited by either ASCs or SDSCs did not exhibit 
enhanced adipogenic differentiation of ASCs. 
Conclusion.   Ex vivo expansion of ASCs on ECM, deposited by either ASCs or SDSCs, had 
a dramatic increase in cell proliferation and chondrogenic differentiation capacity. The 
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expanded cells did not display a similar increase in adipogenesis even on ECM deposited by 
ASCs. The supplementation of BMP-6 enhanced TGF-β3-induced ASC chondrogenesis 
while inhibiting concomitant hypertrophy. The sequential application of ECM for cell 
expansion and combined TGF-β3 with BMP-6 for chondrogenic differentiation may be a 





Articular cartilage is an avascular tissue with limited capacity for self-repair. Current treatment 
options for cartilage injuries vary greatly in success rates. Autologous chondrocyte 
transplantation (ACT) has shown promising results in early clinical studies [1] but, recently, 
randomized trials indicate little difference in the efficacy of this procedure compared with that 
of inducing subchondral bone microfracture [2]. This approach has also been associated with 
significant donor-site morbidity and the initiation of osteoarthritic changes in the joint [3], 
suggesting the need for alternative cell sources for cell-based cartilage repair.  
 
An emerging body of literature suggests that the adult stem cell is a promising cell source for 
cartilage repair due to its proliferation and multilineage differentiation capacity. Of the stem 
cells, bone marrow stromal cells (BMSCs) and adipose stem cells (ASCs) are two typical 
stromal populations isolated from a fatty compartment with similar properties in terms of 
immunogenicity, growth kinetics, cell senescence, gene transduction efficiency, and surface 
marker expression [4-6]. Despite a better chondrogenic potential, BMSCs also showed a 
stronger propensity than ASCs toward a hypertrophic chondrocyte phenotype [7-10]. Compared 
to bone marrow with one stem cell in one hundred thousand cell population, the average yield 
from adipose tissue is in the range of 200,000 – 290,000 cells/g of tissue [11], making adipose 
tissue an abundant and accessible source of stem cells for cell-based therapy.  
 
Despite easy access and abundance, the chondrogenic potential of ASCs from subcutaneous 
adipose tissue was much weaker than that of BMSCs [12,13]. In contrast, ASCs from the 
infrapatellar fat pad (IPFP) exhibited higher chondrogenic capacity [14,15] and surface zone 
protein (SZP)-producing phenotypes [16]. Like synovial tissue [17], the IPFP also has the 
potential to self-regenerate after removal from joints [18] and can be obtained arthroscopically 
by the orthopaedic surgeon with minimal invasion and without causing complications at the 
donor site. However, synovial tissue in patients with osteoarthritis may be heterogeneous due 
to fibrotic or hemorrhagic changes or inflammation [19]; in contrast, inflammatory changes in 
IPFP of the osteoarthritic knee were less frequent. Therefore, the IPFP may be a better cell 
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source for superficial zone cartilage tissue engineering for osteoarthritic patients.  
 
The goal of this study was to find an ex vivo expansion approach for the reprogramming of 
IPFP-derived ASCs toward chondrogenesis. Our recent study suggested that extracellular 
matrix (ECM) deposited by synovium-derived stem cells (SDSCs) enhanced the seeded 
SDSC proliferation and chondrogenic differentiation capacity but not adipogenic and 
osteogenic differentiation ability [20]. These results indicate that ECM deposited by a 
tissue-specific stem cell can provide an in vitro 3D microenvironment for stem cell 
rejuvenation toward chondrogenesis. In this study, we evaluated the efficiency of 
IPFP-derived ASCs expanded by ECM, deposited either from ASCs or SDSCs, in order to 
identify whether the chondrogenic capacity of ASCs will be enhanced after expansion on 
ECM and whether ECM deposited by different cell types will have a different reprogramming 
effect. Our study also evaluated whether or not bone morphogenetic protein 6 (BMP-6) would 
enhance transforming growth factor beta3 (TGF-β3)-induced chondrogenic differentiation but 
inhibit hypertrophy.  
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MATERIALS AND METHODS 
 
Isolation and culture of ASCs and SDSCs 
The protocol was approved by the West Virginia University Animal Care and Use Committee. 
The IPFP and synovial membrane were harvested from both knees of two 3-month-old 
minipigs (Marshall BioResources, North Rose, NY) and finely minced into pieces with scapel 
blades. The IPFP tissue was digested in 0.1% collagenase P (Roche, Indianapolis, IN) at 37ºC 
for 1 h to release ASCs. The synovial membrane was digested at 37ºC in 0.1% trypsin (Roche) 
for 30 min and then in 0.1% collagenase P (Roche) for 2 h. Both released cells were filtered 
through 70-μm nylon filter (BD Falcon, Bedford, MA) and plated at 3000 cells/cm2 in complete 
medium [α-minimum essential medium (α-MEM, Invitrogen, Carlsbad, CA) containing 10% 
fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA), 100 U/ml penicillin, 100 
µg/ml streptomycin and 0.25 μg/ml fungizone (Invitrogen)] at 37ºC in humidified 5% CO2 and 
21% O2 incubator. Nonadherent cells were removed by medium change every two days. For 
negative isolation of SDSCs from primary cultures [21], a cell suspension (107 cells/mL) was 
incubated with 5 × 107/mL Dynabeads® M-450 CD14 containing a monoclonal antibody 
specific for macrophages (Dynal Biotech, Oslo, Norway) at 4ºC for 1 h. The conjugated cells 
and the unbound Dynabeads® were collected using the Dynal Magnetic Particle Concentrator® 
(Dynal Biotech), and the depleted supernatant with SDSCs was saved for further passaging. 
 
Preparation of ASC-ECM and SDSC-ECM 
The procedure of obtaining cell-free ECM was described in our previous study [20]. Briefly, 75 
cm2 of plastic flasks and 6-well plates were pretreated with 0.2% gelatin solution (Sigma, St. 
Louis, MO) for 1 h at 37̊C, followed by 1% glutaraldehyde (Sigma) and 1 M ethanolamine 
(Sigma) sequentially for 30 min each at room temperature. Passage 3 ASCs and SDSCs 
were seeded on pretreated plastic flasks and 6-well plates at 3000 cells/cm2 in complete 
medium for 7 days. When cells reached 90% confluence, culture medium was supplemented 
with 50 μg/mL L-ascorbic acid phosphate (Wako Chemicals USA Inc., Richmond, VA) for an 
additional 8 days. The ECMs deposited by ASCs and SDSCs were incubated with 0.5% 
Triton X-100 (Sigma) containing 20 mM ammonium hydroxide (Sargent-Welch, Skokie, IL) at 
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37ºC for 5 min.  
 
Culture of ASCs on Plastic and ECM 
Passage 1 ASCs were cultured in complete medium for two passages in three conditions: 
plastic flasks (Plastic), flasks coated with ASC-derived ECM (AECM), and flasks coated with 
SDSC-derived ECM (SECM). The culture period for each passage was seven days and the 
medium was changed every 3 days. At each passage, cell number was counted using a 
counting hemacytometer (Hausser Scientific, Horsham, PA) for cell proliferative rate. 
 
Measurement of intracellular reactive oxygen species (ROS) 
Intracellular ROS generation was measured with 2′,7′-dichlorofluorescein-diacetate 
(DCFH-DA) (Sigma). In brief, 0.2 × 106 of the detached ASCs were washed with PBS and 
incubated in 10 μM DCFH-DA at 37ºC for 10 min. After washing twice with PBS, the 
fluorescence from 2′,7′ -dichlorofluorescein (DCF) was analyzed by a dual-laser 
fluorescence-activated cell sorting (FACS) Calibur CytoFluorimeter (BD Biosciences
 
, Bedford, 
MA) using FCS Express Software Package (De Novo Software, Los Angeles, CA) and 20000 
events of each sample were analyzed. 
Chondrogenic differentiation of the expanded ASCs 
3 × 105 of ASCs at passage 1 and passage 3 cultured on Plastic, AECM and SECM were 
centrifuged at 500 g for 5 min to form a pellet in a 15-ml polypropylene tube. After 24 h of 
incubation, the pellets were incubated in a serum-free chondrogenic medium [high-glucose 
DMEM, 40 µg/ml proline (Sigma), 100 nM dexamethasone (Sigma), 100 U/ml penicillin, 100 
µg/ml streptomycin, 0.1 mM ascorbic acid-2-phosphate and ITS™ Premix (6.25 µg/mL insulin, 
6.25 µg/mL transferrin, 6.25 µg/mL selenous acid, 5.35 µg/mL linoleic acid and 1.25 µg/mL 
bovine serum albumin, from BD Biosciences] with the supplementation of 10 ng/ml of TGF-β3 
(PeproTech Inc., Rocky Hill, NJ) alone or 10 ng/mL of TGF-β3 combined with 10 ng/ml of 
BMP-6 (PeproTech Inc). The pellets were collected at days 0, 7 and 14 for histology, 




Adipogenic differentiation of the expanded ASCs  
Passage 3 ASCs were cultured on Plastic, AECM, or SECM in 6-well plates until 95% 
confluence, and the complete medium was switched to adipogenic differentiation medium 
[low glucose DMEM (Invitrogen), 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 10-6 
M dexamethasone, 0.5 mM isobutyl-1-methy xanthine (Sigma), 100 μM indomethacin (Sigma) 
and 10 μg/mL insulin (Sigma)] for an additional 14 days. The cultured cells were fixed in 4% 
paraformaldehyde (Sigma), stained with Oil Red O solution (Diagnostic Biosystems, 
Pleasanton, CA) and counterstained with hematoxylin (Vector Laboratories Inc., Burlingame, 
CA). The expanded cells were also collected for quantitative evaluation of adipogenic gene 
expression using real-time PCR. 
 
Histology and Immunohistochemistry 
The pellets (n = 2) were fixed at 4˚C in 4% paraformaldehyde, embedded in paraffin blocks 
and cut into 5-μm thick sections. Safranin O solution (Sigma) was used to stain sulfated 
glycosaminoglycans (GAGs). For immunohistochemical analysis, the sections were 
immunolabeled with primary antibodies against collagen II (II-II6B3, DSHB, Iowa City, IA), 
collagen I (Abcam, Cambridge, MA), and collagen X (Sigma), followed by the secondary 
antibody of biotinylated horse anti-mouse IgG (Vector). Immunoactivity was detected using 
Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a substrate.   
 
Biochemical analysis  
The pellets (n = 5) were digested for 4 h at 60ºC with 125 μg/mL papain in PBE buffer (100 
mmol/L phosphate, 10 mmol/L EDTA, pH 6.5) containing 10 mmol/L cysteine, by using 100 μL 
enzyme per sample. DNA amount in the papain digestion was measured using the QuantiTTM 
PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor® Series 4000 (Applied Biosystems, 
Foster City, CA). GAG was measured using dimethylmethylene blue dye and a SpectronicTM 
BioMateTM 3 Spectrophotometer (Thermo Scientific, Milford, MA) with bovine chondroitin 
sulfate (Sigma) as a standard. 
 
Real-time polymerase chain reaction (Real-time PCR) 
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The total mRNA from pellets (n = 4) was extracted using TRIzol® (Invitrogen) and 1 µg of 
mRNA was converted to cDNA with a High-Capacity cDNA Archive Kit (Applied Biosystems). 
Chondrogenic marker genes [aggrecan, types I and II collagen, and SRY (sex determining 
region Y)-box 9 (Sox9)], hypertrophy marker genes [type X collagen and matrix 
metalloproteinase 13 (MMP13)], and adipogenic marker genes [lipoprotein lipase (LPL), 
peroxisome proliferator activated receptor γ (PPARγ), and CCAAT enhancer binding protein 
α (C/EBPα)] were customized by Applied Biosystems as part of the Custom TaqMan® Gene 
Expression Assays. Eukaryotic 18S rRNA (Assay ID HS99999901_s1 ABI) was carried out 
as the endogenous control gene. Real-time PCR was performed with the iCycler iQTM Multi 
Color RT-PCR Detection and calculated by computer software (Perkin-Elmer, Waltham, MA). 




The Kruskal-Wallis test was used to test for significant differences among all groups and the 
Mann-Whitney U test was used for pairwise comparison. All the statistical analysis was 
performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less than 






ECM expansion enhanced ASC proliferation and sustained stem cell morphology  
(Figure 3.1A) Passage 1 ASCs were expanded on Plastic, AECM, or SECM for two passages. 
In regard to cell morphology, ASCs grown on Plastic appeared large and flattened while 
ASCs plated on ECM became smaller and spindle-like and overlapped with time in a 3D 
format. Intriguingly, ASCs grown on AECM or SECM exhibited similar cell morphology and 
underwent directional migration along the ECM fibrils whereas the cells on Plastic grew in a 
random direction. (Figure 3.1B) During a seven-day incubation, the proliferative rate of ASCs 
on Plastic dropped with each passage, with a 4.53-fold increase at passage 2 and a 7.47-fold 
increase at passage 3 compared to a 15.47-fold increase at passage 1. On the contrary, 
ASCs plated on AECM and SECM exhibited a robust and stable proliferative ability, with a 
43.73-fold increase at passage 2 and a 44.8-fold increase at passage 3 for ASCs expanded 
on AECM and a 43.73-fold increase at passage 2 and a 48.8-fold increase at passage 3 for 
ASCs expanded on SECM. There was no significant difference in the cell yield number in two 
different ECMs. 
 
(Figure 3.1C) In order to determine whether ECM expansion could decrease cell stress, we 
examined the intracellular levels of ROS accumulation in ASCs cultured in Plastic, AECM, or 
SECM using flow cytometry. The ASCs cultured in Plastic indeed showed a higher level of 
DCF fluorescence compared with those expanded in AECM or SECM. (Figure 3.1D) The 
mean fluorescent intensity (MFI) of ROS in ASCs in Plastic was 148 ± 6, which was 2.4-fold 
that in AECM and 3.5-fold that in SECM, indicating that ECM effectively reduced the 
generation or accumulation of the intracellular ROS in ASCs. 
 
ECM expansion enhanced ASC chondrogenic capacity  
After expansion on Plastic, AECM, and SECM, ASCs were cultured in a serum-free pellet 
system supplemented with 10 ng/mL of TGF-β3 to evaluate the effect of expansion approach 
on ASC chondrogenic capacity. (Figure 3.2) Compared to nondetectable staining at day 0, 
ASC pellets from P1.Plastic or P3.Plastic were barely positive for sulfated GAGs and type II 
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collagen at day 7 despite a gradually positive staining on the periphery of pellets at day 14. 
The pellets from P3.AECM and P3.SECM, however, were intensively positive for sulfated 
GAGs and type II collagen even at day 7 and dramatically improved in range and density after 
incubation in chondrogenic medium for 14 days.  
 
(Figure 3.3) At the protein level, ASCs from P3.Plastic yielded pellets with a lower 
chondrogenic index (GAG/DNA) compared with that from P1.Plastic. In contrast, ASCs from 
P3.AECM and P3.SECM yielded pellets with not only a sustained cell number but also a 
greatly enhanced chondrogenic index. There was no significant difference in chondrogenic 
index for ASCs expanded on AECM or SECM. (Figure 3.4) At the mRNA level, ASCs from 
P3.AECM or P3.SECM yielded pellets with higher mRNA levels in type II collagen (at days 7 
and 14), aggrecan (at days 7 and 14), and Sox9 (at day 7) than that from P1.Plastic and 
P3.Plastic. Similar to protein expression, there was no significant difference in the above 
chondrogenic marker genes for ASCs expanded on AECM or SECM.  
 
BMP-6 increased TGF-β3-induced ASC chondrogenic differentiation but inhibited 
hypertrophy 
(Figure 3.2) Compared to the expanded ASCs on ECM, the combined treatment with TGF-β3 
and BMP-6 yielded pellets from Plastic-expanded ASCs with more intense sulfated GAGs 
and type II collagen than the treatment with TGF-β3 alone. Intriguingly, the expanded ASCs 
on ECM yielded pellets with less type I collagen stain when the pellets were treated with 
TGF-β3 combined with BMP-6 than that with TGF-β3 alone. No type X collagen was 
detectable in either Plastic- or ECM-expanded ASCs. (data not shown)  
(Figure 3.3) The combination of TGF-β3 with BMP-6 maintained cell number in ASC pellets 
compared to treatment with TGF-β3 alone, especially after a 14-day incubation. More 
importantly, the combined treatment significantly increased ASC chondrogenic index in all 
groups except P3.Plastic compared to treatment with TGF-β3 alone. (Figure 3.4&3.5) 
Consistent with histology data, the combined treatment significantly decreased mRNA levels 




ECM expansion delayed the decrease of ASC adipogenic capacity 
(Figure 3.6A) ASCs from P1.Plastic exhibited more Oil Red O stained spots than the other 
three groups. (Figure 3.6B) As an early marker gene of adipogenesis, the level of LPL mRNA 
was the highest in P1.Plastic with only 5.6% in P3.Plastic, 18.7% in P3.AECM, and 27.5% in 
P3.SECM. (Figure 3.6C,D) PPARγ and C/EBPα are the transcription factors involved in 





ASCs are increasingly becoming a promising stem cell source for the treatment of cartilage 
defects. However, it is still a big challenge to establish an in vitro microenvironment for 
reprogramming autologous ASCs toward chondrogenic differentiation. In this study, we found 
that ECM enhanced ASC proliferation, maintained stem cell morphology and lowered ASC 
intracellular ROS level; ECM-expanded ASCs exhibited a decreased level of intracellular 
ROS; and the expansion on ECM enhanced ASC chondrogenic differentiation capacity. 
Interestingly, there was no significant difference in ASC proliferation and differentiation using 
two different ECMs deposited by either ASCs or SDSCs. Our findings also suggested that 
BMP-6 increased TGF-β3-induced ASC chondrogenic differentiation but inhibited 
concomitant hypertrophy. Surprisingly, we did not find that the expanded ASCs exhibited an 
enhanced adipogenic capacity, regardless of expansion on ECM deposited by ASCs or 
SDSCs.  
 
Plenty of stem cells are needed for stem cell-based tissue engineering and regeneration. 
Adult tissues contain unique local niches with tissue-specific stem cells; however, ex vivo 
expansion on conventional plastic flasks results in stem cell senescence, indicated by the 
loss of proliferation and differentiation capacity. In this study, we found that ECM expansion 
could decrease ASC intracellular ROS level, indicating that ROS associated cell stress may 
play a major role in monolayer culture on plastic flasks; this could be prevented by expansion 
on 3D ECM. Due to the 3D growth format on ECM, expanded ASCs grew much faster and 
were more orderly than 2D growth on plastic flasks. Moreover, ECM deposited by stem cells, 
either SDSCs or ASCs, could maintain the expanded ASC stem cell characteristics (small 
with spindle-shape). The connection between stem cell size and function is consistent with 
bone marrow derived MSCs, which have also been shown to possess more “stemness” when 
the MSCs are small and rapidly dividing [22]. This result is also in agreement with reports from 
us and other investigators. We found ECM deposited by SDSCs could dramatically enhance 
seeded SDSC proliferation [20]. Chen et al. demonstrated that ECM deposited by BMSCs 
enhanced plated BMSC expansion [23]. These cell-derived matrices appear to more closely 
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approximate native tissue [24] rather than the ‘‘reconstituted’’ matrices (such as 3D pure 
collagen gels and Matrigel matrices [25]). As noted previously [24,26,27], cells within this in 
vivo-like 3D environment developed an elongated shape and had reduced lamella, confined 
predominantly to one of the cell ends. In contrast, control fibroblasts grown on 
fibronectin-coated surfaces had a flattened and triangular shape with an increased number of 
peripheral lamellae. No significant difference was observed in ASC proliferation after 
expansion on ECM deposited by either ASCs or SDSCs, indicating that the stimulatory effect 
of the matrix is most probably due to its three-dimensionality, rather than to its composition, as 
flattening of the matrix by mechanical force abolishes the formation of 3D matrix adhesions 
and ERK-stimulated cell proliferation [24,28].  
 
In our previous study, expanded SDSCs on SDSC-derived ECM exhibited a robust 
chondrogenic differentiation potential. Since SDSCs are considered a tissue-specific stem 
cell for chondrogenesis, we proposed that the chondrogenic potential of ASCs would be 
improved after expansion on ECM deposited by SDSCs instead of ASCs while the adipogenic 
potential of ASCs would be improved after expansion on ECM deposited by ASCs. 
Surprisingly, ASCs expanded on ECM deposited from either SDSCs or ASCs developed a 
similar enhanced chondrogenic differentiation capacity, indicating that 3D ECM may induce 
sustained activation of the extracellular signal-activated kinase 1/2 (ERK1/2) via Src/Ras/Raf 
signaling pathway [26] and the high level of phosphorylated ERK1/2 could be responsible for 
the improved chondrogenic differentiation potential of ASCs. This signal transduction 
pathway needs to be further demonstrated.  
 
Our study also found that supplementation of BMP-6 enhanced TGF-β-induced ASC 
chondrogenesis but inhibit hypertrophy, which is in agreement with reports from other 
investigators [29,30]. Although TGF-β can inhibit chondrocyte hypertrophy [31], perhaps the 
chondrogenic differentiation potential of ASCs treated by ECM was very robust, and the level 
of TGF-β3 used in this study was insufficient to completely stop further development into 
hypertrophy. Despite the fact that BMP-6 combined with TGF-β results in 
hypertrophy/endochondral ossification pathway in BMSCs [32,33,34], BMP-6 alone is a strong 
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chondrogenic inducer and also acts as a hypertrophy inhibitor in ASCs [29]. This was in 
agreement with our results that supplementation of BMP-6 enhanced ASC chondrogenic but 
inhibited hypertrophic differentiation. The underlying mechanism may be associated with the 
reduced expression of BMP-2, -4, and -6 mRNA and no expression of TGF-β-receptor-1 
protein in ASCs, which BMSCs have. BMP-6 treatment induced TGFβ-receptor-1 expression 
and combined application of TGF-β and BMP-6 eliminated the reduced chondrogenic 
potential of ASCs inducing a gene expression profile similar to differentiated BMSCs. [30] 
 
The decreased adipogenic and osteogenic differentiation (data not shown) of ASCs culturing 
on ASC- and SDSC-derived ECMs could be correlated with the effect of suppressing 
“spontaneous” differentiation. ECM was proven to modulate the activity of growth factors, 
interact with cell surface receptors to prevent activation, and absorb growth factors from 
serum [23,35-37]. Expansion of MSCs on ECM not only increased the proliferative rate but also 
suppressed “spontaneous” differentiation and maintained stem cell properties. However, the 
molecular mechanism that ECM used to interact with cells and improve the proliferation and 
chondrogenic potential still needs to be investigated.  
 
In summary, our study proved that the utilization of ECM on ASC ex vivo expansion was able 
to dramatically increase the cell proliferative rate and improve the chondrogenic 
differentiation potential. The combination of TGF-β3 and BMP-6 promoted chondrogenic 
induction but suppress hypertrophic gene expression. The large-scale cell number of ADSCs 
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Figure 3.1. The morphology and proliferative rate of ASCs grown in plastic flasks (Plastic), 
AECM-coated flasks (AECM), or SECM-coated flasks (SECM). (A) Representative phase 
contrast images of passage 2 ASCs; (B) the cell numbers of ASCs expanded for two 
passages. Data are shown as average ± SD for n = 4. * p < 0.05 compared with ASCs 
cultured in Plastic at the same passage. # p < 0.05 compared with ASCs at passage 1. (C) 
Flow cytometry was used to measure intracellular ROS level in ASCs after expansion in 
Plastic, AECM, or SECM. (D) The mean fluorescence intensity (MFI) was for the intracellular 
level of ROS in ASCs. Data are shown as average ± SD for n = 4. $ p < 0.05 compared with 
ASCs cultured in AECM in the same passage.  
 
Figure 3.2. Histology and immunohistochemistry of ASC-pellets after 14-day chondrogenic 
induction in a serum-free chondrogenic medium (CM) supplemented with 10 ng/mL TGF-β3 
or 10 ng/mL TGF-β3 combined with 10 ng/mL BMP-6. ASCs from passage 1 in Plastic 
(P1.Plastic) were expanded for two passages in Plastic (P3.Plastic), AECM (P3.AECM), or 
SECM (P3.SECM). Safranin O staining (Saf.O) was used to detect sulfated 
glycosaminoglycans (GAGs), and immunohistochemical staining (IHC) was for type I (COL I) 
and type II (COL II) collagen. The scale bar is 800 µm. 
 
Figure 3.3. Biochemical analysis for GAG (A) and DNA content (B) in ASC-pellets after a 
14-day chondrogenic induction in a serum-free chondrogenic medium supplemented with 10 
ng/mL TGF-β3 (T) or 10 ng/mL TGF-β3 combined with 10 ng/mL BMP-6 (T+B). ASCs from 
passage 1 in Plastic (P1.Plastic) were expanded for two passages in Plastic (P3.Plastic), 
AECM (P3.AECM), or SECM (P3.SECM). The rate of GAG to DNA (C) was used to represent 
chondrogenic index. Data are shown as average ± SD for n = 5. * p < 0.05 compared with 
ASC-pellets incubated in a medium with TGF-β3 alone. # p < 0.05 compared with ASC-pellets 
from P3.Plastic incubated in the same medium. $ p < 0.05 compared in the pellets from 




Figure 3.4. TaqMan real-time PCR for the evaluation of chondrogenic markers (Col I, Col II, 
aggrecan, and Sox9) at mRNA levels in ASC-pellets after a 14-day chondrogenic induction in 
a serum-free chondrogenic medium supplemented with 10 ng/mL TGF-β3 (T) or 10 ng/mL 
TGF-β3 combined with 10 ng/mL BMP-6 (T+B). ASCs from passage 1 in Plastic (P1.Plastic) 
were expanded for two passages in Plastic (P3.Plastic), AECM (P3.AECM), or SECM 
(P3.SECM). 18S rRNA was used as an internal control. * p < 0.05 compared with ASC-pellets 
incubated in a medium with TGF-β3 alone at the same time point. # p < 0.05 compared with 
ASC-pellets incubated in the same medium. $ p < 0.05 compared in the pellets from 
expanded ASCs in AECM or SECM in the same medium.  
 
Figure 3.5. TaqMan real-time PCR for the evaluation of hypertrophic markers (Col X and 
MMP-13) at mRNA levels in ASC-pellets after 14-day chondrogenic induction in a serum-free 
chondrogenic medium supplemented with 10 ng/mL TGF-β3 (T) or 10 ng/mL TGF-β3 
combined with 10 ng/mL BMP-6 (T+B). ASCs from passage 1 in Plastic (P1.Plastic) were 
expanded for two passages in Plastic (P3.Plastic), AECM (P3.AECM), or SECM (P3.SECM). 
18S rRNA was used as an internal control. * p < 0.05 compared with ASC-pellets incubated in 
a medium with TGF-β3 alone. # p < 0.05 compared with ASC-pellets incubated in the same 
medium. $ P < 0.05 compared in the pellets from expanded ASCs in AECM or SECM in the 
same medium.  
 
Figure 3.6. Adipogenic differentiation of ASCs was evaluated after expansion in Plastic, 
AECM, or SECM for two passages and incubation in adipogenic medium for 14 days. (A) Oil 
Red O staining for oil drops produced by adipocytes with hematoxylin as a counterstain. (B) 
TaqMan real-time PCR for the evaluation of adipogenic genes (LPL, PPARγ and C/EBPα). 
18S RNA was used as an internal control. Lower case letters (i.e. a, b, and c) indicate the 
results of one-way analysis of variance (ANOVA) at p < 0.05. Groups with a letter in common 
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Articular cartilage has a limited capacity for self heal once damaged. Autologous chondrocyte 
transplantation is a promising approach for cartilage defect repair. However, in vitro 
expansion can cause chondrocyte dedifferentiation. Our aim is to assess the rejuvenation 
effect of extracellular matrix (ECM) deposited by synovium-derived stem cells (SDSCs) on 
articular chondrocyte expansion and maintenance of differentiation status and 
redifferentiation capacity. Passage 0 (P0) porcine articular chondrocytes were expanded for 
six passages on plastic flasks (Plastic), SDSC-derived ECM (ECM), or substrate switching 
from either Plastic to ECM (PtoE) or ECM to Plastic (EtoP). Cell morphology, gene 
expression profiles and immunophenotypes at each passage were used to characterize 
differentiation status of expanded cells. Expanded chondrocytes at P0, P2 and P6 were 
assessed for redifferentiation capacity in a pellet culture system treated with either TGF-β1- 
or serum-containing medium for 14 days, using histology, immunohistochemistry, 
biochemistry, western blot and real time PCR. We found that ECM not only greatly enhanced 
chondrocyte expansion but also delayed dedifferentiation of expanded chondrocytes. 
Intriguingly, compared to a dramatic decrease in CD90+/CD105+ cells and CD90+ cells, 
CD105+ cells dramatically increased when chondrocytes were plated on Plastic; on the 
contrary, ECM expansion dramatically increased CD90+ cells and delayed the decrease of 
CD90+/CD105+ cells. Interestingly, expanded chondrocytes on ECM also acquired a strong 
redifferentiation capacity, particularly in the pellets treated with TGF-β1. In conclusion, the 
ratio of CD90 to CD105 may serve as a marker indicative of proliferation and redifferentiation 
capacity of dedifferentiated chondrocytes. ECM deposited by SDSCs provides a 
tissue-specific 3D microenvironment for ex vivo expansion of articular chondrocytes while 
retaining redifferentiation capacity, suggesting that ECM may provide a novel approach for 






Articular cartilage is a unique, hypocellular and avascular tissue, mostly made of extracellular 
collagens and proteoglycans (PGs); it has a limited ability to self heal after trauma and 
degenerative disease.1 Since the last century, various clinical and research approaches have 
been adopted to repair articular cartilage damage, including arthroscopic abrasion, 
transplantation of chondrocytes, periosteum graft, mesenchymal stem cells (MSCs), or tissue 
constructs derived from MSCs. Each method, however, has disadvantages in achieving 
satisfactory effects in patients or animal studies. Autologous chondrocyte transplantation 
(ACT), the most current and clinically accepted method for cartilage repair, depends on the 
introduction of autologous chondrocytes into the defect area.2,3 The big hurdle for this 
technique is the limited expandability and dedifferentiation of chondrocytes characterized by 
losing round morphology and changing to a spindle shape. Meanwhile, collagen II and 
aggrecan dramatically decrease in contrast to the increase in collagen I.4,5 Dedifferentiated 
chondrocytes are able to redifferentiate to express cartilage-specific genes and proteins in a 
three-dimensional (3D) culture system, such as pellet,6 agarose gel,4 alginate beads,7 or 
hybrid scaffold8; however, late-passage chondrocytes tend to lose their capacity to generate 
cartilage tissue.9 
 
The prevention of dedifferentiation or the preservation of chondrocyte quality during in vitro 
expansion is one of the major tasks necessary for the innovation of regenerative cartilage 
medicine. Traditional cell culture on two-dimensional (2D) substrate lacks a proper 
microenvironment and is proposed to be responsible for the dedifferentiation of chondrocytes; 
this problem can be overcome by using in vitro 3D models because of its ability to mimic the 
in vivo environment.10 There is increasing evidence demonstrating that superficial zone 
protein (SZP) synthesized by both chondrocytes and synovial cells bordering the joint cavity11 
provides a protective microenvironment for cartilage progenitor cells at the surface of articular 
cartilage.12 Our most recent study developed a novel 3D expansion system based on the 
extracellular matrix (ECM) deposited by synovium-derived stem cells (SDSCs), which 
dramatically enhanced SDSC proliferation and chondrogenic differentiation potential.13 In this 
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study, SDSCs serve as a tissue-specific stem cell for chondrogenesis;14 we hypothesized that 
SDSC-derived ECM could provide a tissue-specific microenvironment by improving articular 




MATERIALS AND METHODS 
 
Isolation of porcine articular chondrocytes and SDSCs 
Two 3-month-old pigs were collected from a local slaughterhouse and harvested to provide 
articular cartilage and synovial tissue from the knee joints. The minced cartilage was digested 
in 0.2% collagenase P (Roche, Indianapolis, IN) at 37ºC overnight. The finely minced 
synovial tissue was digested in 0.1% trypsin (Roche) and then placed in 0.1% collagenase P 
at 37ºC for 2 h. After filtration through 70-μm nylon filter, both cells were plated in culture 
medium [DMEM containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 0.25 μg/mL fungizone (Invitrogen, Carlsbad, CA)]. Synovial fibroblasts 
were negatively isolated from primary culture and characterized as SDSCs according to our 
previous study.14  
 
Preparation of SDSC-derived ECM 
The preparation of SDSC-derived ECM was described in our previous study (13). Briefly, cell 
culture flasks were pre-coated with fibronectin (BD Biosciences, Bedford, MA) for 1 h at 37ºC. 
When the plated SDSCs reached 90% confluence, 50 µM L-ascorbic acid phosphate (Wako, 
Richmond, VA) was added for eight days. After washing with phosphate buffered saline (PBS), 
ECM was incubated in 0.5% Triton X-100 containing 20 mM ammonium hydroxide for 5 min 
followed by100 units/mL DNase (Sigma-Aldrich, St.Louis, MO) for 60 min.  
 
Ex vivo expansion of chondrocytes   
Passage 0 (P0) chondrocytes were expanded for six passages on two substrates: plastic 
flasks (“Plastic”) and SDSC-derived ECM (“ECM”). To identify if the substrate switch would 
affect cell expansion and redifferentiation capacity (short-term effect), P4 chondrocytes 
initially expanded on Plastic were plated on ECM for two more passages (“PtoE”) or from 
ECM to Plastic for two more passages (“EtoP”). Chondrocyte morphology expanded on 
Plastic or ECM was assessed using phase contrast microscope and immunoflurescent 
microscope. Briefly, P4 chondrocytes were stained with Vybrant DiI cell-labeling solution 
(Invitrogen) and plated on Plastic or ECM for three days. The samples were fixed in 4% 
142 
 
paraformaldehyde for 15 min and blocked in 1% BSA (Sigma) for 30 min, followed by 
one-hour-incubation in primary antibody against collagen I (Abcam, Cambridge, MA) and 
then secondary antibody of Alexa Fluor® 488 donkey anti-mouse IgG (H+L) (Invitrogen). The 
samples were counterstained by mounting in Slow Fade® Gold anti-fade reagent with DAPI 
(Invitrogen). Immunofluorescent images were obtained with a Nikon Eclipse E800 
microscope (Japan) and processed by SPOT software (Diagnostic Instruments Inc., Sterling 
Heights, MI). 
 
Flow cytometry  
The expanded chondrocytes from each passage were analyzed using the following primary 
antibodies: CD14 (Abcam), CD90 (BD Biosciences Pharmingen, San Diego, CA), and CD105 
(GeneTex Inc., San Antonio, TX). IgG1 and IgG2a (Beckman Coulter, Fullerton, CA) were 
used as the isotype controls, and R-Phycoerythrin Conjugated Goad Anti-Mouse IgG (H+L) 
was used as the secondary antibody. Samples (n = 3) of each 0.2 × 106 chondrocytes were 
incubated in cold PBS containing 0.1% ChromPure Swine IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA) and 1% NaN3 for 30 min. Then chondrocytes were incubated 
in the primary antibodies followed by the secondary antibody for 30 min in the dark. The 
labeled chondrocytes were analyzed on a BD dual laser FACS Calibur (BD Biosciences) 
using FCS Express software package (De Novo Software, Los Angeles, CA). 
 
Redifferentiation of expanded chondrocytes in a pellet culture system 
The expanded chondrocytes (3 × 105) from P0, P2 and P6 were centrifuged in a 15-mL 
polypropylene tube at 500 g for 5 min. After 24-hour-incubation (day 0), the pellets were 
incubated in two culture mediums: one was serum-free chondrogenic medium [high-glucose 
DMEM, 40 µg/mL proline (Sigma), 100 nM dexamethasone (Sigma), 100 U/mL penicillin, 100 
µg/mL streptomycin, 0.1 mM ascorbic acid-2-phosphate, and ITS™ Premix (BD Biosciences) 
with the supplementation of 10 ng/mL of transforming growth factor beta1 (TGF-β1, R&D 
Systems, Minneapolis, MN)] (14) (“TGF-β1-containing medium”) and the other culture 
medium was regular medium for chondrocyte-based tissue construct culture [high-glucose 
DMEM, 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 10 mM HEPES (Sigma), 0.1 
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mM non-essential amino acids (Sigma), 0.4 mM proline, and 50 mg/L L-ascorbic acid] (8) 
(“serum-containing medium”). The pellets were incubated at 5% CO2, 5% O2, 37ºC for 14 
days. 
 
Histology and Immunohistochemistry 
The chondrocyte pellets (n = 2) were fixed in 4% paraformaldehyde at 4ºC overnight, followed 
by dehydration with a gradient ethanol series, clearing with xylene, and embedding in paraffin 
blocks. Sections 5 μm thick were stained with Alcian blue to detect sulfated 
glycosaminoglycans (GAGs) with fast red as a counterstain. For immunohistochemical 
analysis, the sections were immunolabeled with primary antibodies against collagen I 
(Sigma), collagen II (II-II6B3, DSHB, Iowa City, IA), and collagen X (Sigma), respectively. A 
secondary antibody of biotinylated horse anti-mouse IgG (Vector, Burlingame, CA) was 
incubated on the sections for 30 min. Immunoactivity was detected using Vectastain ABC 
reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a substrate.  Hematoxylin (Vector) 
served as a counterstain. 
 
Biochemical analysis for DNA and GAG content 
For biochemical analysis, pellets (n = 5) were digested at 60ºC for 6 h with 125 μg/mL papain 
in PBE buffer (100 mM phosphate, 10 mM EDTA, pH 6.5) containing 10 mmol/L cysteine. The 
amount of DNA in each pellet was measured using the QuantiTTM PicoGreen® dsDNA assay 
kit (Invitrogen) with a CytoFluor® Series 4000 (Applied Biosystems, Foster City, CA). Sulfated 
GAGs were measured using 16 µg/mL of dimethylmethylene blue (DMMB) dye and a 
SpectronicTM BioMateTM 3 Spectrophotometer (Thermo Scientific, Milford, MA) with bovine 
chondroitin sulfate (Sigma) as a standard. 
 
TaqMan® quantitative real-time PCR 
Total mRNA from pellets (n = 5) was extracted using TRIzol® (Invitrogen) and 1 µg of mRNA 
was converted to cDNA with High-Capacity cDNA Archive Kit as recommended by the 
manufacturer (Applied Biosystems). Chondrogenic (aggrecan, collagen I and II) and 
hypertrophy [collagen X, matrix metalloproteinase 13 (MMP13), and alkaline phosphate 
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(ALP)] marker genes were customized by Applied Biosystems as part of the Custom 
TaqMan® Gene Expression Assays (Table 1). Eukaryotic 18S RNA (Assay ID: 
HS99999901_s1 ABI) was carried out as the endogenous control gene. Real-time PCR was 
performed with the iCycler iQTM Multi Color RT-PCR Detection and calculated by computer 
software (Perkin-Elmer, Waltham, MA).  
 
Western blot 
To assess non-dissolvable collagen II expression in extracellular matrix, SDSC pellets (n = 3) 
were lyophilized and incubated in 4 M guanidine hydrochloride (GuHCl, Sigma) for 20 h at 
4ºC, then digested with 0.6 mg/ml of pepsin (Sigma) in 0.5 M acetic acid at 4ºC for 48 h at a 
ratio of 10:1 (mg/mg) dry sample to pepsin. The samples were centrifuged at 48,000 g for 1 h, 
and the supernatant was lyophilized and dissolved in radioimmunoprecipitation assay (RIPA) 
buffer with protease inhibitors (Pierce, Rockford, IL). To assess dissolvable collagen II 
expression in cytoplasm, the pellets were homogenized and dissolved in RIPA buffer with 
protease inhibitors. Total proteins were quantified using BCATM Protein Assay Kit (Pierce). 40 
μg of protein from each sample was denatured and separated using NuPAGE® Novex® 
Bis-Tris Mini Gels (Invitrogen) in the XCell SureLockTM Mini-Cell (Invitrogen) at 120 volts for 3 
h at 4°C. Bands were transferred onto a nitrocellulose membrane (Invitrogen) using an XCell 
ΙΙTM Blot module (Invitrogen) at 15 volts overnight at 4°C. The membrane was incubated with 
a primary monoclonal antibody against collagen II (II-II6B3) in 1% non-fat milk in TBST for 1 h 
at room temperature (β-actin served as an internal control), followed by the secondary 
antibody of HRP-conjugated goat anti-mouse (Pierce) for 40 min at room temperature and 
exposure using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) and 
CL-XPosure Film (Pierce).  
 
Statistical Analysis 
The Kruskal-Wallis test was used to determine significant differences among all groups and 
the Mann-Whitney U test was used for pairwise comparison. All statistical analysis was 
performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less than 





Expansion on ECM acquired a large number of chondrocytes with delayed dedifferentiation 
To identify the effect of ECM on chondrocyte proliferation and marker gene stability, P0 
chondrocytes were expanded on ECM for six passages with Plastic substrate as a control. 
Compared to the original round morphology, chondrocytes expanded on Plastic exhibited 
flattened and broad morphology (Figure 4.1A and 4.1Biii); in contrast, ECM-expanded 
chondrocytes displayed a smaller size with a glistening surface and fibroblast-like shape that 
were aligned in rows (Figure 4.1A and 4.1Bii). ECM was positively stained with collagen I 
(Figure 4.1Bi). From P1 to P5, the cell number fold-change in the Plastic group continued to 
decrease (on average 5-fold); surprisingly, chondrocyte expansion on ECM yielded 4 to 10 
times more cells than on Plastic (Figure 4.1C). Despite a sharp decrease of collagen II mRNA 
in chondrocytes from both groups, ECM expanded chondrocytes restored more collagen II 
mRNA than those plated on Plastic (Figure 4.1D). In contrast, collagen I mRNA dramatically 
increased in chondrocytes after isolation from cartilage despite a burst increase at P1 and P4 
and a decrease at P6 in the ECM group (Figure 4.1E). 
 
To evaluate the effect of ECM on immunophenotypic changes of articular chondrocytes 
during in vitro expansion, CD14, CD90 and CD105 were chosen to identify differentiation 
status of expanded chondrocytes (Figure 4.2A-C and 4.2a-c). After an instant increase at P1, 
both CD14+ cells and CD90+ cells decreased with passage when chondrocytes were 
expanded on Plastic; intriguingly, ECM expansion dramatically increased CD14+ cells and 
CD90+ cells up to P6. On the contrary, compared to an increase in CD105+ cells after 
expansion on Plastic, ECM expansion exhibited a lower expression of CD105+ cells. The 
change of culture substrate from either PtoE or EtoP resulted in the same conclusion.  
 
To identify the effect of ECM on CD90+ cells and/or CD105+ cells during in vitro expansion, 
single positive (CD90+/CD105- or CD105+/CD90-), dual positive (CD90+/CD105+), and dual 
negative (CD90-/CD105-) cells were measured in expanded chondrocytes at P0, P2, and P6 
using flow cytometry (Figure 4.2D). Interestingly, when chondrocytes were expanded on 
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Plastic, both CD90+/CD105+ cells and CD90+/CD105- cells decreased dramatically with a 
sharp increase in CD105+/CD90- cells and CD90-/CD105- cells.  However, ECM expansion 
delayed a decrease in CD90+/CD105+ cells but increased CD90+/CD105- cells despite a 
concomitant increase in CD90-/CD105- cells.  
 
Chondrocytes expanded on ECM acquired enhanced redifferentiation capacity 
To evaluate the redifferentiation capacity of expanded chondrocytes, pellets from P0, P2 
(Plastic and ECM), and P6 (Plastic, PtoE, ECM, and EtoP) were incubated in either TGF-β1- 
or serum-containing medium for 14 days.   
 
Redifferentiation of expanded chondrocytes in a TGF-β1-containing medium 
Histology and immunostaining was performed to evaluate the density and distribution of 
chondrogenic markers in pellets from expanded chondrocytes. At Day 0 (Supplemental 
Figure 4.S1), there was no detectable staining for sulfated GAGs or collagen except in the 
pellets from P0, P2.ECM, and P6.ECM. At day 7 (Supplemental Figure 4.S1) and day 14 
(Figure 4.3A), sulfated GAGs and collagen II were distributed intensively throughout the 
pellets from P0, P2.Plastic, P2.ECM and P6.ECM despite a weaker and comparable staining 
of collagen I in all pellets except from P0. At P6, the pellet sizes from Plastic and EtoP were 
smaller than those from ECM and PtoE. There was no detectable collagen X in any pellets 
(data not shown).  
 
To confirm our histology data, western blot was used to semi-quantify the expression of 
collagen II at day 7 (Supplemental Figure 4.S2A) and day 14 (Figure 4.3B). We found that 
collagen II was intensively expressed in both cytoplasm (immature) and extracellular matrix 
(mature) in the pellets from P0, P2.Plastic, P2.ECM, and P6.ECM but not P6.Plastic. P6 
chondrocytes expanded on either PtoE or EtoP yielded pellets with enhanced collagen II 
expression compared to those from P6.Plastic. Biochemical analysis was used to quantify 
GAGs in the pellets from expanded chondrocytes at day 0 (Figure 4.3C), day 7 
(Supplemental Figure 4.S2B), and day 14 (Figure 4.3C). At day 0, pellets of P0 chondrocytes 
contained the highest GAGs compared to other groups. After incubation in TGF-β1-containing 
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medium for 14 days, pellets of P2 chondrocytes expanded on ECM exhibited a comparable 
GAG amount to those plated on Plastic. In contrast, pellets of P6 chondrocytes expanded on 
ECM yielded the highest level of GAGs, which was 7.9-fold greater than those from 
P6.Plastic. Intriguingly, pellets of P6 chondrocytes from EtoP exhibited higher GAGs than 
those from P6.Plastic but lower than those from P6.PtoE. Meanwhile, compared to a 
time-dependent increase in cell number of pellets from P0 chondrocytes (“162% ± 7%” at Day 
7 and “204% ± 4%” at Day 14), the cell number in the pellets from P6.Plastic dropped to 50% 
even after a 7-day incubation; however, the pellets from P6 chondrocytes expanded on ECM 
maintained the cell number at 124% after a 14-day incubation. The pellets of P6 
chondrocytes from EtoP exhibited an increased expansion rate compared to those of 
P6.Plastic. Expanded chondrocytes from P2.Plastic and P6.ECM yielded pellets with the 
highest chondrogenic index whereas the pellets from P6.Plastic had the lowest chondrogenic 
index after 14-day incubation with TGF-β1. The pellets of P6 chondrocytes from EtoP yielded 
a higher chondrogenic index compared to those from P6.Plastic but was lower than those 
from PtoE.  
 
To assess the effect of ECM on redifferentiation capacity of expanded chondrocytes at the 
mRNA level, real-time PCR was used to quantify chondrogenic marker genes (Figure 4.4A - 
collagens I and II, and aggrecan) and hypertrophic marker genes (Figure 4.4B - collagen X, 
ALP, and MMP13) at day 0 (Figure 4.4), day 7 (Supplemental Figure 4.S2C), and day 14 
(Figure 4.4). Our data showed that collagen II and aggrecan presented a similar profile of 
gene expression without significant variations. Despite the highest expression of both genes 
in pellets from P0 chondrocytes at day 0, 14-day-incubation with TGF-β1 yielded pellets with 
a higher expression of both genes in pellets from chondrocytes of P0, P2.ECM, and P6.ECM. 
At P6, pellets from chondrocytes expanded on Plastic exhibited the lowest expression of both 
genes. As an early marker of chondrogenic differentiation, collagen I mRNA decreased in all 
pellets when incubated in a TGF-β1-containing medium. Despite the highest collagen X in 
chondrocytes from P2.ECM after 14-day incubation with TGF-β1, expanded chondrocytes 
from P6.ECM had comparable collagen X mRNA to those from P6.Plastic. Another two 
hypertrophic markers, ALP and MMP13, both displayed a higher expression in chondrocytes 
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from P6.Plastic than those from P6.ECM (6.1-fold and 9.0-fold, respectively). 
 
Redifferentiation of expanded chondrocytes in a serum-containing medium 
Although the pellets from P0 chondrocytes incubated in a serum-containing medium were 
strongly stained by Alcian blue for sulfated GAGs and immunostained for collagen II as well 
as non-detectable staining for collagen I as those treated with TGF-β1, the pellets from P2 
chondrocytes were smaller in size and weaker in staining for both GAGs and collagen II, 
especially for the pellets from P2.Plastic. More interestingly, 14-day-incubated pellets (Figure 
4.5A) were weaker in chondrogenic marker staining than those from 7-day-incubated pellets 
(Supplemental Figure 4.S1). At P6, only pellets from ECM maintained their size and were 
positive for sulfated GAGs, collagens I and II; the pellets from other groups were tiny and less 
stained.  
 
To confirm our histology data, western blot was used to semi-quantify collagen II in pellets 
incubated in a serum-containing medium (Figure 4.5B). Only three groups, the pellets from 
P0, P2.ECM, and P6.ECM, could be extracted to yield sufficient proteins for immunoblotting. 
The data showed that the pellets from P0 chondrocytes exhibited the highest expression of 
collagen II in both cytoplasm and extracellular matrix. Despite undetectable collagen II in 
those from P6.ECM, the pellets from P2.ECM exhibited detectable collagen II expression only 
in extracellular matrix. Our biochemical analysis data (Figure 4.5C) showed that, compared to 
those treated by TGF-β1, the pellets from P0 chondrocytes incubated in a serum-containing 
medium yielded more GAG amounts and a higher DNA ratio as well as chondrogenic index. 
However, the pellets from P2 chondrocytes incubated in a serum-containing medium 
exhibited much less redifferentiation response despite the fact that 14-day-pellets from 
P2.ECM had higher GAG amounts and maintained higher DNA ratio compared to those from 
P2.Plastic.  
 
Our mRNA data (Figure 4.6) showed that collagen II and aggrecan presented a similar profile 
of gene expression without significant variation. Both genes exhibited a positive response to 
serum incubation despite an initial increase at day 7 and a later decrease at day 14. The 
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pellets from P2.ECM and P6.ECM displayed higher expression levels of both marker genes 
not only before but also after serum incubation compared to the chondrocytes expanded on 
Plastic. However, all pellets from expanded chondrocytes incubated in a serum-containing 
medium displayed much less collagen II and aggrecan gene expression compared to culture 
in a TGF-β1-containing medium except the pellets from P0 chondrocytes. There was no 
significant difference in collagen I expression in the pellets from expanded chondrocytes, 






A generally accepted opinion is that passage 3-4 is considered as a threshold for irreversible 
dedifferentiation of chondrocytes.9,11 Although multiple chondrocyte passaging decreases 
their redifferentiation capacity,15 our study suggested that the sequential application of ECM 
(seeding substrate for cell proliferation) and TGF-β (growth factor for differentiation) affected 
chondrocyte expansion and redifferentiation capacity. In our study, chondrocytes expanded 
on SDSC-derived ECM showed a robust proliferation capacity in a 3D format. The expanded 
cells on ECM retained more chondrocyte gene expression profiles and immunophenotypes 
compared to expansion on Plastic. When incubated in a serum-free TGF-β1-containing 
chondrogenic medium, chondrocytes expanded on ECM exhibited enhanced redifferentiation 
for up to passage 6 compared to expansion on Plastic that retained their redifferentiation only 
in the early passages.  
 
We found that signs of dedifferentiation appeared even after one passage on Plastic, 
evidenced by dramatically decreased collagen II mRNA and increased collagen I mRNA 
compared with the native cartilage; this outcome is in agreement with previous studies.16,17 
We also found that expansion on ECM not only increased cell number but also delayed the 
decrease of a chondrocyte differentiation marker – collagen II. Consistent with a previous 
study,18 our data showed that CD14+ cells decreased when chondrocytes were incubated on 
Plastic. Since CD14 is normally expressed by articular chondrocytes19 instead of by MSCs18, 
expansion on ECM boosted CD14+ cells, indicating that ECM was able to rescue 
differentiated chondrocytes and prevent dedifferentiation during in vitro expansion. This also 
can be explained by a recent report that chondrocytes cultured on collagen I–coated 
substrate showed a tendency of suppressed dedifferentiation.20 Our previous study 
demonstrated that ECM deposited by SDSCs, a tissue-specific stem cell for chondrogenesis, 
provides a 3D microenvironment composed of collagen I–dominated nano-structure fibers; 
SDSC expansion on ECM exhibited an enhanced proliferation capacity and chondrogenic 
potential,13 which is in accordance with this study and indicative that ECM expanded 
151 
 
chondrocytes exhibit an enhanced redifferentiation capacity.  
 
Our data also showed that expansion on Plastic instantly increased CD90+ cells at P1 
followed by a gradual decrease while continuously increasing CD105+ cells. On the contrary, 
expansion on ECM increased CD90+ cells while decreasing CD105+ cells. A recent report 
showed that during monolayer culture, articular chondrocytes expressed higher levels of 
CD90 and lower levels of CD105 compared to MSCs.21 An interesting phenomenon was that 
there was a phenotype switch in expanded chondrocytes from CD90+/CD105+ to 
CD105+/CD90- when plated on Plastic or a gradual decrease in CD90+/CD105+ cells 
concomitant with an increase in CD90+/CD105- when expanded on ECM. As we know, CD90 
and CD105 are MSC markers;22 increased CD90+ cells are also associated with cell 
proliferation capacity and chondrogenic potential23,24 as well as the induction of stress fibers 
in articular chondrocytes19. CD105 (also termed endoglin or SH225) was expressed on 
articular chondrocytes at a high intensity, where endoglin forms a heteromeric complex with 
betaglycan.26 Endoglin-betaglycan association may be critical for achieving a balance 
between the positive and negative regulation of TGF-β signaling. Compared to 
overexpression of betaglycan enhanced TGF-β responses, overexpression of endoglin 
resulted in an inhibition of TGF-β signaling.27 Like bone marrow MSCs, dedifferentiated 
chondrocytes were positive for the CD105 marker. This suggests that, within a chondrocyte 
preparation, subpopulations with higher capacity to form cartilage might correspond to those 
with progenitor characteristics. Our pellet culture data suggested that ECM expanded 
chondrocytes acquired not only a high proliferation capacity but also an enhanced 
redifferentiation capacity, indicating that the CD90/CD105 ratio may serve as a useful index to 
show the proliferation and redifferentiation capacity of dedifferentiated chondrocytes.  
 
To stimulate chondrocyte redifferentiation after in vitro expansion, TGF-β1 was chosen to 
facilitate the formation of cartilage-specific extracellular matrix28 with serum-containing 
medium as a control. Culture medium supplemented with serum was proven to effectively 
induce freshly isolated chondrocytes to differentiate into cartilage tissue constructs in 3D 
biodegradable scaffolds.8 Under the serum treatment, however, our study showed that 
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chondrocytes expanded on Plastic lose their capacity for redifferentiation as early as P2, 
suggesting that serum could only maintain the redifferentiation potential of early-expanded 
chondrocytes. The chondrocytes cultured on ECM were able to maintain cell viability and 
generate cartilage-specific matrix up to P6, albeit much weaker than those treated by 
TGF-β1-containing medium. A recent study showed that there is the existence of a certain 
subpopulation of multipotent MSCs or progenitor cells in the cartilage tissue besides 
terminally differentiated chondrocytes.29 In our study, chondrocytes expanded on ECM 
behaved more like stem cells or progenitors rather than terminally differentiated cells in terms 
of rapid proliferation rate and high level of CD90 surface marker. When culturing on ECM, 
stem cells or progenitors in mixed chondrocyte populations would accelerate the expansion 
rate compared with mature chondrocytes and those cells have strong chondrogenic potential, 
evidenced by generating cartilage-specific matrix in response to stimulation by TGF-β1 in a 
pellet culture system. A potential mechanism underlying ECM enhancing chondrocyte 
proliferation and redifferentiation capacity may be explained by ECM acting through 
integrin-mediated extracellular signal-activated kinase (ERK) signal transduction pathway. 
Chondrocyte expansion in monolayer culture shows the expression of osteoblast cadherin 
(Ob-cadherin) and abundant cell-to-cell contacts, indicative of dedifferentiation.30 On the 
contrary, the 3D expanded cells exhibit lower expression of cadherins than did monolayer 
expanded cells, especially that of Ob-cadherin, which was inhibited to the level of native 
chondrocytes.31 Silencing of Ob-cadherin expression in monolayer cells induced 
redifferentiation in dedifferentiated cells, implying that the 3D microenvironment for cell 
expansion diminishes cell-to-cell contacts like native cartilage, which may result in resistance 
to dedifferentiation.31 ECM would interact with chondrocytes through integrins and other 
signaling receptors, in which specifically α5β1 and αVβ3 integrins were proven highly 
expressed in the cells attaching on the 3D ECM.32,33 Afterwards the phosphorylation of 
ERK1/2 is upregulated by the activated β1 integrin via Src/Ras/Raf signaling pathway;34 then 
the high level of phosphorylated ERK1/2 would enhance TGF-β1-mediated redifferentiation of 
expanded chondrocytes on ECM.35,36 
 
Our study also investigated the short-term effect of culture substrate on chondrocyte 
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expansion and redifferentiation capacity by switching either from Plastic to ECM (PtoE) or 
from ECM to Plastic (EtoP). Our data suggested that expanded chondrocytes from either 
PtoE or EtoP acquired higher proliferation and redifferentiation capacity compared to those 
plated on Plastic but lower than those seeded on ECM. Chondrocytes expanded on PtoE 
acquired a higher redifferentiation capacity than those on EtoP, suggesting that once the 
chondrocytes adapt to the ECM environment, the transition from EtoP would deprive the 
chondrocytes of their expandability and redifferentiation potential. Our study indicated that 
dedifferentiated or aged chondrocytes would regain their redifferentiation capacity with the 
help of ECM deposited by SDSCs. ECM provides an in vitro 3D expansion system that may 
play an important role in autologous chondrocyte transplantation-based cartilage repair.  
 
In summary, we found that ECM deposited by a tissue-specific stem cell was able to 
efficiently expand primary chondrocytes; ECM-expanded chondrocytes retained their 
significant redifferentiation capacity. These results demonstrated that SDSC-derived ECM 
can function as a new ex vivo expansion system to enhance chondrocyte proliferation and 
redifferentiation potential for future clinical applications. Further studies are needed to 
investigate whether redifferentiated chondrocytes from expansion on ECM are capable of 
forming cartilage tissue in vivo, which would ensure the stability and functionality of the 
acquired chondrocyte phenotype. The mechanisms underlying the interaction between 
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Figure 4.1.  In vitro expansion of articular chondrocytes on Plastic, ECM, PtoE or EtoP from 
P0 to P6. (A) Representative cell morphology from expanded chondrocytes at P0, P1, P3 and 
P6. (B) DiI-stained chondrocytes (red) with DAPI as a nuclear counterstain (blue) were 
expanded on either ECM [immunostained with (Bi) or without (Bii) collagen I antibody (green)] 
or Plastic (Biii). (C) Fold-change of expanded cell number was compared for plating on either 
ECM or Plastic. (D) Fold-change of collagen II (Col II) mRNA was compared in cartilage 
tissue and chondrocytes expanded on ECM or Plastic. (E) Fold-change of collagen I (Col I) 
mRNA was compared in cartilage tissue and chondrocytes expanded on ECM or Plastic. 
Data are shown as average ± SD for n = 4.  
 
Figure 4.2.  Immunophenotype changes of chondrocytes expanded on ECM, Plastic, PtoE, 
or EtoP from P0 to P6. Flow cytometry was used to evaluate the percentage (A - C) and mean 
fluorescence intensity (MFI, a - c) of CD14+, CD90+, and CD105+ chondrocytes during cell 
expansion. Dual positive chondrocytes of CD90+ and CD105+ were represented at P0, P2 
and P6 (D). Data are shown as average ± SD for n = 3.  
 
Figure 4.3.  Redifferentiation capacity of expanded chondrocytes was assessed at the 
protein level using chondrocyte-pellets after incubation in a TGF-β1-containing medium for 14 
days. (A) Alcian blue staining was for sulfated GAGs with fast red as a counterstain, and 
immunohistochemistry (IHC) was for collagens I and II (DAB substrate had a brown color 
suggestive of positive staining) with hematoxylin as a counterstain. The scale bar was 800 
µm. (B) Western blot was used to detect collagen II in extracellular matrix (mature) and 
cytoplasm (immature) with β-actin as an internal control. (C) Biochemical analysis was used 
to quantitatively measure DNA and GAG amounts in the pellets. DNA data were represented 
by DNA ratio adjusted by DNA amount at day 0. Ratio of GAG to DNA was used as a 
chondrogenic index. Data are shown as average ± SD for n = 5. Groups not connected by the 




Figure 4.4.  Redifferentiation capacity of expanded chondrocytes was assessed at the 
mRNA level using chondrocyte-pellets after incubation in a TGF-β1-containing medium for 14 
days. TaqMan® RT-PCR was used to quantitatively measure chondrogenic marker genes (A 
– collagen II, aggrecan, and collagen I) and hypertrophic marker genes (B – collagen X, ALP, 
and MMP13) in the pellets of expanded chondrocytes at days 0 and 14. Data are shown as 
average ± SD for n = 5. Groups not connected by the same letter are significantly different 
(p<0.05).  
 
Figure 4.5.  Redifferentiation capacity of expanded chondrocytes was assessed at the 
protein level using chondrocyte-pellets after incubation in a serum-containing medium for 14 
days. (A) Alcian blue staining was used for sulfated GAGs with fast red as a counterstain, and 
immunohistochemistry (IHC) was for collagens I and II (DAB substrate had a brown color 
suggestive of positive staining) with hematoxylin as a counterstain. The scale bar was 800 
µm. (B) Western blot was used to detect collagen II in extracellular matrix (mature) and 
cytoplasm (immature) of pellets with β-actin as an internal control at days 7 and 14. (C) 
Biochemical analysis was used to quantitatively measure DNA and GAG amounts in the 7- 
and 14-day pellets. DNA data were represented by DNA ratio adjusted by DNA amount at day 
0. Ratio of GAG to DNA was used as a chondrogenic index. Data are shown as average ± SD 
for n = 5. Groups not connected by the same letter are significantly different (p<0.05).  
 
Figure 4.6.  Redifferentiation capacity of expanded chondrocytes was assessed at the 
mRNA level using chondrocyte-pellets after incubation in a serum-containing medium for 14 
days. TaqMan® RT-PCR was used to quantitatively measure chondrogenic marker genes 
(collagen II, aggrecan, and collagen I) in the pellets of expanded chondrocytes at days 7 and 
14. Data are shown as average ± SD for n = 5. Groups not connected by the same letter are 
significantly different (p<0.05).  
 
Figure 4.S1. Redifferentiation capacity of expanded chondrocytes was assessed at the 
protein and mRNA level using chondrocyte-pellets after incubation in a TGF-β1- or 




Figure 4.S2. Redifferentiation capacity of expanded chondrocytes was assessed at the 
protein and mRNA level using chondrocyte-pellets after incubation in a TGF-β1-containing 
medium at Day 7. (A) Western blot was used to detect collagen II in extracellular matrix 
(mature) and cytoplasm (immature) of pellets with β-actin as an internal control at Day 7 in 
the group of TGF-β1 treatment. (B) Biochemical analysis was used to quantitatively measure 
DNA and GAG amounts in the 7-day pellets treated by TGF-β1. (C) mRNA level using 
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Study Design.  After plating for six passages on either plastic flasks or extracellular matrix 
(ECM) deposited by synovium-derived stem cells (SDSCs), expanded nucleus pulposus (NP) 
cells were evaluated for redifferentiation capacity. 
Objective.  The aim was to assess the feasibility of using ECM deposited by a tissue-specific 
stem cell to provide a 3D microenvironment for NP cell rejuvenation.  
Summary of Background Data.  Autologous disc cell-based therapy is a promising approach 
for intervertebral disc (IVD) regeneration. Unfortunately, the current in vitro expansion of NP 
cells in monolayer results in dedifferentiation of these cells. 
Methods.  Primary NP cells were plated on either plastic flasks or ECM for six consecutive 
passages. At each passage, cell numbers were counted for proliferation rate, cell phenotype 
was evaluated using flow cytometry and cell differentiation status was assessed using 
real-time PCR. The pellets from expanded NP cells at passages 1, 4 and 6 were incubated in 
a serum-free defined medium for 14 days. Redifferentiation capacity of the expanded NP 
cells was evaluated using histology, biochemistry, and real-time PCR. 
Results. NP cells expanded on ECM grew much faster with a smaller size and fibroblast-like 
shape compared to those on plastic flasks. ECM-treated NP cells acquired an enhanced 
CD90 expression and higher mRNA levels of types I, II, and X collagen and aggrecan, as well 
as a robust redifferentiation capacity, evidenced by dramatically increased type II collagen, 
aggrecan and Sox9 and decreased type I collagen for up to six passages. 
Conclusion. SDSC-derived ECM can provide a tissue-specific microenvironment for the 
rejuvenation of NP cells with a higher proliferation rate and redifferentiation capacity, which 
may play a role in improving an autologous disc cell-based minimally invasive therapeutic 
approach toward physiological reconstruction of a biologically functional disc in the clinical 
setting. 
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Key points: 
• Monolayer culture can result in NP cell dedifferentiation, evidenced by losing cell 
proliferation and gene expression profiles as well as redifferentiation capacity 
• ECM deposited by SDSCs provides a tissue-specific 3D microenvironment for NP cell 
large-scale expansion 
• NP cells expanded on ECM acquire a higher expression of CD90 and differentiated 
gene profiles 
• NP cells expanded on ECM also acquire a robust redifferentiation capacity 
• The expansion microenvironment switched from plastic flasks to ECM can improve 





Approximately 80% of the adult population is affected by low back pain (LBP); this has a 
massive economic impact due to both health care costs and loss of productivity.1 Although the 
causes of LBP are complicated and not fully understood, degeneration of the intervertebral 
disc (IVD) is an important underlying cause.2;3 IVD degeneration begins in the nucleus 
pulposus (NP) with a progressive decrease in proteoglycan content, leading to a loss of 
hydrogel properties of the NP.4 Clinical treatments of IVD disease include various noninvasive 
and invasive therapies, but are limited to symptomatic relief. Much of the recent research in 
this area has focused on biological restoration of the IVD.5;6 Although human IVD cells share 
matrix-producing properties with chondrocytes, studies have shown that there are indeed 
phenotypic differences between NP cells and articular chondrocytes.7 Stem cells seem to be 
another candidate for cell transplantation; however, the lack of a definitive cell marker to 
distinguish NP cells from other cells has made clinical application more difficult and less 
realistic.  
 
Animal studies8-10 and an early clinical trial (Euro Disc Randomized Trial)11 have indicated 
that autologous disc cell transplantation (ADCT) is technically feasible and biologically 
relevant to repairing disc damage and retarding disc degeneration. However, one concern of 
critics of ADCT is that cells isolated from degenerative discs may lack the potential of healthy 
counterparts, making them poorly suited for repair in an inhospitable degenerated disc 
environment.12 In addition, the preparation of NP cells for reimplantation is problematic 
because autologous transplantation requires more cells than can be harvested from a small 
biopsy. With low cellular yields and low proliferative activity of NP cells in monolayer culture, 
further enhancement of the biological and metabolic viability of NP cells is desirable.  
 
Our recent study has shown that synovium-derived stem cells (SDSCs) can be used to 
prepare a 3D microenvironment for SDSC proliferation while maintaining and enhancing their 
chondrogenic differentiation capacity.13 Since NP cells are chondrocyte-like cells, in this study, 
we hypothesize that SDSC-derived ECM can serve as a tissue-specific microenvironment for 
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ex vivo expansion of NP cells while maintaining NP cell differentiated phenotype and 
redifferentiation capacity. Our long-term goal is to develop an autologous disc cell-based 
minimally invasive therapeutic approach toward physiological reconstruction of a biologically 





Isolation and culture of SDSCs and NP cells 
Two 3-month-old pigs were collected from a local slaughterhouse and harvested to provide 
synovial tissue from both knees and NP tissue from the lumbar spine (L1-L5). The synovial 
tissue was finely minced and digested at 37ºC for 30 min in 0.1% trypsin (Roche, Indianapolis, 
IN) and then for 2 h in 0.1% collagenase P (Roche) to release synovial cells. The NP tissue 
was digested with 0.1% collagenase A (Sigma, St. Louis, MO) and 10 U/mL hyaluronidase 
(Sigma) at 37oC for 4 h. Synovial cells and NP cells were collected from the filtrate by 
centrifugation and plated in complete medium [αMEM containing 10% fetal bovine serum 
(FBS), 100 U/mL penicillin, 100 µg/mL streptomycin and 0.25 μg/ml fungizone]. Synovial 
fibroblasts were negatively isolated from primary culture and characterized as SDSCs 
according to our previous study14. 
 
Preparation of SDSC-derived ECM 
The preparation of SDSC-derived ECM was described in our previous study.13 Briefly, 
fibronectin was pre-coated on plastic flasks at 37ºC for 1 h. When the plated SDSCs reached 
90% confluence, 50 µM L-ascorbic acid phosphate (Wako, Richmond, VA) was added for 
eight days. ECM was washed with phosphate buffered saline (PBS), and incubated with 0.5% 
Triton X-100 containing 20 mM ammonium hydroxide in PBS at 37ºC for 5 min and stored in 
PBS. 
 
NP cells grown on SDSC-derived ECM 
Passage one (P1) NP cells were plated at 3,000 cells/cm2 in plastic flasks with (“ECM”) or 
without ECM (“Plastic”) -coating for six consecutive passages. The third group was grown on 
plastic flasks for five passages and then switched on ECM for one passage (“PtoE”). 






Triple individual samples of 0.3 × 106 cells each were incubated on ice in PBS containing 
0.1% ChromPure Swine IgG (Jackson Immuno Research, West Grove, PA) and 1% NaN3 for 
30 min. Primary monoclonal antibodies were applied for 30 min, including CD29 (Abcam, 
Cambridge, MA), CD44 (Abcam), CD90 (BD Pharmingen, San Jose, CA), CD105 (GeneTex 
Inc., San Antonio, TX) and isotype-matched IgGs (Beckman Coulter, Fullerton, CA). After 
washing with cold PBS, NP cells were incubated with the secondary antibody 
[FITC-conjugated goat anti-mouse Ig (Abcam)] for 30 min in the dark followed by fixation in 
400 μL of 0.4% paraformaldehyde. NP cells were analyzed on a BD dual laser FACS Calibur 
(BD Biosciences) using the FCS Express Version 3 (De Novo Software, Los Angeles, CA) 
software package. 
 
Redifferentiation of expanded NP cells 
0.3 × 106 of NP cells from P1, P4, and P6 were centrifuged at 500 g for 5 min to form a pellet. 
After 24 h incubation (day 0), the pellets were cultured in a defined medium consisting of 
high-glucose DMEM, 40 µg/mL proline, 100 nM dexamethasone, 100 U/mL penicillin, 100 
µg/mL streptomycin, 0.1 mM ascorbic acid-2-phosphate and 1 × ITS™ Premix (BD 
Biosciences) with 10 ng/mL transforming growth factor β1 (TGF-β1) (R&D Systems, 
Minneapolis, MN) for 14 days.  
 
Histochemistry and immunohistochemistry 
The pellets (n=3) were fixed in 4% paraformaldehyde, dehydrated in a gradient ethanol series, 
cleared with xylene, and embedded in paraffin blocks. 5-μm sections were histochemically 
stained with Safranin-O (Sigma). For immunohistochemical analysis, the sections were 
immunolabeled with primary antibodies against collagen I (Sigma) and collagen II (II-II6B3, 
DSHB, Iowa City, IA), respectively. A secondary antibody of biotinylated horse anti-mouse 
IgG (Vector, Burlingame, CA) was incubated on the sections for 30 min. Immunoactivity was 
detected using Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a 




Biochemical analysis for DNA and GAG content  
The pellets (n=6) were digested for 4 h at 60ºC with 125 μg/mL papain in PBE buffer (100 
mmol/L phosphate, 10 mmol/L EDTA, pH 6.5) containing 10 mmol/L cysteine using 100 μL 
enzyme per sample. To quantify cell density, the amount of DNA in the papain digestion was 
measured using the QuantiTTM PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor® 
Series 4000 (Applied Biosystems, Foster City, CA). GAG was measured using 
dimethylmethylene blue dye and a SpectronicTM BioMateTM 3 Spectrophotometer with bovine 
chondroitin sulfate as a standard. 
 
TaqMan® Quantitative PCR  
The total RNA was extracted from samples (n=5) using an RNase-free pestle in TRIzol® 
(Invitrogen). 1 µg of mRNA was used for reverse transcriptase (RT) with a High-Capacity 
cDNA Archive Kit at 37ºC for 120 min as recommended by the manufacturer (Applied 
Biosystems). Chondrogenic marker genes (types I, II, and X collagen, Sox9, and aggrecan) 
were customized by Applied Biosystems as part of the Custom Taqman® Gene Expression 
Assays.13 Eukaryotic 18S RNA (Assay ID: HS99999901_s1 ABI) was carried out as the 
endogenous control gene. Real-time PCR was performed with the iCycler iQTM Multi Color 
RT-PCR Detection and calculated by computer software (Perkin-Elmer, Waltham, MA). 




The Kruskal-Wallis test was used to test for significant differences among all groups and the 
Mann-Whitney U test was used for pairwise comparison in flow cytometry data, biochemistry 
analysis, and real-time PCR data. All statistical analyses were performed with SPSS 13.0 






SDSC-derived ECM enhances NP cell proliferation while retaining their differentiation 
phenotypes 
Primary NP cells were plated in plastic flasks without or with ECM coating for six passages. 
NP cells plated on plastic flasks were shown to proliferate slowly; in contrast, NP cells grown 
on ECM had their cell number increased dramatically by overlapping in a 3D format after 
reaching confluence (Figure 5.1A). Relative to NP cells expanded on plastic flasks, 
ECM-treated NP cells yielded 7.8-fold greater cell numbers at P1. Despite a decreased 
proliferation rate with passage in both groups, NP cells expanded on ECM yielded 10.8-fold at 
P2, 19.1-fold at P3, 13.9-fold at P4, and 15.0-fold at P6 greater cell numbers than those 
plated on plastic flasks (Figure 5.1B). 
 
To identify if NP cells expanded on ECM acquired mesenchymal stem cell (MSC) phenotypes, 
CD29, CD44 and CD90 were assessed using flow cytometry (Figure 5.2A). Despite a 
comparable percentage of CD29+ cells (Figure 5.2B), NP cells expanded on ECM were lower 
in mean fluorescent intensity (MFI) than those on plastic flasks (Figure 5.2C). Interestingly, 
NP cells expanded on ECM acquired CD90+ cells greater than those grown on plastic flasks 
in both percentage (Figure 5.2D) and MFI (Figure 5.2E), indicating that SDSC-derived ECM 
provides a 3D microenvironment to enhance NP cell “stemness” toward chondrogenic 
differentiation.15 For CD44, ECM-treated NP cells shared a similar expression phenotype as 
those grown on plastic flasks except slightly higher at P3 and P6 in both percentage (Figure 
5.2F) and MFI (Figure 5.2G). Noticeably, NP cells expanded from PtoE acquired 
immunophenotypes close to those on ECM, particularly in MFI (Figure 5.2C, 5.2E, 5.2G).  
 
To identify differentiation status of expanded NP cells, types I, II, and X collagen and 
aggrecan were assessed using real-time PCR. Chondrogenic marker genes [collagen II 
(Figure 5.3A) and aggrecan (Figure 5.3B)] decreased their expression with passage, 
particularly in the early subculture of NP cells on plastic flasks. In contrast, ECM-treated NP 
cells showed greater collagen II and aggrecan mRNA in all passages than those seeded on 
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plastic flasks. Intriguingly, ECM-treated NP cells also exhibited higher collagen I mRNA 
(Figure 5.3C) and collagen X mRNA (Figure 5.3D) than those grown on plastic flasks. 
Collagen I mRNA was elevated in the initial passage followed by a gradual decrease until P6 
in both groups.    
 
In vitro tissue-specific microenvironment restores redifferentiation capacity of expanded NP 
cells 
Despite no positive staining at day 0, the pellets from expanded NP cells on either plastic 
flasks or ECM at P1 were stained intensively with sulfated GAGs and types I and II collagen 
at day 7 while type I collagen became weaker with the maturation of pellets. 
Fourteen-day-pellets from NP cells expanded on ECM were larger in size and more 
homogeneous in the distribution of sulfated GAGs and type II collagen than those on plastic 
flasks. More evidently, ECM-treated NP cells at P4 yielded pellets with more sulfated GAGs 
and types I and II collagen at day 7 than those grown on plastic flasks. ECM-treated NP cells 
at P6 yielded pellets with more intense staining of sulfated GAGs and collagen II at days 7 
and 14 than those from NP cells expanded on plastic flasks. The pellets of NP cells expanded 
from PtoE exhibited more intense expression of collagen II and sulfated GAGs than those on 
plastic flasks (Figure 5.4).  
 
To evaluate redifferentiation capacity of expanded NP cells, biochemical analysis was used to 
quantify GAG amount, DNA amount and ratio of GAG to DNA (chondrogenic index) in pellets. 
Adjusted by those at day 0, pellets from P1 NP cells expanded on ECM exhibited a huge 
increase in DNA and GAG amounts compared to a drop in those grown on plastic flasks 
despite the fact that both groups had a comparable chondrogenic index at day 14 (Figure 
5.5A, 5.5B, 5.5C). After six consecutive passages, NP cells expanded on either ECM or PtoE 
maintained their cell numbers in pellets more than the corresponding NP cells on plastic 
flasks. NP cells expanded on ECM also exhibited the highest GAG amount compared to the 
other two groups, which contributed to the highest chondrogenic index in pellets of 




Redifferentiation capacity of expanded NP cells was also evaluated at the mRNA level 
(Figure 5.6). At P1, ECM-treated NP cells had a comparable collagen II but higher aggrecan 
mRNA than those expanded on plastic flasks after a 14-day incubation in chondrogenic 
medium. Although both collagen II and aggrecan mRNA levels decreased with passage, 
ECM-treated NP cells at P6 exhibited 10.8-fold of collagen II and 10.0-fold of aggrecan 
mRNA levels compared to those expanded on plastic flasks. ECM-treated NP cells also 
displayed a higher expression of Sox9 mRNA, which may be responsible for the enhanced 
expression of collagen II and aggrecan mRNAs. Our data also showed that ECM-treated NP 
cells at P6 exhibited about half the collagen I mRNA but comparable collagen X mRNA 
compared to those expanded on plastic flasks when incubated in chondrogenic medium for 






IVD degeneration is associated with a loss of matrix molecules resulting in altered biochemical 
and biomechanical properties of the tissue.4;16;17 Since there is no risk of disease transmission 
and immune rejection, autologous IVD cells are a promising cell source for disc regeneration. 
However, quality and quantity of NP cells from patients are a concern.18 To make clinical 
application a reality, in vitro expansion cultures are expected to yield large amounts of cells in 
a short period of time. Moreover, these expanded NP cells should express or be able to 
reexpress their NP cell phonotype (redifferentiation capacity) facilitating a functional 
extracellular matrix. Thus, cell numbers and redifferentiation capacity are two important 
parameters in disc regeneration. Our study indicated, for the first time, that ECM deposited by 
SDSCs can provide such an in vitro microenvironment to rejuvenate NP cells by greatly 
enhancing cell proliferation ability, differentiation status and redifferentiation capacity. 
 
After notochordal cells disappear during childhood, lumbar discs show evidence of 
degeneration with age.19 Interestingly, some species that retain their notochordal cells in 
adulthood do not show age-related IVD degeneration,20 suggesting that notochordal cells can 
provide a microenvironment preventing NP cells from degenerating. During in vitro expansion, 
NP cells undergo a characteristic process of dedifferentiation, marked by a loss in the 
expression of collagen II21;22 and aggrecan23 as well as the induction of collagen I 
expression24;25. There is a discrepancy in the dedifferentiation process between articular 
chondrocytes and NP cells; the former accumulates collagen I while the later loses collagen 
I26. Many reports demonstrate that cells grown in a more physiological 3D environment can 
differ considerably in their morphology, cell-cell and cell-matrix interactions, and 
differentiation from those grown on flat 2D tissue culture substrates27;28, suggesting that there 
exists a critical feature of the specialized environment (niche) in ECM that is responsible for 
the maintenance of MSC “stemness” by supporting their self-renewal capability and 
maintaining multipotentiality while facilitating differentiation in response to appropriate 




It is postulated that ECM deposited by stem cells provides a microenvironment that can 
benefit adult cells in proliferation and redifferentiation capacity. Studies from our group and 
other groups suggest that a tissue-specific stem cell can be used to prepare its own in vitro 
niche for stem cell proliferation while maintaining and enhancing its lineage-specific 
stemness.13;30 A great challenge during chondrogenesis is to generate articular cartilage-like 
chondrocytes that do not undergo hypertrophy as a terminal differentiation stage.31-33 
Cartilage and synovial tissue are derived from a common precursor pool34 and share similar 
profiles.35-37 Recent studies demonstrate that synovial tissue can provide a superior type of 
MSC for chondrogenesis compared to other sources.38-41 Since NP cells are chondrocyte-like 
cells, SDSC-derived ECM may provide a tissue-specific microenvironment for the 
rejuvenation of NP cells.  
 
In our study, NP cells grown on SDSC-derived ECM yielded greater cell numbers and higher 
chondrogenic marker genes than those plated on plastic flasks despite the declining trend 
with passage in both groups. In contrast, NP cells grown on plastic flasks resulted in cell 
dedifferentiation; our finding also demonstrated that these dedifferentiated cells were no 
longer capable of redifferentiation, especially for NP cells expanded more than four passages, 
which is consistent with a previous study.42 Interestingly, ECM-expanded NP cells acquired a 
higher redifferentiation capacity for up to six passages. Compared to being plated on plastic 
flasks, NP cells grown on SDSC-derived ECM regained a higher CD90 percentage and 
median as well as a lower CD29 median, which is consistent with our previous study in which 
SDSCs displayed a similar change in phenotypes when grown on SDSC-derived ECM.13 
CD90 expression was reported to be positively related with MSC chondrogenic capacity43 
and immunosuppressive capacity44, suggesting that ECM-treated NP cells not only acquire 
enhanced redifferentiation capacity but also are able to better survive the immune reaction 
after implantation.  
 
There is a recent report indicating that the pathologically degenerate human disc contained 
populations of skeletal progenitor cells.45 These stem cells or progenitor cells would be 
responsible for the NP cell redifferentiation and IVD regeneration, evidenced by a higher 
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proliferation capacity and multi-lineage differentiation potentials into adipogenesis, 
osteogenesis and chondrogenesis.46;47 The nucleus pulposus cells expanded on our ECM 
deposited by SDSCs behaved more like stem cells or progenitor cells rather than terminally 
differentiated cells, suggested by the fast proliferation rate, the high expression of CD90 
surface marker, and redifferentiation capacity to generate tissue-specific matrix. The 
specialized microenvironment is able to up-regulate a decapentaplegic (dpp) niche signaling 
pathway of incoming cells. Empty niches have the potential to alter cell fate as well as the 
growth properties of already committed and maturing cells,48;49 and therefore may be able to 
impose a stem cell state on more mature cells, enhancing cell proliferation and differentiation 
potential.  
 
Our study demonstrated that SDSC-derived ECM may provide a tissue-specific 
microenvironment to rejuvenate NP cells for proliferation and redifferentiation. Our study also 
indicated that the in vitro microenvironment from young donors may reprogram and 
rejuvenate seeded cells from elderly donors that have lower proliferation and differentiation 
capacity.50;51 In clinics, most patients are adults or elders. Stem cells from older patients are 
not able to provide a high-quality “soil” (microenvironment) for cell rejuvenation. Stem cells 
from young donors in a human tissue bank could be utilized to prepare a high-quality 
microenvironment on which NP cells from patients can be greatly expanded while maintaining 
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Figure 5.1. Effect of SDSC-derived ECM on NP cell morphology and proliferation. NP cells 
were expanded on either plastic flasks or ECM for six consecutive passages. NP cell 
morphology at P1 and P4 was shown at day 6 using a phase contrast microscope (A). Cell 
number from both groups was compared with passage (B). Data are shown as average ± SD 
for n = 3. 
 
Figure 5.2. Flow cytometry analysis of typical MSC surface antigens (CD29, CD44, and 
CD90) with isotype-specific control (A). The percentage (B, D, F) and mean fluorescent 
intensity (MFI, C, E, G) of positive cells were compared for MSC phenotype changes in NP 
cells grown on plastic flasks or ECM for six passages.    
 
Figure 5.3. Quantitative real-time PCR of differentiated (A: collagen II mRNA, B: aggrecan 
mRNA, and C: collagen X mRNA) and dedifferentiated (D: collagen I mRNA) phenotypes of 
NP cells expanded on plastic flasks or ECM for six passages. The data were adjusted by 
mRNA level of P1 NP cells expanded on plastic flasks. Data are shown as average ± SD for n 
= 5. 
 
Figure 5.4. Histological evaluation of redifferentiation capacity of NP cells expanded on 
plastic flasks or ECM for six passages using safranin O staining for sulfated GAGs and 
immunostaining for types I and II collagen at days 0, 7, and 14. NP cells grown on plastic 
flasks for five passages and switched to ECM for one passage (PtoE) served as the third 
group.  The scale bar is 800 µm.  
 
Figure 5.5. Biochemical analyses were used to detect DNA (A,D) and GAG amounts (B,E) 
per pellet at P1 (A,B,C) and P6 (D,E,F). DNA amount at days 7 and 14 was adjusted by that 
at day 0 to minimize the initial difference in pellet preparation. Chondrogenic index was 
presented as ratio of GAG to DNA at P1 (C) and P6 (F). Data are shown as average ± SD for 




Figure 5.6. TaqMan real-time PCR was used to quantitatively assess chondrogenic markers 
[collagen II (A/B), aggrecan (C/D), Sox9 (E/F), collagen I (G/H), and collagen X (I/J)] at mRNA 
level. All marker gene expression was presented as relative mRNA level adjusted with 18S 
RNA. Data are shown as average ± SD for n = 5. Significant differences are indicated as *p < 
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The three-dimensional (3D) cell-deposited extracellular matrix (ECM) was previously 
reported as a new expansion system in vitro mimicking tissue-specific mesenchymal stem 
cell microenvironment, but the mechanism of the interaction between ECM and cells and the 
intracellular signaling transduction pathway was not clear due to the complexity of the 3D 
ECM compared with the 2D conventional monolayer culture. In this study we expanded 
human bone marrow stem cells (hBMSCs) in vitro under the 3D hBMSC-deposited ECM 
environment (ECM) or conventional plastic flasks (Plastic). The 3D ECM greatly improved 
hBMSC proliferative rate and attenuated the intracellular reactive oxygen species but 
increased the cell apoptosis. Chondrogenic differentiation was induced by transforming 
growth factor - β3 (TGF-β3) and hBMSCs expanded on 3D ECM showed robust 
chondrogenic potential to generate cartilage-specific genes and matrix, including sulfated 
glycosaminoglycans, Sox9 and type II collagen. We compared several key signaling kinases 
expression and activity in hBMSCs cultured on ECM and Plastic. The 3D ECM increased the 
expression of SSEA-4, integrin α2, α4, and β5, and induced sustained activation of Src kinase, 
ERK1/2 and cyclin D1. Not only the expression but also the activity of TGF-β receptor II was 
enhanced by 3D ECM in hBMSCs. These observations suggested that the 3D cell-deposited 
ECM promoted hBMSC proliferative capacity may through integrin/Src/ERK1/2 signaling 
pathway and enhanced the chondrogenic potential by improving the responsiveness of 





Mesenchymal stem cells (MSCs) are considered a promising source for cell therapy and 
regenerative medicine, because not only they can be isolated from various adult tissues, but 
also they have excellent self-renewal potential and multipotent differentiation capacities.1-4 
The current expansion technique in vitro, however, limits the utilization of MSCs due to 
inadequate cell quantity and impaired multipotent differentiation after monolayer passages.5;6 
In previous studies, we developed a novel mesenchymal stem cells expansion system based 
on the three-dimensional (3D) extracellular matrix (ECM) deposited by synovium-derived 
stem cells (SDSCs). This system dramatically improved the proliferation and chondrogenic 
potential of SDSCs7 and adipose-derived stem cells (ADSCs). 
 
These natural ECM were first used to investigate tumor progression8;9 and provided an 
excellent model to study cell behaviors in the 3D environment. The native 3D ECM is 
proposed to mimic the in vivo microenvironment, thus directing MSCs in morphology, cell-cell 
and cell-matrix interaction, self-renewal and differentiation.7;10;11 Compared to conventional 
2D reconstructed ECM, which is usually coated with several protein monolayers, including 
fibronectin,12 type I collagen13 or laminins,14 the native cell-deposited ECM not only provides 
3D structure but also has multiply matrix proteins to affect the cell signaling pathway, 
including type I, III and V collagens, syndecan-1, perlecan, fibronectin, laminin, biglycan and 
decorin.7;10;15 
 
Integrins are heterodimeric transmembrane receptors that are composed by an α and a β 
subunit. They mediate the interaction between ECM and cells, thus affecting the cell 
adhesion, survival, self-renewal, apoptosis, migration and differentiation16. Attaching to 
various ECM proteins, integrins combine two different α and β subunits. β1 integrin are 
proven to bind collagen and fibronectin17 and α5β1 and αVβ3 integrins were reported in the 
process of cells attaching on the 3D ECM.15;18 ECM provides a structural scaffold to resist 
tensile and compressive stress and functions as a tight connection to cell cytoskeleton 
through cell-surface receptors enabling cells to sense and respond to the extracellular 
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mechanical and chemical signals.16;19;20  
 
However, the cell signaling pathway associated with 3D native ECM is still unclear and 
different from that on 2D reconstructed ECM. It is reported that the activity of focal adhesion 
kinase (FAK) which mediates integrin activation is suppressed by 3D ECM. But ECM induced 
sustained phosphorylation of Src kinase, whose downstream extracellular signal regulated 
kinases 1 and 2 (ERK1/2) thus is elevated.11;15;21 Integrins also play an important role in cell 
proliferation through ERK1/2 dependant pathway by activating cyclin D1 to promote cell 
division.19;22;23 Several integrins, including α5β1, αVβ3 and α4β1 were reported to be activated 
when binding to ECM components such as fibronectin and collagens.16;20;24-27 
 
In this study, we expanded human bone marrow stem cells (hBMSCs) under two different 
conditions: (1) cells grown on conventional plastic flasks were used as the control group 
(Plastic); (2) cells were cultured on 3D native hBMSC-deposited ECM (ECM). Considering 
the importance of integrins and ERK1/2 in mediating cell proliferation, we tested 10 integrin 
subunits immunophenotype, and the activation level of Src kinase, ERK1/2 and cyclin D1. 
After separate expansion on ECM and Plastic, hBMSCs were induced to chondrogenesis and 
several key proteins were examined including transforming growth factor β receptor II (TGF-β 
receptor II), Sox9, type II collagen and ERK1/2. Interestingly, we found that 3D 
hBMSC-deposited ECM induced sustained activation of ERK1/2 and cyclin D1 and enhanced 
TGFβ receptor II activity during chondrogenesis. 
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MATERIALS AND METHODS 
 
Preparation of hBMSC-derived extracellular matrix (ECM)  
Human bone marrow stem cells (hBMSCs) were purchased from Lonza (Lonza Group Ltd., 
Switzerland). The procedure of obtaining cell-free extracellular matrix was described 
previously7. 75 cm2 plastic flasks were pretreated with 0.2% gelatin solution (Sigma, St. Louis, 
MO) for 1 hour at 37˚C, followed by  1% glutaraldehyde (Sigma) and 1 M ethanolamine 
(Sigma) for 30 minutes separately at room temperature. Human BMSCs were seeded on 
pretreated plastic flasks at the density of 3,000 cells/cm2 in culture medium [α-minimum 
essential medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS, 
Atlanta Biologicals, Lawrenceville, GA), 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 
μg/ml fungizone (Invitrogen)] for 7 days. After reaching 90% confluence, 50 mg/mL of 
L-ascorbic acid phosphate (Wako, Richmond, VA) was added and continued to culture for an 
additional 8 days. To obtain cell-free ECM, ECM deposited by hBMSCs was incubated with 
0.5% Triton X-100 (Sigma) containing 20 mM ammonium hydroxide (Sargent-Welch, Skokie, 
IL) for 5 minutes at 37ºC, followed by 100 u/mL DNase I (Sigma) for 1 hour at 37˚C and 
stored at 4ºC.  
 
In vitro culture of hBMSCs on Plastic and ECM 
Passage 6 BMSCs were expanded under two different conditions: conventional plastic flasks 
(Plastic) and flasks coated with hBMSC-derived ECM (ECM). Non-adherent cells were 
removed by medium change every three days. At each passage, cell number was calculated 
by a counting hemacytometer (Hausser Scientific, Horsham, PA) for cell number fold change. 
 
Cell proliferation assay 
Before subculturing on Plastic and ECM, passage 6 hBMSCs were labeled with CellVue® 
Claret (Sigma) at 2 × 10-6 M for 5 minutes according to the manufacture protocol. After the 
7-day expansion, cells were collected and measured by a BD dual laser FACS Calibur (BD 





Measurement of intracellular reactive oxygen species (ROS) 
Intracellular ROS generation was measured with 2′,7′-dichlorofluorescein diacetate (DCF-DA) 
(Sigma). In brief, after detachment, 2 × 105 of cells (n = 3) were incubated with 10 μM of 
DCF-DA for 10 minutes at 37ºC. After washing twice with PBS, the DCF fluorescence was 
measured by a BD dual laser FACS Calibur (BD Biosciences) using FCS Express software 
package (De Novo Software, Los Angeles, CA) and 10000 events of each sample were 
analyzed. 
 
Apoptosis analysis of hBMSCs on Plastic and ECM 
Vybrant® Apoptosis Assay Kit (Invitrogen) was used to detect hBMSCs apoptosis. By 
following the manual, samples (n = 3) of each 2 × 105 cells were labeled with FITC annexin V 
and propidium iodide for 15 minutes at room temperature. After washing with PBS the 
fluorescence was measured by FACS Calibur (BD Biosciences) and 10000 events of each 
sample were analyzed. 
 
Flow cytometry analysis 
The following primary antibodies were used in flow cytometry analysis to detect hBMSCs 
surface immunophenotype profiles: CD14, CD24, integrin β1 (CD29), CD44, CD45, CD71, 
CD73, CD166 were purchased from Abcam (Abcam, Cambridge, MA); CD105, SSEA-4, 
integrins of α1 (CD49a), α2 (CD49b), α3 (CD49c), α4 (CD49d), α5 (CD49e), α6 (CD49f), β3 
(CD61), and β4 (CD104) were from Santa Cruz (Santa Cruz Biotechnology, Santa Cruz, CA); 
CD90 (BD Biosciences); Integrin β5 (Cell Signaling Technology, Danvers, MA). IgG1 and 
IgG2a (Beckman Coulter, Fullerton, CA) were used as the isotype controls, and the 
secondary antibody was goat anti-mouse IgG (H+L) R-phycoerythrin conjugated (Invitrogen). 
Samples (n = 3) of each 0.2 × 106 chondrocytes were incubated on ice in cold PBS containing 
0.1% ChromPure Human IgG whole molecule (Jackson ImmunoResearch Laboratories, 
West Grove, PA) and 1% NaN3 (Sigma) for 30 minutes. After that cells were incubated in the 
primary antibodies and the secondary antibodies for 30 minutes separately in the dark. The 
fluorescence was analyzed by a FACS Calibur (BD Biosciences) using FCS Express software 
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package (De Novo Software). 
 
Chondrogenic differentiation of hBMSCs 
3 × 105 of hBMSCs at passage 6 cultured on Plastic and ECM were centrifuged to form 
pellets in a 15-ml polypropylene tube at 500 g for 5 minutes. After 24 hours the pellets were 
incubated in chondrogenic medium [high-glucose DMEM, 40 µg/ml proline, 100 nM 
dexamethasone (Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin, 0.1 mM ascorbic 
acid-2-phosphate and ITS™ Premix (BD Biosciences) with the supplementation of 10 ng/ml 
of TGF-β3 (PeproTech Inc., Rocky Hill, NJ)]. Pellets at day 0, day 7 and day 15 were collected 
for further analysis. 
 
Histology and Immunohistochemistry 
The chondrogenic pellets (n = 2) were fixed in 4% paraformaldehyde, embedded in paraffin 
blocks and cut into 5-μm thick sections. To detect glycosaminoglycans, sections were stained 
with 0.2% Alcian blue solution (Sigma). For immunohistochemistry the sections were 
incubated with primary antibodies against type II collagen (II-II6B3, DSHB, Iowa City, IA), 
type I collagen (Sigma) and type X collagen (Sigma), followed by the secondary antibody of 
biotinylated horse anti-mouse IgG (Vector, Burlingame, CA) and detected by using Vectastain 
ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as the substrate. 
 
Biomechanical analysis for hBMSC pellets  
The pellets (n = 4) were placed into a reservoir filled with PBS and loaded onto the custom 
miniature stepper motor driven compression device. This device used a 10 gram load and a 
miniature displacement readout. A small preload of 10-4 Newton was applied before a 10 
percent strain at a 1 second duration. From the linear portion of the load displacement curve, 
the stiffness and Young’s modulus were calculated for the spherical shaped pellet.28 
 
Biochemical analysis for DNA and glycosaminoglycan content 
To exam DNA and sulfated glycosaminoglycans (GAGs) content, pellets (n = 4) were 
digested for 6 hours at 60ºC with 125 μg/ml papain in PBE buffer (100 mM phosphate, 10 mM 
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EDTA, pH 6.5) containing 10 mmol/L cysteine. The amount of DNA was measured by e 
QuantiTTM PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor® Series 4000 (Applied 
Biosystems, Foster City, CA) followed by the protocol. Sulfated GAGs were measured by 
using 16 µg/ml of dimethylmethylene blue dye and a SpectronicTM BioMateTM 3 
Spectrophotometer (Thermo Scientific, Milford, MA) with bovine chondroitin sulfate (Sigma) 
as the standard. 
 
Real-time polymerase chain reaction (Real-time PCR) 
The total mRNA from pellets (n = 4) was extracted by using TRIzol® (Invitrogen) and 
converted to cDNA with High-Capacity cDNA Archive Kit as recommended by the 
manufacturer (Applied Biosystems). Chondrogenic marker genes (aggrecan, type I and II 
collagen, and Sox9) and hypertrophy marker genes (type X collagen, MMP13) are 
customized by Applied Biosystems as part of the Custom Taqman® Gene. Expression Assays 
Eukaryotic 18S rRNA (Assay ID HS99999901_s1 ABI) was carried out as the endogenous 
control gene. Real-time PCR was performed with the iCycler iQTM Multi Color RT-PCR 
Detection and calculated by computer software (Perkin-Elmer, Waltham, MA). Relative 




RIPA lysis buffer (Thermo Scientific) supplemented with halt protease and phosphatase 
inhibitor cocktail (Thermo Scientific) was used to extract protein from the cells. The protein 
concentration was quantified using BCATM Protein Assay Kit (Thermo Scientific). The 
samples was denatured and separated by NuPAGE® Novex® Bis-Tris Mini Gels (Invitrogen) 
at 200V for 45 minutes at 4oC, then transferred onto a nitrocellulose membrane (Invitrogen) 
using XCell IITM blot module (Invitrogen) at 30V for 1 hour at 4oC. The membranes were firstly 
blocked in SuperBlock (TBS) Blocking Buffer (Thermo Scientific), then incubated with the 
primary monoclonal antibodies at recommended dilution overnight at 4oC. The membranes 
were incubated in the secondary antibody of Goat Anti-Mouse IgG (H+L) and Goat 
Anti-Rabbit IgG (H+L) (Thermo Scientific) for 40 minutes at room temperature and exposed 
206 
 
using SuperSignal® West Pico Chemiluminescent Substrate (Thermo Scientific) and 
CL-XPosureTM Film (Thermo Scientific). The following primary antibodies were used in 
immunoblotting: integrin α2, integrin α5, cyclin D1, transforming growth factor - β receptor II 
(TGF-β RII), and phospho-TGFβ receptor II (Tyr424) were purchased from Santa Cruz; integrin 
β5, phospho-cyclin D1 (Thr286), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), p44/42 MAPK 
(Erk1/2), phospho-Src family (Tyr416), and Src were from Cell Signaling; Sox9  and β-actin 
were from Abcam; type II collagen (CIIC1) was from DSHB. 
 
Statistical Analysis 
The Kruskal-Wallis test was used to determine significant differences among all groups, and 
Mann-Whitney U test was used for pairwise comparison. Statistical analyses were performed 
with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less than 0.05 were 





ECM promoted hBMSC proliferative rate and induced directional migration 
Passage 6 hBMSCs were expanded on conventional plastic flasks (Plastic) and flasks coated 
with extracellular matrix (ECM) at the initial density of 3,000 cells/cm2 for 7 days. In regard to 
cell morphology, hBMSCs on Plastic appeared large and flattened, consistent with our 
previous study on SDSCs. In contrast, hBMSCs on ECM were smaller and spindle-like during 
the whole expansion period; the cells overlapped but maintained the same morphological 
appearance. It was observed that hBMSCs grown on ECM underwent directional migration 
along the ECM fibrils whereas the cells grown on Plastic showed random movement (Figure 
6.1A). 
 
After 7-day expansion, hBMSCs on ECM yielded 16.8 ± 2.3 fold change of the cell number, 
while Plastic group produced 6.7 ± 0.4 fold increase (Figure 6.1B). The proliferation index of 
ECM group created by Proliferation Wizard Basic Model was 11.2 ± 0.2 and that of Plastic 
group was 5.3 ± 0.1 (Figure 6.1C). The proliferation index is the sum of all hBMSC 
generations divided by the parent cells measured at the start of expansion.  
 
ECM attenuated the stress of intracellular reactive oxygen species but increased apoptosis 
We examined the intracellular level of ROS stress in hBMSCs cultured on Plastic and ECM by 
staining the cells with DCF-DA. The hBMSCs cultured on Plastic showed a markedly higher level 
of DCF fluorescence compared with those cultured on ECM. At the start of passage 6 expansion, 
the mean fluorescence intensity (MFI) of DCF was 184 ± 15. At day 4 the MFI of Plastic group was 
202 ± 5 which was 2.1-fold that on ECM (98 ± 12). At day 7 the MFI of Plastic group reached 241 
± 15 which was 1.7-fold that on ECM (139 ± 5) (Figure 6.1D). In the regard to apoptosis analysis, 
however, ECM group showed higher apoptotic stress than Plastic group. The percentage of both 
annexin V and propidium iodide positive cells on ECM was 14% - 144% higher than that on 
Plastic (Figure 6.1E).  
 
Immunophenotype profile of hBMSCs on Plastic and ECM 
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Flow cytometry was used to identify the immunophenotype profile of hBMSCs expanded on 
Plastic and ECM. Five-surface antigen expression level (Mean florescence intensity) increased in 
ECM group compared to Plastic group Figure 6.2A): SSEA-4 (100 vs. 48), CD71 (12 vs. 9), 
CD49b (integrin α2, 40 vs. 15), CD49d (integrin α4, 15 vs. 12) and integrin β5 (374 vs.74). 
Ten-antigen expression level decreased after culturing on ECM (Figure 6.2B): CD90 (367 vs. 
502), CD105 (177 vs. 273), CD166 (58 vs. 66), CD49a (integrin α1, 12 vs. 22), CD49c (integrin α3, 
227 VS. 695), CD49e (integrin α5, 68 vs. 103), CD29 (integrin β1, 141 vs. 210), and CD61 (integrin 
β3, 14 vs. 19). However, seven-antigen expression level showed no difference between the two 
groups (Figure 6.2C): CD14, CD44, CD45, CD73, CD24, CD49f (integrin α6) and CD104 (integrin 
β4). 
 
Extracellular matrix induced changes of integrin and TGFβ receptor II expression and 
promoted phosphorylation of Src, ERK1/2 and cyclin D1 
Immunoblotting analysis demonstrated that the expression of integrin α2 and β5 was 
up-regulated when hBMSCs were expanded on ECM, while the level of integrin α5 was 
down-regulated (Figure 6.3), consistent with the immunophenotype profile. Interestingly, the 
expression of TGF-β receptor II (TGF-β RII) dramatically increased after treatment with ECM 
rather than Plastic, and TGF-β receptor I showed the same tendency (data not shown). 
Considering the relationship between integrin and extracellular-signal regulated kinases (ERK), 
we tested the activity of Src kinase and ERK1/2. The phosphorylation level of Src and ERK1/2 
was dramatically enhanced after hBMSC culturing on ECM compared with the control group 
(Plastic). The Src level was lower in ECM group at Day 5 but higher at Day 9, whereas ERK1/2 
total protein content was continuously higher in ECM group. In order to illuminate the potential 
mechanism that ECM improved hBMSC proliferative rate, we used antibodies to probe the 
steady-level and phosphorylation of cyclin D1. After ECM expansion, we found a higher level of 
cyclin D1 expression and phosphorylation in BMSCs during the whole expansion period. Since 
the expression and activation of cyclin D1 was directly related to cell division and proliferation, the 





ECM enhanced hBMSC chondrogenic differentiation potential 
To compare the chondrogenic potentials of hBMSCs cultured on Plastic and ECM, cells were 
induced to differentiate in the pellet culture system by 10 ng/mL of TGF-β3. After 15-day 
differentiation, pellets of ECM group exhibited a larger size than those of Plastic group 
(Figure 6.4A). At Day 0 no positive histology staining was detectable in either groups (data 
not shown). At Day 7 Plastic group was barely positive for Alcian blue, which stained sulfated 
glycosaminoglycans (GAGs). However, pellets of ECM group were strongly positive for 
sulfated GAGs. The results of type II collagen immunohistochemistry were similar to those of 
Alcian blue staining, in which pellets cultured with ECM treatment displayed stronger 
expression than those on Plastic. Immunohistochemistry of type I collagen was nearly 
negative except for positive area on the edge of the pellets of ECM group. At Day 15 pellets of 
ECM group were more intensive in Alcian blue staining and type II and type I collagen 
immunohistochemistry than those of Plastic. Type X collagen immunohistochemistry was 
negative in all pellets (Figure 6.4B). 
 
Pellets of ECM group yielded more sulfated GAGs than Plastic group (7.7 μg vs. 4.7 μg at 
Day 7 and 34.4 μg vs. 9.9 μg at Day 15) (Figure 6.5A). With respect to DNA amount, at Day 
15 hBMSC of ECM group maintained the DNA level better than Plastic group (79% vs. 61% at 
Day 15) (Figure 6.5B). The chondrogenesis index, defined by the ratio of GAGs and DNA, 
illustrated the grade of hBMSC chondrogenic potential. Similar to the GAG amount, hBMSCs 
of ECM group showed stronger chondrogenic differentiation than the cells of Plastic group 
(3.6 vs. 1.6 at Day 7 and 16.6 vs. 3.8 at Day 15) (Figure 6.5C). 
 
To obtain mechanical properties, chondrogenic pellets were examined for stiffness and 
Young’s modulus. At Day 15, pellets of ECM group were 39.9 ± 9.5 N/M in stiffness compared 
with 24.9 ± 4.7 of Plastic (Figure 6.5D). In regard to Young’s modulus, ECM group was 0.6 ± 
0.1 MPa and Plastic group was 0.3 ± 0.1 MPa (Figure 6.5E). 
 
Four typical chondrogenic marker genes were detected in hBMSCs expanded on ECM and 
Plastic. At the level of type II collagen mRNA expression, pellets of ECM group produced 
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217-fold at Day 7 and 9-fold at Day 15 compared to Plastic group (Figure 6.6A). Aggrecan 
mRNA expression showed the same tendency; ECM group yielded a 5.5-fold increase 
compared with Plastic group at Day 7 (Figure 6.6B). Type I collagen was the chondrogenic 
maker at the early stage, which was expressed higher in ECM group at Day 7 but lower at 
Day 15 (Figure 6.6C). In regard to Sox9 mRNA level, pellets of Plastic group produced 5% at 
Day 7 and 36% at Day 14 more than ECM group (Figure 6.6D). 
 
The level of phosphorylation of TGF-β receptor II and expression of Sox9 was enhanced after 
expansion on ECM in the process of chondrogenic differentiation 
In the expansion period, we found that hBMSCs expressed a higher level of TGF-β RII after 
culturing on ECM. To determine if the high level of TGF-β RII would improve hBMSC 
chondrogenic potential, we tested the phosphorylated level of TGF-β RII during chondrogenic 
induction. At Day 7 and Day 15, hBMSC pellets of ECM group showed a higher level of activation 
of TGF-β RII than that of Plastic group. Sox9, as a chondrogenic-related transcription factor, had 
stronger expression in ECM group. The higher level of phosphorylation of TGF-β RII and Sox9 
would be responsible for the improvement of chondrogenic differentiation potential. Type II 
collagen was examined by immunoblotting and hBMSCs of ECM group yielded more amount than 
Plastic group, which was consistent with immunohistochemistry data. The activity of ERK1/2 was 






In this study we expanded human bone marrow stem cells in conventional plastic flasks and 
on native 3D hBMSC-deposited extracellular matrix. Human BMSCs cultured on ECM had a 
higher proliferative rate, attenuated stress of intracellular ROS, a different immunophenotype 
profile from those expanded on Plastic, and gained an enhanced chondrogenic differentiation 
potential. We also explored the activity of several key signaling molecules of hBMSCs on 
Plastic and ECM during in vitro expansion and chondrogenesis. The results demonstrated 
that native 3D hBMSC-deposited ECM induced an increase of integrin α2 and β5, and 
enhanced the activity of tyrosine kinase Src, the downstream of ERK1/2 and cyclin D1. At the 
same time, 3D ECM also elevated the expression of TGF-β receptor II in hBMSCs and 
promoted the phosphorylation of TGF-β receptor in chondrogenic differentiation. 
 
Consistent with our previous study of synovium-derived stem cells (SDSCs),7 the 3D ECM 
improved hBMSC proliferative rate that was 2.5-fold that of Plastic group. Cyclin D1 is proven to 
control the cell cycle progression through G1 phase and entry into S phase.22;29 The steady-state 
level of activation of ERK1/2 is necessary for cyclin D1 phosphorylation and translocation, while 
the inhibition of ERK1/2 and the upstream kinases results in the decreased activity of cyclin 
D1.22;23 Not only the expression level of cyclin D1 but also the phosphorylation was greatly 
increased in hBMSCs after expanding on 3D ECM; this could be one of the reasons for the higher 
proliferative rate induced by ECM. In this study the higher activation of cyclin D1 possibly resulted 
from increased Src kinase and ERK1/2.29 A similar 3D ECM deposited from NIH 3T3 cells also 
induced sustained activation of Ras and ERK1/2 through Src kinase and the blockage of Src 
resulted in suppression of ERK1/2.11 
 
Intracellular ROS plays an important role in cell adhesion, migration, and proliferation and 
thus is essential for cell survival.30 The low concentration of ROS has a promotional effect on 
cell adhesion, whereas the high level of ROS would result in cell death.31 A high level of ROS 
has an inhibitory influence on cell proliferation by arresting the cell cycle at the G1, S, and G2 
phases through down-regulation of cyclin D1 and D3 signaling.32 Kim et al. showed that an 
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increase of intracellular ROS generation arrested the cell cycle at G0 - G1 phase by inhibiting 
the cyclin D1/CDK4 complex.33 The attenuated level of ROS by 3D ECM was reported 
previously,34 and the suppression of ROS production resulted in the activation of FAK and Src 
kinases to improve the cell adhesion and survival.35  
 
The 3D ECM induced changes in the cell immunophenotype profile that was reported in our 
previous and other studies.7;34 The cell surface marker expression is closely related to cell 
proliferation, differentiation and immunosuppression of mesenchymal stem cells.36 SSEA-4 that 
was originally discovered as an early embryonic glycolipid antigen in embryonic stem cells, was 
recently reported to express in mesenchymal stem cells and indicated that SSEA-4 would be a 
promising cell surface marker for cell identification and isolation37-39. In this study the increase of 
SSEA-4 positive cell population induced by 3D ECM might be correlated to the improved 
chondrogenic differentiation capacity, consistent with other studies.40 However, CD90 
immunofluorescence intensity was attenuated in hBMSCs expanded on ECM which was 
inconsistent with our previous study on SDSCs; the difference could be due to the different MSC 
tissue sources.41-44 
 
The interaction between ECM and cells is mainly dependent on integrin-induced signaling 
transduction. The conventional 2D ECM was proven to induce integrin activation through focal 
adhesion kinase (FAK), Src family kinase, and integrin-linked kinase (ILK) signaling 
pathways.16;45-47 The FAK pathway was activated by integrin α5, αV, and β1 in the process of cell 
adhesion to fibronectin and collagen substrates48 and the FAK autophosphorylation at Tyr397 
to induce the activation of Src family kinase and mitogen-activated protein kinase (MAPK) 
cascades.20;49-52 However Damianova et al. reported on 3D ECM the autophosphorylated 
level of FAK was attenuated.11;15 The three-dimensional structure and the complex 
components of the native cell-deposited ECM resulted in a distinct intracellular signaling 
pathway compared to that in an 2D conventional environment.11;15;16;53 The increase of 
integrin α2 and β5 and the decrease of integrin α5 and β1 was confirmed by FACS and 
immunoblotting in this study. Integrin α2 and β5 contribute significantly to cell focal adhesion 
and survival on fibrillar collagen substrate through Src and ERK-mediated signaling 
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pathways.26;54-56 Meanwhile the activated Src increased the expression of α2 integrin to 
improve cell survival.57 However, Src is also activated by other receptor kinases,27;58;59 so it is 
still unclear how the sustained activation of Src and ERK1/2 was induced by 3D ECM through 
certain specific integrins or other signaling receptors. 
 
The greatly enhanced chondrogenic differentiation capacity of hBMSCs after expansion on 3D 
ECM was similar to our previous study on SDSCs7, adipose-derived stem cells and articular 
chondrocytes. We first demonstrated that the expression of TGF-β receptor II was increased by 
the 3D ECM expansion system in hBMSCs. The high expression of TGF-β receptor II in 
hBMSCs after culturing on ECM and the sustained steady-state phosphorylated level of 
TGF-β receptor II induced by TGF-β1 in chondrogenesis would be responsible for the strong 
expression of Sox9 and type II collagen.60 Moreover, decorin, fibronectin, laminins, and type I 
and III collagens, identified in the 3D hBMSC-deposited ECM10;34, played an important role in 
TGF-β receptor responsiveness and modulating TGF-β bioactivity during cell proliferation and 
differentiation61-64. Decorin was also reported to promote α2β1 integrin-dependant cell 
adhesion and migration65 that was related in this study to the elevated level of integrin α2. The 
improved chondrogenic differentiation potential of BMSCs expanded on the 3D ECM is 
possibly due to the high responsiveness and sensitivity to TGF-β. Integrins also played a 
crucial role in chondrogenesis such as integrin β166 and interacted with type II collagen 
through integrin α2 when differentiating to mature chondrocytes67. The mechanism of 
elevated TGF-β receptor II expression is still unclear but possibly related to the crosstalk 
between TGF-β receptors and integrin. Reynolds et al. reported that, in dermal fibroblasts, the 
deficiency of integrin β3 caused the increased expression of both TGF-β receptor I and 
receptor II.68 Myofibroblastic differentiation in dermal fibroblasts was induced by αVβ5 integrin 
because of the recruitment of latent TGF-β1 and activation of TGF-β receptors.69 However the 
mechanism of integrin interaction with TGF-β receptors induced by 3D ECM remains to be 
established. 
 
The role of ERK1/2 in chondrogenic differentiation is controversial. The conventional opinion 
is that MAPK cascade was activated by TGF-β and the phosphorylated ERK1/2 promoted the 
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expression of chondrogenic genes such as aggrecan and type II collagen.70;71 However 
recent research suggested that the inhibition of ERK1/272-74 or JNK75 can improve the 
chondrogenic differentiation of MSCs that were considered as two important TGF-β 
non-Smad signaling pathways. We found similar decreased activity of ERK1/2 during the 
chondrogenic differentiation especially in hBMSCs expanded on ECM. The possible 
explanation is that the activation of ERK1/2 initiates the transcription of chondrogenic-specific 
genes such as aggrecan and type II collagen but, in the long-term induction to 
chondrogenesis, ERK1/2 would give way to other signaling pathways such as PI3K/Akt to 
generate cartilage-specific matrix.73;75 
 
In summary our study demonstrated that the utilization of the new 3D cell-deposited ECM on 
hBMSC in vitro expansion was able to dramatically increase the cell proliferative rate, 
attenuate the stress of intracellular ROS, and improve the chondrogenic differentiation 
potential. We demonstrated that 3D ECM induced sustained activation of Src kinase and 
ERK1/2 and phosphorylated cyclin D1 to promote the cell-cycle and proliferation. The 
enhanced chondrogenic differentiation ability of hBMSCs by the 3D ECM was because of the 
high expression and sensitivity of TGF-β receptor II. Due to the complexity of the 3D ECM, 
the cell signaling transduction is different from that in 2D monolayer culture condition and 
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Figure 6.1 Extracellular matrix (ECM) induces changes in the human bone marrow stem cells 
(hBMSCs) affacting cell morphology, proliferative rate, intracellular reactive oxygen species 
(ROS) and apoptosis level in the period of monolayer expansion. (A) Representative phase 
contrast images of hBMSC in the middle of expansion; (B) hBMSC cell number fold change 
after 7-day monolayer expansion under Plastic and ECM culture conditions; (C) the 
proliferation index of hBMSC on Plastic and ECM analyzed by flow cytometry; (D) 
intracellular ROS level decreases when culturing on ECM; (E) the percentage of apoptotic 
cells varies differently on Plastic and ECM. Data are shown as average ± SD. 
 
Figure 6.2 Immunophenotype profile of hBMSCs cultured on Plastic and ECM. (A) hBMSCs 
cultured on ECM showed increase in the positive-percentage and fluorescence intensity of 
SSEA-4, CD71, CD49b, CD49d, and integrin β5; (B) hBMSCs cultured on Plastic have higher 
expression of CD73, CD90, CD105, CD166, CD44, CD49a, CD49c, CD49e, CD29 and CD61; 
(C) the expression level of CD14, CD45, CD24, CD49f and CD104 shows no difference 
between Plastic and ECM groups.  
 
Figure 6.3 Immunoblotting of hBMSCs when expanding on Plastic and ECM. Total lysates of 
hBMSCs were detected to the antibodies of integrin α2, integrin β5, integrin α5, transforming 
growth factor β receptor II (TGFβ receptor II). The lysates were also probed to 
phospho-Cyclin D1 (Thr286), Cyclin D1, phospho-Src family (Tyr416), Src, phospho-p44/42 
MAPK (Erk1/2) (Thr202/Tyr204), and p44/42 MAPK (Erk1/2). β actin was used as an internal 
control for protein loading. 
 
Figure 6.4 Phase image, histology and immunohistochemistry of hBMSC pellets under 
chondrogenic stimulation. (A) typical hBMSC pellets of Plastic and ECM groups phase 
images; (B) Alcian blue staining was used to detect sulfated glycosaminoglycans (GAGs), 





Figure 6.5 Biochemistry to analyze glycosaminoglycans (GAGs) and DNA content of 
hBMSCs chondrogenic differentiation of Plastic and ECM groups. (A), GAGs of hBMSC 
pellets were measured at day 0, day 7 and day 15; (B), DNA content of hBMSC pellets 
changes during 15 days normalized by the content of pellets at day 0; (C), chondrogenesis 
index (the ratio of GAGs and DNA) represented the degree of chondrogenic differentiation of 
hBMSCs; mechanical testing was used to examine the stiffness (D) and Young’s modulus (E) 
of hBMSC pellet after chondrogenic differentiation. Data are shown as average ± SD for n = 5 
for DNA and GAGs analysis and n=4 for mechanical testing. 
 
Figure 6.6 (A) to (D) Real-time PCR to examine the chondrogenic marker gene expression 
level (type I and II collagen, aggrecan, sox-9) normalized by 18S rRNA. (E) and (F) the 
hypertrophic gene expression (type X collagen and MMP13) was tested in hBMSC pellets. 
Data are shown as average ± SD for n = 4. 
 
Figure 6.7 Immunoblotting of hBMSC chondrogenic pellets was used to detect 
phospho-TGFβ receptor II (Tyr 424), Sox9, type II collagen, phosphorylated ERK1/2 and 
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Three-dimensional extracellular matrix (ECM) has been used as an in vitro expansion system 
for mesenchymal stem cells. However it is unknown whether different ECMs distinctly affect 
cell proliferation and differentiation. We generated two types of ECM separately from 
synovium-derived stem cells (SDSCs) and articular chondrocytes. SDSC-deposited ECM 
(S-ECM) contains fibrillar type I collagen whereas chondrocyte-deposited ECM (C-ECM) 
composes fibrillar type I and II collagens with proteoglycans. SDSCs and chondrocytes were 
separately expanded on three substrates: conventional plastic culture flasks (Plastic), S-ECM 
and C-ECM. The cell proliferative rate was improved by the two ECMs compared with the 
conventional plastic culture system. S-ECM promoted cell self-renewal of SDSCs and 
chondrocytes but C-ECM showed strong support on chondrocytes only. SDSC and 
chondrocyte pellets were induced to chondrogenic differentiation with transforming growth 
factor β-1. The chondrogenic potential of SDSCs and chondrocytes after expansion on ECM 
was enhanced. However SDSCs expanded on S-ECM expressed a higher level of 
chondrogenic genes and generated more cartilage-specific matrix than those on C-ECM. 
Chondrocytes expanded on S-ECM and C-ECM showed a similar chondrogenic 
differentiation level. The enhanced chondrogenic potential by 3D ECM is partially related to 
the high sensitivity of TGF-β receptor II. In conclusion, we demonstrated that 
SDSC-deposited ECM was superior to chondrocyte-deposited ECM and functions as a 
universal expansion system in vitro for MSCs and differentiated cells to promote proliferative 





Articular cartilage is a unique tissue with an avascular structure.1 Due to the limited self-repair 
mechanism, cartilage is vulnerable to degenerative disease after trauma or osteoarthritis.2;3 
Autologous chondrocyte transplantation (ACT) has been successfully used in clinical practice 
to repair cartilage defects.4;5 ACT relies on a biopsy from a non-weight bearing cartilage area, 
expansion of articular chondrocytes in vitro, and transplantation into the defect site which is 
sealed with a periosteal graft or collagen membrane.6;7 The disadvantages of ACT includes 
the rapid dedifferentiation of chondrocytes during in vitro expansion, which is the process of 
cell morphology changing to a fibroblast-like shape and an elevated expression of type I 
collagen instead of type II collagen.5-7 
 
Adult mesenchymal stem cells (MSCs) provide a promising approach for the cartilage 
regeneration; these cells are derived from various tissues including bone marrow,8;9 adipose 
tissue,10 synovium,11 periosteum,12 skeletal muscle13 and other connective tissues14. 
Numerous researchers have reported the successful generation of hyaline cartilage-like 
tissue in vitro15;16 and the use of this tissue to repair partial-thickness or full-thickness 
cartilage defects in animal models.17;18 Among the various MSCs, synovium-derived stem 
cells (SDSCs) are considered to have superior proliferative ability and chondrogenic 
potential.19;20  
 
MSC-based cartilage regeneration, however, faces similar challenges as ACT. The limited 
self-renewal ability of MSCs is one of disadvantages compared with embryonic stem cells 
(ESCs) and induced pluripotent stem (iPS) cells.21;22 The proliferative ability of MSCs usually 
dramatically decreases after 10 passages and eventually disappears.23;24 To retain the 
proliferative ability of MSCs, cells are required to be cultured from a relatively low seeding 
density25;26 or stimulated with growth factors such as fibroblast growth factor 2 (FGF-2).27 The 
conventional in vitro culture of MSCs requires weekly passage in order to maintain their 
proliferative and multipotential abilities.28 However MSCs of late passages (≥15) still lose their 
multipotency and only differentiate to adipocytes.29 The limitation of the current in vitro culture 
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of MSCs is that, once isolated from the in vivo microenvironment, they lose their proliferation 
and multipotent differentiation potentials similar to aged cells.30-32 
 
Our previous work demonstrated that the utilization of a natural, three-dimensional (3D), 
cell-deposited extracellular matrix (ECM)33 in the expansion of SDSCs can dramatically 
improve SDSC self-renewal and chondrogenic potential. This native 3D ECM has also been 
deployed in the culture of articular chondrocytes that successfully delayed chondrocyte 
dedifferentiation and enhanced redifferentiation. However this proposed another question 
whether tissue-specific generated ECM would have a similar or opposite effect on cell 
proliferation and differentiation.  
 
Type I collagen was confirmed to be one of the components in SDSC-deposited ECM33 that 
has been used to promote proliferation and differentiation of MSCs and articular 
chondrocytes in two-dimensional (2D) substrate34 and 3D gel format.35 Type II collagen is 
another candidate to improve cell attachment and chondrogenesis; it is less commonly used 
than type I collagen. Hyaline cartilage is composed of type II collagen and sulfated 
proteoglycans (mainly aggrecan) that support chondrocyte morphology and gene 
expressions.36 Therefore, chondrocytes or MSCs in scaffolds made by type II collagen coated 
with proteoglycans have a better potential to promote cell proliferative rate and chondrogenic 
differentiation potential than type I collagen gel.37;38 
 
In the current study, we hypothesized that ECM deposited by different cells can influence cell 
proliferation and differentiation potentials in distinct ways. We manufactured two distinct 
ECMs deposited by SDSCs or articular chondrocytes. Porcine SDSCs and chondrocytes 
were separately expanded under three conditions: the conventional plastic culture flasks 
(Plastic) serving as the control group and SDSC-deposited ECM (S-ECM) and 
chondrocyte-deposited ECM (C-ECM) serving as experimental groups. The data showed that, 
when culturing SDSCs, S-ECM showed superiority in cell proliferation and chondrogenesis 
over C-ECM and Plastic. Surprisingly, we found that chondrocytes expanded on S-ECM and 
C-ECM showed similar improvement that was much greater than cells grown on Plastic. 
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MATERIALS and METHODS 
 
Isolation and culture of SDSCs and chondrocytes 
Synovium and cartilage tissue were collected from two 3-month-old miniature pigs as 
previously described.20;39 Briefly, chondrocytes were digested with 0.2% collagenase P 
(Roche, Indianapolis, IN) at 37ºC overnight after being finely minced into pieces with a 
scalpel. Synovium membrane was digested at 37ºC for 30 minutes in 0.1% trypsin (Roche) 
and then for 2 hours in 0.1% collagenase P to release SDSCs. Chondrocytes and SDSCs 
were resuspended and plated in culture medium [α-minimum essential medium (Invitrogen, 
Carlsbad, CA) containing 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, 
GA), 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 μg/ml fungizone (Invitrogen)] at 
37ºC in a humidified atmosphere of 5% carbon dioxide and 95% air. Non-adherent cells were 
removed by medium change every three days. For negative isolation of SDSCs from primary 
cultures, cell suspension was incubated with Dynabeads® M-450 CD14 conjugated with a 
monoclonal antibody specific for macrophages (Dynal Biotech, Oslo, Norway) at 4ºC for 1 
hour. The conjugated cells and the unbound Dynabeads® were collected by using the Dynal 
Magnetic Particle Concentrator® (Dynal Biotech) and the depleted supernatant with SDSCs 
was saved for further passaging. 
 
Preparation of SDSC-ECM (S-ECM) and Chondrocyte-ECM (C-ECM) 
The procedure of obtaining cell-free extracellular matrix was described previously33. 75 cm2 
plastic flasks were pretreated with 0.2% gelatin solution (Sigma, St. Louis, MO) for 1 hour at 
37˚C, followed by 1% glutaraldehyde (Sigma) and 1 M ethanolamine (Sigma) for 30 minutes 
separately at room temperature. SDSCs were seeded on pretreated plastic flasks at the 
density of 3,000 cells/cm2 in culture medium for 7 days. After reaching 90% confluence, 50 
mM of L-ascorbic acid phosphate (Wako, Richmond, VA) was added and culturing was 
continued for an additional 8 days. Chondrocytes were seeded on pretreated plastic flasks at 
the density of 3,000 cells/cm2 to reach 90% confluence and changed to complete medium 
[high-glucose DMEM (Cellgro, Herdon, VA), 10% FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 10 mM HEPES (Sigma), 0.1 mM non-essential amino acids (Sigma), 0.4 mM 
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proline (Sigma), and 50 mg/L l-ascorbic acid] for an additional 8 days under 5% oxygen. To 
obtain cell-free ECM, S-ECM and C-ECM were incubated with 0.5% Triton X-100 (Sigma) 
containing 20 mM ammonium hydroxide (Sargent-Welch, Skokie, IL) for 5 minutes at 37ºC, 
followed by 100 u/mL DNase I (Sigma) for 1 hour at 37˚C and stored at 4ºC.  
 
In vitro culture of SDSCs and chondrocytes on Plastic and ECM 
SDSCs were expanded from passage 4 to passage 6 under three conditions: plastic flasks 
(Plastic), flasks coated with SDSC-deposited ECM (S-ECM), and flasks coated with 
chondrocyte-deposited ECM (C-ECM). Chondrocytes were cultured similarly to SDSCs for 3 
further passages. The culture period of each passage was 7 days and the medium was 
changed every 3 days. At each passage, cell number was calculated by a counting 
hemacytometer (Hausser Scientific, Horsham, PA) for cell proliferative rate. 
 
In vitro chondrogenic differentiation of SDSCs and chondrocytes 
3 × 105 of SDSCs and chondrocytes of passage 6 cultured on Plastic, S-ECM and C-ECM 
were centrifuged to form pellets in a 15-ml polypropylene tube at 500 g for 5 minutes. After 24 
hours, the pellets (Day 0) were incubated in chondrogenic medium [high-glucose DMEM, 40 
µg/ml proline, 100 nM dexamethasone (Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin, 
0.1 mM ascorbic acid-2-phosphate and ITS™ Premix (BD Biosciences, Bedford, MA) with the 
supplementation of 10 ng/ml of TGF-β1 (Pepro Tech Inc., Rocky Hill, NJ)]. Pellets at Day 0, 
Day 7 and Day 14 were collected for further analysis. 
 
Histology and immunohistochemistry 
The ECM deposited by SDSCs and chondrocytes and the chondrogenic pellets (n = 2) were 
fixed in 4% paraformaldehyde, embedded in paraffin blocks and cut into 5-μm thick sections. 
To detect glycosaminoglycans, sections were stained with 0.2% Alcian blue solution (Sigma). 
For immunohistochemistry, the sections were incubated with primary antibodies against type 
II collagen (II-II6B3, Developmental Studies Hybridoma Bank DSHB, Iowa City, IA), type I 
collagen (Sigma) and type X collagen (Sigma), followed by the secondary antibody of 
biotinylated horse anti-mouse IgG (Vector, Burlingame, CA) and detected by using Vectastain 
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ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB) as a substrate. 
 
Biochemical analysis for DNA and glycosaminoglycan (GAG) content 
To examine DNA and glycosaminoglycan content in pellets, samples (n = 4) were digested for 
6 hours at 60ºC by 125 μg/ml papain in PBE buffer (100 mM phosphate, 10 mM EDTA, pH 6.5) 
containing 10 mmol/L cysteine. The amount of DNA was measured by QuantiTTM PicoGreen® 
dsDNA assay kit (Invitrogen) and CytoFluor® Series 4000 (Applied Biosystems, Foster City, 
CA) following by the protocol. The GAG content was measured by using 16 µg/ml of 
dimethylmethylene blue dye and a SpectronicTM BioMateTM 3 Spectrophotometer (Thermo 
Scientific, Milford, MA) with bovine chondroitin sulfate (Sigma) as the standard. 
 
Real-time polymerase chain reaction (Real-time PCR) 
The total mRNA from pellets (n = 4) was extracted using TRIzol® (Invitrogen) and converted to 
cDNA with High-Capacity cDNA Archive Kit as recommended by the manufacturer (Applied 
Biosystems). Chondrogenic marker genes (aggrecan, type I and II collagen, and Sox9) and 
hypertrophy marker genes (type X collagen, MMP13) were customized by Applied Biosystem 
as part of the Custom Taqman® Gene. Expression Assays Eukaryotic 18S rRNA (Assay ID 
HS99999901_s1 ABI) was carried out as the endogenous control gene. Real-time PCR was 
performed with the iCycler iQTM Mutil Color RT-PCR Detection and calculated by computer 
software (Perkin-Elmer, Waltham, MA). Relative transcript levels were calculated as χ=2-ΔΔCt, 
in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s. 
 
Immunoblotting 
The cytoplasm protein of pellets was extracted by using RIPA lysis buffer (Thermo Scientific) 
supplemented with halt protease and phosphatase inhibitor cocktail (Thermo Scientific). The 
protein concentration was quantified using the BCATM Protein Assay Kit (Thermo Scientific). 
The samples was denatured and separated by NuPAGE® Novex® Bis-Tris Mini Gels 
(Invitrogen) at 200V for 45 minutes at 4oC, then transferred onto a nitrocellulose membrane 
(Invitrogen) using XCell IITM blot module (Invitrogen) at 30V for 1 hour at 4oC. The 
membranes were first blocked in SuperBlock (TBS) Blocking Buffer (Thermo Scientific), then 
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incubated with the primary monoclonal antibodies of phospho-TGFβ RII (Tyr 424) (Santa 
Cruz Biotechnology, Santa Cruz, CA), Sox9 (Abcam, Cambridge, MA),  type II collagen 
(II-II6B3), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling Technology, 
Danvers, MA), p44/42 MAPK (Erk1/2) (Cell Signaling) and β-actin (Abcam) at the 
recommended dilution overnight at 4oC. The membranes were incubated in the secondary 
antibody of Goat Anti-Mouse IgG (H+L) or Goat Anti-Rabbit IgG (H+L) (Thermo Scientific) for 
40 minutes at room temperature and exposured using SuperSignal® West Pico 
Chemiluminescent Substrate (Thermo Scientific) and CL-XPosureTM Film (Thermo Scientific). 
 
Statistical Analysis 
The Kruskal-Wallis test was used to test for significant differences among all groups and the 
Mann-Whitney U test was used for pairwise comparison. All statistical analyses were 
performed with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). P values less than 






Immunohistochemistry of SDSC-deposited ECM and chondrocyte-deposited ECM 
S-ECM showed strong expression of type I collagen but absence of sulfated GAGs or type II 
collagen. The composition of S-ECM was consistent with previous studies on ECM derived 
from bone marrow stem cells and fibroblasts.33;40 The components of C-ECM were revealed 
to be more complex than S-ECM, which contained sulfated GAGs, type I and II 
collagen.(Figure 7.1). 
 
In vitro expansion of SDSCs and chondrocytes on Plastic, S-ECM and C-ECM 
The cell morphology of SDSCs and chondrocytes on Plastic is flat and large, but when cells 
were cultured on S-ECM and C-ECM, they appeared spindle-like and small. The morphologic 
appearance of S-ECM and C-ECM was unchanged within 3 passages. Moreover, cell 
migration was directional on S-ECM and C-ECM compared to the random movement on 
Plastic (Figure 7.1B). 
 
The proliferative rate of SDSCs on S-ECM had a 2.4- to 7.2- fold increase compared to cells 
on Plastic and average 2-fold higher than cells on C-ECM (Figure 7.1C). At passage 4 
chondrocytes on S-ECM and C-ECM yielded a similar cell number that was 6-fold that of 
Plastic. At passage 5 and 6, chondrocytes on S-ECM exhibited 20%-40% higher proliferative 
ability than that on C-ECM, and maintained 4- to 12-fold that on Plastic (Figure 7.1D). Cells 
on S-ECM regained the highest proliferative rate; the proliferation ability was improved on 
C-ECM but still lower than S-ECM and both S-ECM and C-ECM were higher than Plastic. 
 
S-ECM mostly improved chondrogenic differentiation potential of SDSCs  
Passage 6 SDSCs expanded on Plastic, S-ECM and C-ECM were centrifuged to form pellets 
and induced to chondrogenic differentiation by TGF-β1. SDSCs of S-ECM group showed 
strong expression of sulfated GAGs stained by Alcian blue, and extensive expression of type 
I and II collagen. SDSCs of C-ECM group were positive for Alcian blue staining; 
immunohistochemistry showed type I and II collagens at Day 14 but the results were weaker 
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than S-ECM group. SDSCs of Plastic group had the worst chondrogenic differentiation 
potential as proven by the partial positive staining at Day 14 (Figure 7.2). 
 
At Day 14 pellets of S-ECM group generated 23.5 ± 1.6 μg of sulfated GAGs compared to 
11.1 ± 1.6 μg in C-ECM group and 2.5 ± 0.8 μg in Plastic group (Figure 7.3A). The DNA 
content was maintained in S-ECM group; it was 81% at Day 14 which is higher than that of 
C-ECM (45%) and Plastic groups (21%) (Figure 7.3B). The chondrogenic index, defined by 
the ratio of sulfated GAGs to DNA, had the highest level in S-ECM group (39.3 ± 3.1 at Day 
14), with lower level in C-ECM (27.8 ± 4.4) and Plastic groups (7.6 ± 2.2) (Figure 7.3C). 
 
The expression of chondrogenic and hypertrophic genes was quantified by real-time PCR. 
The level of type II collagen mRNA in S-ECM was 464-fold and 4-fold that of Plastic group 
and C-ECM group at Day 7, respectively (Figure 7.3D). The expression of aggrecan mRNA 
was highest in S-ECM; it was 11-fold and 2-fold that of Plastic and C-ECM at Day 7, 
respectively (Figure 7.3E). The expression of type I collagen mRNA was similar in S-ECM 
and C-ECM groups and was at least 30% higher than that of Plastic group (Figure 7.3F). 
Sox-9, the transcription factor in chondrogenesis, mRNA expression was highest in S-ECM 
group (Figure 7.3G). During chondrogenesis the level of type X collagen mRNA was not 
significantly different between the three groups (Figure 7.3H), but the level of MMP13 mRNA 
was highest in S-ECM group at Day 7 and higher in S-ECM and C-ECM than Plastic group 
(Figure 7.3I). 
 
S-ECM and C-ECM elevated the activity of receptors of TGF-β in SDSCs 
During the induction of chondrogenesis, immunoblotting showed that the TGF-β receptor II 
(TGF-β RII) in the three groups was activated but the activity of TGF-β RII was higher in 
S-ECM and C-ECM groups than that in Plastic group. Correspondingly, the expressions of 
Sox9 and type II collagen were stronger in S-ECM and C-ECM groups than in Plastic group. 
However, ERK1/2 activity was suppressed during chondrogenesis except the high 




The chondrogenic potential of chondrocytes was improved by S-ECM and C-ECM 
After expansion on Plastic, S-ECM and C-ECM, chondrocytes of passage 6 were induced to 
chondrogenesis in the pellet culture system. At Day 7 and 14, chondrocyte pellets of S-ECM 
and C-ECM groups showed stronger expression of sulfated GAGs, type I and II collagens 
than those of Plastic group. The chondrogenic differentiation potential was improved in 
chondrocytes after S-ECM and C-ECM expansion (Figure 7.5). 
 
To compare the chondrogenic differentiation effect, biochemistry was used to quantify the 
content of sulfated GAGs and DNA in each group. At Day 14 chondrocyte pellets generated 
high amount of sulfated GAGs in S-ECM and C-ECM groups at the similar level (58.1 ± 2.5 
μg vs. 56.1 ± 3.0 μg), but the level of GAGs in Plastic group was only 47% of that in ECM 
groups (27.2 ± 1.6 μg) (Figure 7.6A). At Day 14 the DNA content of chondrocyte pellets in 
Plastic group dropped to 35% but increased to 111% in S-ECM group and 119% in C-ECM 
group (Figure 7.6B). The chondrogenic index in the three groups at Day 14 was relatively 
high and that of Plastic group reached 92.7 ± 3.0. The chondrogenic index of C-ECM group 
was 8.3% higher than that of S-ECM (105.5 ± 4.9 vs. 97.5 ± 5.2) and both were higher than 
Plastic group (Figure 7.6C). 
 
At the level of mRNA expression chondrocyte pellets of S-ECM and C-ECM groups had a 
higher level than those of Plastic group in chondrogenic and hypertrophic genes (Figure 7.6 
D-I). But the difference between S-ECM and C-ECM was not significant. At the level of type II 
collagen and aggrecan mRNA, pellets of S-ECM and C-ECM groups expressed 5-fold and 
7-fold, respectively, as that of Plastic group (Figure 7.7 D&E). At Day 7 the expression of type 
X collagen in S-ECM and C-ECM groups was 80% higher than that of Plastic group (Figure 
7.6H). At Day 14 the level of MMP13 mRNA in S-ECM and C-ECM groups was 6.2-fold that of 
Plastic group (Figure 7.6I). 
 
S-ECM and C-ECM improved the activity of receptors of TGF-β in chondrocytes 
Before treatment with TGF-β1, the level of phosphorylated TGF-β RII in Plastic group was 
much higher than that in ECM groups. After the chondrogenic induction the activity of TGF-β 
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RII in S-ECM and C-ECM groups was higher than that of Plastic group. The expression of 
Sox9 and type II collagen in S-ECM and C-ECM groups was stronger than that of Plastic 
group. The phosphorylation of ERK1/2 was decreased after expansion on S-ECM and 





In this study we used porcine SDSCs to deposit S-ECM composed of a fibrillar type I collagen 
network and articular chondrocytes to generate C-ECM that contained a type I and II collagen 
network with proteoglycans. Though the two types of ECMs had three-dimensional structure 
and were deprived of the original feeder cells, they showed a distinct influence on cell 
proliferative rate and chondrogenic potential. SDSC-deposited ECM improved the 
proliferation rate and chondrogenic differentiation of both SDSCs and chondrocytes, while 
chondrocyte-deposited ECM only significantly affected chondrocyte expansion rate and 
chondrogenesis. However both S-ECM and C-ECM promoted cell self-renewal and 
chondrogenic potential compared to the conventional plastic culture system. 
 
The traditional 2D reconstructed ECM uses monomeric proteins to coat substrates such as 
fibronectin, laminin, gelatin, and denatured collagens, to improve MSC proliferation and 
differentiation. However, the 3D culture system has been proven more efficient than 2D 
culture substrates in cell expansion and preserving the multipotent capability for MSCs in vitro. 
The 3D natural cell-deposited ECM used in this study has been adopted to study the 
signaling pathway in cell adhesion41 and cell invasion.42;43 Recent studies showed that the 
utilization of 3D ECM in expansion of MSCs in vitro can greatly improved cell proliferation and 
enhanced multipotential differentiation.33;40;44 Not only MSCs but also terminally differentiated 
cells such as adult articular chondrocytes and nucleus pulposus cells exhibited enhanced 
self-renewal and redifferentiation potential after expansion on 3D ECM. However it is 
important to establish a tissue-specific microenvironment in vitro to direct MSC differentiation. 
Due to the similar properties shared by MSCs from many sources and the same procedure to 
generate ECM, MSC-deposited ECMs are identical in structure and composition.33;40;41;45 We 
chose articular chondrocytes to reconstruct the native 3D ECM that mimics hyaline cartilage 
tissue. The component of fibrillar type II collagen associated with proteoglycans in 
chondrocyte-deposited ECM was one of the major differences from SDSC-deposited ECM. 
The presence of type I collagen in C-ECM was partially due to the dedifferentiation of articular 




Type I collagen was used as a substrate and gel to facilitate cell expandability and 
differentiation and achieved better results than other ECM proteins. Compared to type I 
collagen, type II collagen was less commonly used for cell expansion but was proven to 
induce chondrocyte redifferentiation more effectively. Bosnakovski et al. provided evidence 
that bone marrow stem cells seeded in type II collagen hydrogel generated more 
cartilage-specific genes and matrix than cells in type I collagen gel.46 Moreover, Buma et al. 
reported that using type II collagen scaffold to repair full-thickness articular cartilage defects 
generated hyaline cartilage-like tissue instead of fibro-cartilaginous tissue by type I 
collagen.47 Moreover, proteoglycans were found in C-ECM rather than S-ECM. Previous 
studies showed that type II collagen-GAG scaffolds were able to enhance cell 
chondrogenesis48 and had more stiffness than a type I collagen scaffold.49 Besides the 
different composition, the rigidity of the two ECMs caused distinct proliferation and 
differentiation potentials in SDSCs and chondrocytes. Winer et al. compared the effect of 
substrates with different rigidity on human BMSCs and demonstrated that cells became 
quiescent on the soft matrix (250 Pa) but resumed the proliferation when transferred to a stiff 
substrate.50  
 
The great improvement on cell proliferative rate after culturing on the two types of ECM was 
partially induced by the activation of the integrin/Src/ERK1/2 signaling pathway and the 
activation of cyclin D1.51-53 However, the different proliferation rates of SDSCs on the two 
ECMs suggested that the signaling pathway may not be exactly the same. Cells recognize 
fibrillar collagens mainly through integrin α2β1 and α5β154-57 but recently it was reported that 
Rock 2 expression was suppressed in type II collagen-rich gel instead of type I collage gel.58 
Besides the increased proliferative rate, SDSCs and chondrocytes showed directional 
migration along the fibrils of ECM rather than the random migration found on Plastic. One 
possible explanation is that ECM can effectively reduce the activity of Rac that is responsible 
for the random cell migration.59-61 
 
Induced by TGF-β, SDSCs showed higher chondrogenic differentiation potential after 
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expansion on S-ECM and chondrocytes cultured on S-ECM and C-ECM showed a similar 
level of chondrogenic genes and matrix. The enhanced chondrogenic potential caused by 
ECM is explained by the high activity of TGF-β RII when induced with TGF-β. More 
interestingly, chondrocytes cultured on Plastic had a highly phosphorylated level of TGF-β RII 
before chondrogenesis that was possibly autophosphorylation and induced spontaneous 
differentiation in the monolayer culture period.40;62;63 The spontaneous differentiation was 
reported by Chen et al. and it suppressed the later growth factor-induced specific 
differentiation.40 ECM significantly reduced the degree of autophosphorylation, increased the 
sensitivity of TGF-β RII and enhanced the effectiveness of TGF-β induction to 
chondrogenesis. Among the various ECM proteins, decorin may play an important role in 
preventing TGF-β receptor autophosphorylation that was proven to exist in BMSC-deposited 
ECM.40 Decorin, often found in type I collagen-rich matrices and composed of a leucine 
repeated core protein attached with a glycosaminoglycan chain of varying length and 
composition, is considered as the antagonist of TGF-β, masks the binding site of TGF-β 
receptors64;65 and contributes to the low level of autophosphorylation of TGF-β receptor. 
 
The MAPK signaling pathway was previously considered to promote chondrogenic 
transcription factors and induce the expression of chondrogenic genes.66;67 Recently several 
studies suggested that the inhibition of the MAPK signaling pathway can improve MSC 
chondrogenic differentiation.68-70 Consistent with our immunoblotting data, ERK1/2 activity 
was suppressed during chondrogenesis and was significantly lower in SDSCs and 
chondrocytes expanded on ECM than those expanded on Plastic. The robust elevation of 
phosphorylated ERK1/2 at Day 14 in SDSCs of C-ECM and chondrocytes in S-ECM is 
possibly related to the increased expression of hypertrophic genes.71 Type X collagen is the 
well-accepted hypertrophic marker and in late chondrogenesis MMP13 and ALP are 
proposed as other markers for hypertrophy.72;73 The increase of hypertrophic genes after 
ECM expansion is not consistent with our previous study33 and due to the complex 
mechanism of chondrocyte hypertrophic differentiation, future studies will be conducted on 
the hypertrophic issue by applying different growth factors in vitro and conducting 




In summary, we compared the influence of two natural 3D extracellular matrices, deposited 
by SDSCs and chondrocytes, on cell proliferation and chondrogenic potential. 
SDSC-deposited ECM can improve the proliferative and chondrogenic capacities of SDSCs 
and chondrocytes. Chondrocyte-deposited ECM can only promote chondrocyte proliferation 
and chondrogenesis. The enhanced chondrogenic potential of cells expanded on 3D ECM is 
related to the high sensitivity of TGF-β receptor II. Together with previous studies, we 
demonstrate that SDSC-deposited extracellular matrix functions as a universal expansion 
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Figure 7.1 (A) Histology and immunohistochemistry of SDSC-derived ECM (S-ECM) and 
chondrocyte-derived ECM (C-ECM). Alcian blue and alcian blue staining was used to detect 
sulfated glycosaminoglycans (GAGs), and immunohistochemistry staining (IHC) was for type 
I (COL I) and type II (COL II) collagen; (B) S-ECM and C-ECM induces a cell morphology 
change in SDSCs and chondrocytes in monolayer expansion; (C) the mean cell number of 
SDSCs harvested from passage 4 to passage 6 on the three different substrates (Plastic, 
S-ECM and C-ECM); (D) the mean cell number of chondrocytes harvested on Plastic, S-ECM 
and C-ECM. Data are shown as average ± SD for n = 4. 
 
Figure 7.2 Histology and immunohistochemistry of SDSC pellets of Plastic, S-ECM and 
C-ECM groups induced chondrogenic differentiation. Alcian blue (blue) staining was used to 
detect sulfated glycosaminoglycans (GAGs), and immunohistochemistry was for type I (COL 
I), II (COL II) and X collagens (COL X).  
 
Figure 7.3 (A) Biochemistry analysis for GAGs of SDSC pellets were measured at day 0, day 
7 and day 14. (B), DNA content of SDSC pellets changes during 14 days normalized by the 
content of pellets at day 0. (C), chondrogenic index (the ratio of GAGs and DNA) showed the 
degree of chondrogenic differentiation of SDSCs. (D) to (G) Real-time PCR to examine the 
chondrogenic marker gene expression level (type I and II collagen, aggrecan, sox-9) 
normalized by 18S rRNA. (H) and (I) the hypertrophic gene expression (type X collagen and 
MMP13) was tested in the SDSC pellets. Data are shown as average ± SD for n = 4. 
 
Figure 7.4 Immunoblotting of the SDSC chondrogenic pellet was used to detect 
phospho-TGFβ RII (Tyr 424), Sox9 and type II collagen expression level. β actin was used as 
an internal control for protein loading. 
 
Figure 7.5 (A) Histology and immunohistochemistry of chondrocyte pellets of Plastic, S-ECM 
and C-ECM groups that underwent induced chondrogenic differentiation. Alcian blue (blue) 
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staining was used to detect GAGs, and immunohistochemistry determined type I (COL I), II 
(COL II) and X collagen (COL X).  
 
Figure 7.6 (A) Biochemistry analysis for GAGs of SDSC pellets were measured at day 0, day 
7 and day 14. (B), DNA content of chondrocyte pellets changes during 14 days normalized by 
the content of pellets at day 0. (C), chondrogenic index (the ratio of GAGs and DNA) showed 
the degree of chondrogenic differentiation of chondrocytes. (D) to (G) Real-time PCR to exam 
the chondrogenic marker gene expression level (type I and II collagen, aggrecan, sox-9) 
normalized by 18S rRNA. (H) and (I) the hypertrophic gene expression (type X collagen and 
MMP13) was tested in the chondrocyte pellets. Data are shown as average ± SD for n = 4. 
 
Figure 7.7 Immunoblotting of chondrocyte chondrogenic pellet was used to detect 
phospho-TGFβ RII (Tyr 424), Sox9 and type II collagen expression level. β actin was used as 













































The objective of this dissertation is to develop a novel strategy for cell-based cartilage 
regeneration (including mesenchymal stem cells and autologous differentiated cells) that can 
promote cell expandability, enhance chondrogenic differentiation, and improve the repair 
effect for cartilage defects in animal studies and clinical trials. A native cell-deposited 
three-dimensional (3D) extracellular matrix (ECM) provides a promising approach to improve 
current in vitro MSC expansion system not only increasing cell proliferative ability but also 
enhancing chondrogenic differentiation potential. The central hypothesis of this dissertation is 
that the natural three-dimensional cell-deposited extracellular matrix can provide a proper 
microenvironment to improve MSC self-renewal and multipotent differentiation. This natural 
3D ECM can also improve the current procedures of autologous cell transplantation for 
cartilage defects and intervertebral disc degeneration.  
 
8.1 Extracellular matrix improves MSC self-renewal 
 
Mesenchymal stem cells are attractive for tissue repair and regeneration, because of their 
multipotential differentiation to various lineages, including chondrocytes for cartilage repair,1;2 
osteoblasts for bone reconstitution,3 adipocytes for adipose tissue regeneration,4 cardiac 
myoblasts for cardiovascular repair,5;6 myoblasts for skeletal muscle regeneration7 and 
neuronal cell for neurological system repair.8 It is extremely important for MSC to obtain 
sufficient cell numbers and to maintain their stemness in the in vitro culture process.9 
Sufficiency of MSCs is a basic requirement for MSC-based tissue regeneration. Typically the 
intracellular injection therapy to repair partial-thickness cartilage defects requires minimal 10 
million cells for a single injection.10 For infracted heart repair 4 million cells are necessary for 
a single injection.11 Moreover, in cartilage repair the loss of regenerative cells will occur due to 
leakage or cell apoptosis.12 In autologous chondrocyte transplantation, the leakage of 
injected chondrocytes from repaired sites usually results in the failure of implantation, multiple 
complications and extra cost of patients. In clinical practice, cartilage repair using autologous 
chondrocyte transplantation usually requires several injections instead of a single injection to 
enhance the repair effect.12-14 Besides, apoptosis or cell death are also induced by 
inflammatory cytokines, metalloproteinase, intracellular oxygen species or mechanical 
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forces.9 Osteoarthritis, which was considered a degenerative disease, now is more realized 
as an immune disorder. It is evident that several inflammatory factors, including interleukin - 
Iβ (IL-Iβ), IL-I7, IL-I8, TNF-α and oncostatin M (OSM), are responsible mediators for cartilage 
degeneration and osteoarthritis. These inflammatory factors not only stimulate the turnover of 
cartilage extracellular matrix but also increase chondrocyte apoptosis.15 Overall, to obtain 
adequate cell number is one of the most important issues in cell-based tissue regeneration. 
 
The current in vitro culture condition limits the use of MSC-based tissue regeneration. Once 
isolated from the in vivo microenvironment, MSCs rapidly lost the ability of proliferation and 
multipotent differentiation like aged cells.16-18 In this dissertation, we tried to use a native 3D 
cell-deposited ECM to replace conventional MSC expansion process, not only shortening 
expansion time but also increasing yielded cell numbers. Starting at a relatively high seeding 
density (3,000 cells/cm2), it only took 5 - 6 days to reach 90% confluence, while at low 
seeding density (1,000 cells/cm2) the expansion period extented to 7 to 10 days depending 
on specific cell types. More importantly, the complete confluence did not inhibit cell 
proliferation, since cells continued to grow overlaply in 3D format.19;20 The adequate cell 
number produced by ECM expansion system provided sufficient cells for transplantation.  
 
The high proliferative rate on ECM is related to activated cyclin D1 and reduced intracellular 
reactive oxygen species (Chapter 3 and Chapter 6). Cyclin D1 is proven to control cell cycle 
progression through G1 phase into S phase. The steady-state level of phosphorylated ERK1/2 is 
essential for cyclin D1 phosphorylation and translocation to promote cell cycle from G1 to S phase, 
while inhibition of ERK1/2 or upstream kinases such as MAPK results in decreased activity of 
cyclin D1.21 Except MAPK cascade, Rac1 is another distinct mediator to activate cyclin D1 and 
promote cell-cycle.22;23 Page et al. showed that overexpression of activated Rac increased the 
activity of cyclin D1, but the transcription of mutant Rac attenuated cyclin D1 activity. The Rac1 
signaling pathway is completely independent of ERK activation. Westwick et al. showed that Rac1 
regulated the activity of at least four protein kinases including PAK, JNK, p38 and serum response 
factor (SRF), among which Rac1 stimulated the transcription of cyclin D1 promoter associated 
with PAK binding.22 Besides, they also showed that low level of intracellular ROS induced 
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activation of cyclin D1 and antioxidant treatment attenuated Rac1-induced cyclin D1 promotor 
activity.24 In this dissertation, human BMSCs expanded on ECM showed a sustained activation of 
ERK1/2 and cyclin D1. Besides, phosphatidylinositol 3-kinase (PI3-kinase) signaling pathway also 
modulates the activity of cyclin D1 and the progression from G1 to S phase of cell cycle. 
Jirmanova et al. showed the evidence that activated PI3-kinase induced an increased 
steady-state level of cyclin D1 and the decrease of GSK3β-dependent rate of cyclin D1 
degradation.25 Considering the regulatory effect of PI3-kinase/Akt signaling pathway in TGF-β 
induced chondrogenesis, it is possible that PI3-kinase influences cell proliferation and 
chondrogenic potential when expanding on ECM; this particular signaling pathway will be 
examined in the future studies. One of the limitations in this dissertation is that the assay to 
study the effect of inhibition of Src or ERK1/2 on cell proliferation is not available due to 
serious apoptotic response in a short time. 
 
Intracellular reactive oxygen species (ROS) are proven to play an important role in cell 
adhesion, migration, proliferation and cell survival.26-29 The low concentration of ROS had a 
promotional effect on cell adhesion and the threshold, demonstrated by Lamari et al., was 
between 5 to 7 nanmoles / mL of superoxide anions, whereas the high level of ROS resulted 
in cell death.30 High level of ROS had an inhibitory influence on cell proliferation by arresting 
cell cycle at G1, S, and G2 phases through down-regulation of cyclin D1 and D3.31 The high 
level of ROS or treatment of hydrogen peroxide resulted in cyclin D1 degradation, which was 
reversed in the presence of antioxidants or overexpression of hypoxia-inducible factor (HIF) - 
1α.32 Kim et al. also showed that the increase of intracellular ROS generation arrested cell 
cycle at G0 - G1 phase by inhibition of cyclin D1/CDK4 complex.33 Besides, Lai et al. reported 
an elevated activity of telomerase in human BMSCs expanded on a similar natural 3D ECM 
that might also promote cell proliferation.20 
 
8.2 3D cell-deposited ECM is different from 2D reconstructed ECM 
 
Traditional 2D reconstructed ECM uses monomeric proteins such as fibronectin and 
laminin-1 to coat substrates and showed little effect on cell morphology or proliferation.34 Tsai 
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et al. provided evidence that type I collagen achieved better result in promoting human MSC 
proliferation and osteogenesis than fibronectin, laminins or gelatin. The improved osteogenic 
differentiation was related to activated ERK and Akt pathways instead of FAK; the inhibition of 
ERK attenuated osteogenic process.35 More importantly, the 3D environment can result in 
different cell responses and behaviors from the 2D ones. Fassett et al. showed that 
hepatocytes in type I collagen gel remained round and arrested growth, whereas on the 
monomeric type I collagen coating film the cells spreaded and proliferated. The different 
activity of cAMP-dependent protein kinase (PKA) was responsible for the distinct cell 
proliferation responses, because inhibition of PAK restored ERK activation and cyclin D1 to 
promote cell cycle from G1 to S phase.36 However, 2D ECM containing multiple proteins was 
able to induce stem cell self-renewal and to promote chondrogenic differentiation.34 3D 
culture system has been proven more efficient in cell expansion and preserving multipotent 
characters of MSCs in vitro. Majd et al. recently developed a new 3D dynamic culture for 
MSCs that yielded 10-fold cells more than conventional plastic culture in nine weeks; it also 
maintained MSC multipotential to differentiate into osteoblasts, adipocytes, chondrocytes and 
myoblasts that was lost in the conventional culture.37 
 
The compositions of MSC-deposited ECM included type I collagen, fibronectin, laminins and 
decorin detected by immunohistochemistry.19;20;38;39 Proteomics provides a novel method to 
analyze the components in ECM. A detailed analysis of the compositions in ECM can help us 
understand the interactions between cells and ECM. Overall, the improved proliferative and 
chondrogenic potential of MSCs induced by ECM is related to the integration of multiple 
matrix molecules and the unique three-dimensional structure. 
 
MSCs on 3D ECM exhibited distinct behaviors compared to conventional plastic flasks or 
constructed 2D ECM. Cells migrated along the fibrils of ECM instead of random movement on 
plastic flasks. The directional migration was closely related to decreased activity of Rac1 that 
was demonstrated to control cell migration.40 Moreover, the uneven distribution of matrix 
components resulted in different rigidity of ECM. Cells liked to move from an area with higher 
flexibility to a region with more rigidity.41 On conventional plastic flasks or reconstructed 2D 
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ECM the well-distribution of molecules leaded to random cell migration. Also the elasticity of 
ECM affected cell shape and proliferation. For example, fibroblasts appeared round shape on 
soft substrates but changed to stressed shape when they were cultured on matrix with high 
rigidity. Winer et al. compared the effect of substrates with different rigidity on human BMSCs 
and demonstrated that cells became quiescent on soft matrix (250 Pa) but resumed 
proliferation when transferring to a stiff substrate.42 
 
During cell adhesion, 3D ECM induced decreased FAK related to focal adhesion and formed 
new contacts with cells. The MAPK cascade and ERK1/2 in cell adhesion, migration and 
proliferation has been studied in depth. Sustained activation of ERK1/2 was necessary for 
cell cycle progession by induction of cyclin D1; the inhibition of ERK1/2 resulted in reduction 
of cyclin D1 and arrest at G1 phase.43 The attachment of cells onto ECM, including fibronectin, 
vitronectin, laminins and collagens, induced the activation of integrin α1, α2, α5, αV, β1, β3 and 
β5. Integrin system transduced extracellular signals into intracellular pathways by activating 
FAK, Src, MAPK cascade, ERK1/2 and cyclin proteins to control cell cycles.44;45 Park et al. 
cultured embryonic stem cells on fibronectin-coated surfaces and showed an upregulation of 
integrin β1, FAK, Src, ERK1/2, Akt and caveolin-1. The intracellular signaling pathways 
induced by fibronectin increased cell cycle regulatory proteins such as cyclin D1 and cyclin E. 
The inhibition of integrin β1 or blockage of kinases such as Src, FAK, caveolin-1, Akt or 
ERK1/2 resulted in significantly decreased [3H]-thymidine incorporation and attenuated cell 
cycle regulatory proteins.46 Roovers et al. showed that integrin α5β1 controlled cyclin D1 
expression through sustained activation of ERK1/2 on fibronectin to promote cell cycle.47 
Cukierman et al. used a similar 3D ECM deposited by fibroblasts to study cell adhesion and 
demonstrated that integrin α5β1 translocated to the region of fibronectin and induced 
intracellular signaling transduction.39 On fibronectin-coated surface, integrin α5β1 mediated 
epithelial cell proliferation through epithelial growth factor (EGF) receptor. Kuwada et al. 
showed that, in the presence of EGF receptor antagonistic antibody, epithelia cells 
overexpressed with integrin α5 grew at a normal rate, while control group was inhibited in cell 
proliferation.48 Meanwhile, integrin αV activation in 3D collage gel contributed cell survival 
through phosphorylation of MAPK and ERK1/2, while the inhibition of ERK1/2 induced 
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serious cell apoptosis.49  
 
8.3 The interaction between integrin system and 3D ECM 
 
In Chapter 6, integrin α2 and β5, receptors for fibrillar collagens, showed an elevated level. 
The elevated level of integrin α2 was closely related to focal adhesion and cell motility. 
Sawhney et al. identified the role of integrin α2 in cell adhesion that activated FAK, ERK1/2 
and μ-calpain pathways on type IV collagen. Inhibition of integrin α2 by a specific antibody 
suppressed FAK activation and ERK1/2 phosphorylation.50 Integrin α2β1 was proven to induce 
cyclin expression and promote cell cycle on type IV collagen. This process involved activation 
of the ERK1/2 signaling pathway and the production of ROS by NADPH oxidase.51 In this 
dissertation, increased integrin α2 may result in activation of ERK1/2. Meanwhile, integrin 
α2-regulated cell adhesion and migration were modulated through activation of Src and were 
completely inhibited in the presence of Src inhibitor PP2.52 Overall, Integrin α2 plays an 
important role in cell adhesion and migration involving FAK, Src, p38 and MAPK cascade 
signaling transduction and contributes to cell-cycle progression. Besides, Priestley et al. 
demonstrated the role of integrin α4 in stem cell self-renewal by knocking-out of integrin α4 
that seriously restricted cell proliferation.53 In this dissertation, we found an increased level of 
integrin α4 in human BMSCs expanded on ECM that was possibly related to the high rate of 
cell self-renewal (Chapter 6).  
 
Integrin β5 plays an important role in cell migration and proliferation proven by previous 
studies. Zhang et al. showed that in human breast carcinoma cells p21-activated kinase 4 
(PAK4) contributed to cell migration; PAK4 attached to integrin β5 cytoplasmic domain. Cell 
migration involved the engagement of integrin αVβ5 and extracellular matrix such as 
vitronectin; it induced a redistribution of PAK from cytosol to dynamic lamellipodial 
structures.54 Braam et al. also provided evidence that vitronectin-coated surface promoted 
human embryonic stem cell attachment and self-renewal through integrin αVβ5.55 Cukierman 
and his colleagues used a similar ECM deposited by human fibroblast and showed that ECM 
induced activation of PI3K and Akt/PKB through the integrin β1 dependent signaling 
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pathway.56 In this dissertation, we found other integrin receptors at a decreased or 
unchanged level. However, in future it is important to establish a full analysis of integrin and 
other ECM receptors, not only by flowcytometry but also using immunofluorescence. 
 
Intracellular reactive oxygen species affect cell adhesion, survival and proliferation. The 
increase of ROS inhibited cell adhesion and migration by decreasing the activity of focal 
adhesion-related and integrin-related molecules.57 Song et al. provided evidence that 
hydrogen peroxide treatment induced detachment of MSCs and significantly decreased cell 
adhesion and migration. The cell detachment was caused by decreased integrin αVβ1 and 
focal adhesion-related molecules such as FAK and Src in the presence of high level of 
intracellular ROS.57 Moreover, ROS-induced cell adhesion was related to the modification of 
integrin system by altering the exposure of integrin outside cell surface or their clustering. 
Low level of ROS decreased the expression of integrin α5 but increased αV that was related to 
cell adhesion.30;58-60 In this dissertation, we found human BMSCs expanded on ECM showed 
decrease of integrin α5 that was possibly induced by the low level of ROS. Meanwhile, 
integrin β4 had a negatively regulatory effect on the production of ROS. Lv et al. showed that 
inhibition of integrin β4 in primary mouse neuron cells elevated significant apoptosis and 
declined cell viability; the process was associated with increased activity of NADPH oxidase 
and production of intracellular ROS.61 In this dissertation we found that integrin β4 slightly 
increased when human BMSCs were cultured on ECM that possibly was related to the 
declined level of ROS. 
 
In this dissertation, flowcytometry showed that the expression of integrin α1, α3, α5, β1 and β3 
decreased compared to those expanded on plastic culture (Chapter 6). Hayashi et al. 
cultured embryonic stem cells on ECM to promote cell self-renewal and showed that the 
expression of fibronectin- and laminin-binding integrin subunits increased while some 
collagen-binding integrins down-regulated. The overexpression of collagen-binding integrin 
subunits induced stem cell differentiation instead of self-renewal.62 Considering the 
down-regulated expression of certain integrins after expansion on ECM (Chapter 6), it was 
possible that inactivation of certain integrins was essential to promote stem cell self-renewal, 
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and it will be studied in future. 
 
The central role of Src in focal adhesion has been well studied. In FAK-dysfunctional cells, 
overexpression of activated Src can rescue cell apoptotic response. The inhibition of Src 
significantly increased adhesion-dependent apoptosis.63 Activated Src can enhance the 
expression of integrin α2 through protein kinase C-ζ in fibroblasts.63 Xu et al. demonstrated 
that a three-dimensional collagen substrate increased integrin α2 and it was mediated by 
protein kinase C-ζ.64;65 Moreover, Eliceiri et al. reported that Src was indispensible during the 
formation of FAK/integrin αVβ5 complex, when endothelial cells attached to ECM or were 
activated by vascular endothelial growth factor (VEGF). The complex of FAK/αVβ5 and the 
activity of Src were critical to VEGF-induced angiogenesis.66  
 
In Chapter 6 human BMSCs cultured on ECM responded a higher level of apoptosis than 
those on conventional plastic flasks, suggested by an increased immunofluorescence 
intensity of annexin V. In endothelial cells and terminally differentiated chondrocytes, annexin 
V binded to integrin β5 and activated protein kinase C α (PKCα). Activated PKCα induced an 
increase of caspase-3 activity and leaded to ultimate apoptosis.67-69 Integrin β5 showed an 
increase in BMSCs expanded on ECM that might correlate to the elevated level of annexin V, 
but the detail mechanism and the potential effects on MSCs are still unclear. One possible 
explanation is that in the human BMSCs there were mixture cell populations containing 
healthy and aged cells. The healthy BMSCs had a higher proliferative rate that acquired most 
of the nutrients, and had a faster migration to occupy most of the space on ECM. The 
insufficiency of nutrients and space induced apoptosis in aged cells. So the overall increase 
of proliferation was due to the self-renewal in healthy BMSCs and the increase of apoptosis 
was because of the cell death in aged BMSCs. 
 
The robust proliferative rate of MSCs or differentiated cells expanded on ECM aroused 
another potential issue: were ECM-expanded cells uncontrollable or likely to form tumor? In 
this dissertation, cells expanded on ECM were reversible when culture environment changed. 
In Chapter 4, chondrocytes were first cultured on ECM for four passages and then transferred 
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to conventional plastic culture for two passages; cells showed significant decrease in 
proliferation ability. The reduced proliferation after disengagement from ECM suggested that 
the robust proliferative rate was temporary and there was low risk of tumor formation if using 
for cartilage repair and regeneration in vivo. Similarly, late-passaged cells in conventional 
plastic culture system exhibited a decreased proliferative rate, but once contacting with ECM 
they showed stronger proliferation. The native 3D ECM has the potential to expand aged cells 
and can be used in some degenerative diseases. 
 
On the other hand, strong chondrogenic differentiation potential is important to MSC-based 
cartilage repair. In vivo MSCs often stay in a quiescent state but have the potential to 
self-renew or differentiate rapidly once stimulated by intrinsic or extrinsic factors from the 
microenvironment.70 However, conventional in vitro culture system for MSCs impairs their 
multipotential. When reaching 70% - 90% confluence, MSCs contact with neighbor cells and 
inhibit their proliferation, so weekly passaging is required in MSCs expansion.18 To improve 
MSC proliferative rate, low seeding density is used to increase the yielded cell number at the 
cost of long expansion period (usually two to three weeks).16 Another method to improve 
MSC self-renewal is stimulating cells with growth factors such as fibroblast growth factor 2 
(FGF-2). However, some studies suggested that the supplement of FGF-2 inhibited MSC 
chondrogenic potential.71 In spite of various means to promote MSC proliferative rate, the 
intrinsic self-renewal ability of MSCs limits their usage in tissue regeneration. The proliferative 
rate of MSCs usually significantly decreases after 10 passages and eventually disappears.72 
Repeated passaging is able to extent the proliferative ability of MSCs for a longer time but 
seriously impairs the multipotent differentiation. Vacanti et al. compared early-passaged and 
late-passaged porcine MSCs. The late-passaged MSCs lost their multipotential and only 
differentiated to adipocytes. Besides, cell aging symptoms appeared in the late-passaged 
MSCs such as actin accumulation, reduced cell adhesion and high activity of lysosomal acid 
beta-galactosidase.73 The impaired multipotential of MSCs is possibly related to the exposure 





8.4 3D ECM is a potential positive-isolation model for MSCs 
 
We chose SDSCs for cartilage regeneration due to their superior chondrogenic differentiation 
potential to other MSCs such as ADSCs or muscle satellite cells.76 To purify SDSCs we used 
a negative isolation method using Dynabeads conjugated with CD14 antibody to remove type 
A cells (macrophages);77;78 however, this method still failed to separate SDSCs from synovial 
fibroblasts. Karystinou et al. demonstrated that there were multiple MSC sub-populations in 
synovium tissue. They obtained 50 colonies from single cell-derived clonal populations and 
these colonies varied in proliferative doubling time, mean telomere lengths from 5.2 to 10.9 
kb and variable differentiation potency only 30% of which were adipogenic.79 To isolate pure 
adult stem cells, some new cell surface markers were proposed but they were not popularly 
accepted such as CD271, CD140b, CD340 and CD349.80 
 
In this dissertation, 3D SDSC-deposited ECM is a potential positive-isolation model to isolate 
or purify MSCs from multiple cell populations. SDSCs or chondrocytes expanded by 
conventional plastic culture showed diverse expression of cell surface markers, even 
completely positive but with different fluorescence intensity, suggesting that the conventional 
expanded cells were a mixed population. But cells expanded on SDSC-deposited ECM 
exhibited a centralized expression of surface markers and this implied that the cells were 
composed of one or two major populations (Chapter 2). More importantly, after several 
passages on ECM this centralization phenomenon appeared more obvious, suggesting that 
the percentage of the major cell population increased and the yielded cells were likely a 
unique population instead of a mixture. This phenomenon of centralization expression 
surface marker in SDSCs was CD90 (Chapter 2) and in articular chondrocyte was CD29 
(Chapter 4). However, due to the lack of a unique surface marker for MSCs we can’t provide 
direct evidences for the positive isolation function of ECM. 
 
CD90, originally a marker for thymus-derived lymphocytes, is considered an indicator of 
chondrogenic potential in SDSCs. Consistent with our study (Chapter 2), Nagase et al. 
analyzed the ratio of CD90-positive SDSCs and suggested that the ratio decreased with 
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passaging accompanied by a reduced chondrogenic potential.81 In this dissertation, we found 
that the ratio of CD90-positive SDSCs increased dramatically when expanding on ECM and it 
decreased on the conventional plastic culture (Chapter 2). In the expansion of articular 
chondrocytes (Chapter 4) and nucleus pulpous cells (Chapter 5), the percentage of 
CD90-positive cells increased and stayed at a high level on ECM, similar to SDSCs, due to 
the existence of undifferentiated progenitor cells in articular cartilage and nucleus pulpous 
tissue. However, this tendency did not appear in the expansion of human BMSCs, in which 
the ratio of CD90-positive cells decreased on ECM (Chapter 6). Overall, CD90 is a potential 
indicator for chondrogenic differentiation in certain MSCs or progenitor cells and future 
studies are needed to compare the differences between CD90-positive and CD90-negative 
cells not only in chondrogenesis but also in multipotent differentiation. 
 
SSEA-4, a stage-specific embryonic antigen, was recently used to identify mesenchymal 
stem cells and made it as a prospective isolation marker. In human BMSCs, SSEA-4 positive 
cells had a better colony forming ability and stronger multipotential to chondrogenesis, 
osteogenesis and adipogenesis.82 Interestingly, Lai et al. found human BMSCs after 
expansion on ECM showed an increased tendency of SSEA-4 positive cells.20 We also 
showed that not only the percentage of SSEA-4 positive cells but also the fluorescence 
intensity in human BMSCs expanded on ECM was significantly higher than those cultured on 
conventional plastic flasks (Chapter 6). Overall, SSEA-4 provided a potential way for MSC 
purification and an indicator for MSC multipotential differentiation ability. 
 
8.5 MSCs expanded on ECM may have higher potential of integration 
 
The integration of neo-cartilage tissue into articular cartilage defect sites determined the 
success of cartilage repair; however, several factors impeded cell-based cartilage 
regeneration.9;83 Physical trauma significantly increased cell death in lesion edges and 
resulted in a hindering area for neo-cartilage integration.84 Due to the absent ability of 
migration, chondrocytes in neo-cartilage or host cartilage failed to move into lesion edges that 
hindered the full integration of repaired tissue and defect sites.13;85 Archer et al. suggested 
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that the intactness of lesion edges was essential to the integration of cartilage defect repair.84 
The failure of full integration was also related to chondrocyte cell death caused by 
differentiation-related apoptosis or inflammatory factors.9 In vitro chondrogenesis induced by 
TGF-β1 decreased cell viability proven by reduced DNA content.2 Using intracellular injection 
of MSCs or chondrocytes to repair cartilage defect, it required a high cell viability during 
chondrogenesis.86 Conventional expanded cells on plastic culture dramatically lost their cell 
number but ECM-expanded cells maintained their viability during in vitro chondrogenesis.1;87 
The high viability of ECM-expanded cells will improve the integration in cartilage repair in vivo 
and resist the effect of inflammatory factors. In autologous chondrocyte transplantation, 
dedifferentiated chondrocytes leaded to the failure of cartilage repair because the matrix 
generated by dedifferentiated chondrocytes was mostly type I collagen that formed fibrous 
cartilage and degraded eventually.12 However, chondrocytes expanded on ECM delayed 
dedifferentiation and maintained a strong chondrogenic differentiation potential (Chapter 4). 
The usage of chondrocytes expanded on ECM to repair cartilage defects will be conducted in 
future. Similarly, nucleus pulpous cells expanded on ECM preserved their original cell 
phenotype and properties (Chapter 5) and can be used in IVD regeneration.88  
 
8.6 3D ECM reduces chondrogenic hypertrophic risk in MSCs 
 
Chondrocyte hypertrophy is an important stage in cartilage and bone development,  
accompanied by vascularization and calcification.89;90 From the initiation of MSC transition 
toward chondrogenic differentiation, MSCs proceed from type I collagen-positive cells to type 
II collagen-positive chondrocytes, and changed to type X collagen-positive hypertrophic 
chondrocytes, terminally became fully differentiated cells expressed MMP13 associated with 
calcification and ossification. In endochondral bone formation, cartilage was formed first, then 
chondrocytes underwent a proliferative stage following hypertrophy, change in gene 
expression and matrix calcification.91 In chondrogenic induction in vitro and in vivo, MSCs 
proceeded hypertrophic transition that changed cell morphology from chondrocyte-like to 
osteoblasts with the expression of type X collagen, alkaline phosphatase, MMP-13, vascular 
endothelial growth factor (VEGF) and parathyroid hormone–related protein receptor 
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(PTHrPR).92-95 The importance of studying chondrocyte hypertrophic mechanism is not only 
to understand bone development but also to prevent ossification in MSC-based cartilage 
repair and regeneration.  
 
Pelttari et al. reported that after transplantation of pre-chondrogenic differentiated MSC 
aggregates into the ectopic sites in SCID mice, they underwent a change to endochondral 
ossification instead of continuous chondrogenesis, whereas the control group of chondrocyte 
pellets resisted calcification and vascular invasion.96 Moreover, TGF-β97 and high 
concentration of dexamethasone98 exhibited an inhibitory effect on hypertrophy during MSC 
chondrogenesis. Meanwhile, during MSC chondrogenic differentiation induced by TGF-β, the 
expression of type X collagen and MMP13 increased in the early stage but decreased in the 
late stage, indicating an intermediate role that was still unclear.94 The use of type X collagen 
as a marker of chondrocyte hypertrophy may have some limits due to the elevated level in the 
early chondrogenic stage.93 
 
The mechanism of chondrocyte hypertrophy is not fully understood, but the MAPK cascade 
including ERK1/2 and p38 was suggested to modulate the process of hypertrophy. In the 
process of BMP-2 induced chondrocyte hypertrophy, characterized by elevated type X 
collagen, ERK1/2 might have an inhibitory influence. The inhibition of ERK1/2 induced 
activation of type X collagen promotor but had little effect on alkaline phosphatase activity.91 
Stanton et al. provided evidence that p38 MAP kinase was indispensible in chondrocyte 
hypertrophic differentiation and the inhibition of p38 resulted in decreased expression of 
hypertrophic marker genes such as type X collagen, MMP13 and bone sialoprotein.99 
However, Prasadam et al. showed the opposite evidence that subchondral bone osteoblasts 
induced hypertrophic change in articular chondrocytes through ERK1/2 phosphorylation and 
deactivation of p38 phosphorylation. The inhibition of ERK1/2 significantly suppressed the 
hypertrophic change.100 Different from chondrogenesis, ERK1/2 was continuously activated 
during osteogenesis. Phosphorylated ERK1/2 activated other transcription factors such as 
Runx2 and cbfa-1 and induced osteocalcin and mineralization.101-103 Considering the elevated 
level of type X collagen in human BMSCs expanded on ECM (Chapter 6) and the decreased 
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activity of ERK1/2, hypertrophic transition was possibly related to the ERK1/2 signaling 
pathway. 
 
In this dissertation, SDSCs and ADSCs after expansion on ECM showed a suppressed level 
of hypertrophy-related gene expression and negative immunohistochemistry of type X 
collagen (Chapter 2 and Chapter 3), suggesting that there was no evidence at protein level to 
prove the hypertrophic transition of MSCs during in vitro chondrogenesis. With regard to 
chondrocytes and nucleus pulposus cells expanded on ECM or conventional plastic flasks, 
there were not positive data for hypertrophic genes or proteins (Chapter 4 and Chapter 5). 
MSCs from different tissue sources may have distinct potentials of hypertrophy that will be 
taken into account in future. Furthermore, considering the intrinsic differences between 
chondrocytes and MSCs in the resistance to hypertrophy, future studies are needed to 
evaluate MSC chondrogenesis and hypertrophy in native cartilage joints in vivo. 
 
8.7 ECM Improves chondrogenic potential of MSCs and the underlying mechanism 
 
The enhanced chondrogenic potential after ECM expansion was proven by different cell 
types including SDSCs (Chapter 2 and Chapter 7), ADSCs (Chapter 3), BMSCs (Chapter 6), 
chondrocytes (Chapter 4 and Chapter 7) and nucleus pulposus cells (Chapter 5). The 
obvious mechanism was the increased expression and responsiveness of TGF-β type II 
receptor (Chapter 6). However, the reason of elevated expression of TGF-β type II receptor in 
human BMSCs after expansion on ECM is quite unclear. The cross-talk between integrin 
system and TGF-β receptors may be involved in this mechanism. Garamszegi et al. recently 
demonstrated that soluble extracellular matrix proteins can induce Smad signaling that was 
considered to be activated by TGF-β ligand. They showed that soluble collagens and 
laminins induced Smad activation initially from integrin α2β1, then recruited TGF-β receptors, 
formed a complex membrane signaling receptor and activated several kinases including FAK 
and Src. The ECM induced activation of Smads was independent of the activation induced by 
TGF-β ligand. However, they didn’t provide the information of the expression or 




Decorin is an important component in the cell-deposited ECM, confirmed by Chen et al. using 
human BMSCs to generate ECM.38 Decorin is often found in type I collagen-rich matrices and 
is composed of a leucine repeated core protein attached with a glycosaminoglycan chain with 
varied length and composition. Conventionally, decorin was considered an antagonist to 
TGF-β by masking the binding site of TGF-β receptors.105;106 Before chondrogenic 
differentiation, the low level of autophosphorylation of TGF-β type II receptor in human 
BMSCs expanded on ECM was contributed by the presence of decorin in ECM (Chapter 6), 
even though this needs to be confirmed in future. Moreover, decorin can influence 
integrin-dependent cell adhesion and migration. Fiedler et al. provided evidence that decorin 
promoted endothelial cell adhesion on fibrillar type I collagen by modulating the activity of 
integrin α2β1 instead of α1β1 and activating insulin-like growth factor-I receptor.107 In 
accordance to our data of an increased expression of integrin α2β1 after ECM expansion, 
decorin possibly promoted mesenchymal stem cell adhesion and proliferation through 
integrin and Rac signaling pathway that is also needed to be explored in future. 
 
In the process of chondrogenic differentiation induced by TGF-β, non-Smad intracellular 
signaling pathways shared several kinases of integrin-induced signaling pathways. ERK1/2 
were important kinases that could be phosphorylated by integrin activation or TGF-β 
induction.108;109 The role of ERK1/2 in chondrogenesis is not completely understood. 
Watanabe et al. demonstrated that TGF-β induced the phosphorylation of ERK1/2 to activate 
chondrogenic-specific genes expression associated with other transcription factors.110 Bobick 
also provided evidence that the level of phosphorylated ERK1/2 paralleled the progress of 
human BMSC chondrogenesis; the inhibition of MEK1 or ERK1 significantly attenuated the 
expression of chondrogenic marker genes.111 However, several recent studies suggested that 
ERK1/2 played an inhibitory role in MSC chondrogenic differentiation.112;113 Lee et al. showed 
the phosphorylated level of ERK1/2 during chondrogenesis in BMSC that reached the peak at 
10 hours to 1 day after the induction of TGF-β3, but from then until day 14 the activity of 
ERK1/2 showed a decreased tendency. They suggested that ERK1/2 might play an inhibitory 
role in MSC chondrogenesis.114 Zhao et al. demonstrated that TGF-β induced a rapid and 
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transient phosphorylation of ERK1/2, whereas activated p38 was in a slow and sustained 
way.115 In this dissertation, we also found a suppressed activity of ERK1/2 in human BMSCs 
expanded on ECM during chondrogenesis. One possible explanation was that the activation 
of ERK1/2 initiated the transcription of chondrogenic-specific genes such as aggrecan and 
type II collagen, but in a long-term induction of chondrogenesis ERK1/2 may give way to 
other signaling pathways such as PI3K/Akt to generate cartilage-specific matrix.  
 
JNK is another important non-Smad TGF-β signaling molecule that was proven to promote 
cartilage-specific gene expression.108 However, Caerteling et al. recently published their work 
to demonstrate that inhibition of JNK increased chondrogenic gene expression and matrix 
generation.116 The involvement of PI3K-Akt pathway in chondrogenesis was reported. 
Induced by TGF-β, Akt was phosphorylated at T308 and S473 by PI3K and translocated to the 
nucleus to mediate the differentiation process.117-120 However, the lack of PI3K-Atk analysis is 
one of the limitations in this dissertation that will be investigated in future. Different from 
ERK1/2, p38 is considered a positive regulatory protein in chondrogenesis. Oh et al. showed 
that the activity of p38 increased during chondrogenesis while ERK1/2 decreased. Inhibition 
of p38 significantly decreased the expression of chondrogenic-specific genes, whereas the 
blockage of ERK1/2 did not affect.121 Meanwhile, Chang et al. provided evidence that PKC 
promoted MSC chondrogenic differentiation and inhibition of PKC reduced the expression of 
chondrogenic marker genes. More importantly, the inhibition or depletion of PKC induced 
sustained activation of ERK1/2 and suppressed chondrogenesis, while inhibition of ERK1/2 
enhanced chondrogenesis but it had no effect on PKC. The authors concluded that PKC 
regulated chondrogenesis through down-regulating the activity of ERK.122 However, 
TGF-β-induced signaling pathways need to be more investigated in future not only in the in 
vitro chondrogenesis but also in the microenvironment of in vivo. 
 
Hayashida et al. recently published their work about integrin β1 and TGF-β. They showed that 
in epithelia cells knock-down of integrin β1 enhanced type I collagen expression via integrin 
αVβ3 and ERK1/2 signaling pathway stimulated by TGF-β.123 In this dissertation, MSCs 
(Chapter 2 and 6) and terminally differentiated cell (Chapter 4 and 5) expanded on ECM 
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showed declined expression of integrin β1 and enhanced chondrogenic potential with high 
level of type II collagen expression, indicating there possibly was relationship between 
integrin β1 and TGF-β response. Moreover, Bianchi et al. reported that TGF-β upregulated the 
expression of integrin β5 in carcinoma cells; the knock-down of integrin β5 inhibited 
epithelial-mesenchymal-transition but it did not affect TGF-β target genes.124 The interaction 
of integrin β1 and TGF-β induced chondrogenesis needs to be explored in future work. 
 
In Chapter 4 and 5, ECM showed the effect to increase proliferative rate and delayed 
dedifferentiation in terminally differentiated cells such as chondrocytes and nucleus pulposus 
cells. For articular chondrocytes, dedifferentiation underwent during serial monolayer culture 
with declined expression of type II collagen and aggrecan but increased level of type I 
collagen. The delayed dedifferentiation process in chondrocytes expanded on ECM was 
possibly related to PKC and ERK. Yoon et al. showed that the expression of PKCα decreased 
during chondrocyte dedifferentiation but the overexpression of PKC did not affect the 
dedifferentiation process. Meanwhile, ERK activity increased during dedifferentiation and 
inhibition of ERK1/2 successfully retarded chondrocyte dedifferentiation with the elevated 
expression of type II collagen and proteoglycans. They concluded that PKC and ERK 
independently regulated chondrocyte dedifferentiation.125 Moreover, Barbero et al. 
demonstrated that dedifferentiated human articular chondrocytes had multipotent 
differentiation capacity toward chondrogenic, osteogenic and osteogenic lineages; that was 
believed to be the evidence of progenitor cells or MSCs in articular cartilage.126 Future work 
will be conducted in the interaction between chondrocytes and ECM and mechanism of 
delaying chondrocyte dedifferentiation. 
 
In this dissertation, we did not observe the improvement in osteogenesis and adipogenesis of 
SDSCs or ADSCs after ECM expansion. However, Chen et al. demonstrated that human 
BMSCs expanded on a similar 3D ECM gained stronger osteogenic potential.38 The 
inconsistence of osteogenic potential was possibly because we induced MSCs to 
osteogenesis or adipogenesis in vitro and they implanted cells subcutaneously into mice after 
8-week in vitro osteogenic culture. The in vivo environment could induce cells further 
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differentiation with stimulation of certain growth factors and nutrients.  
 
SDSC-deposited ECM not only was able to expand MSCs but also culture differentiated cells 
including chondrocytes and nucleus pulposus cells. ADSC-deposited ECM showed similar 
functions to promote MSC self-renewal and chondrogenic potential. Chondrocyte-deposited 
ECM only improved articular chondrocyte proliferation and redifferentiation. The three types 
of ECMs had three-dimensional structures but they contained different components. The 
different compositions in ECM affected cell adhesion, proliferation and differentiation through 
distinct intracellular signaling pathways. However, SDSC-deposited ECM exhibited a 
universal compatibility to MSCs and terminally differentiated cells that may have a wide 
application in tissue regenerative medicine and establish an in vitro model to study cell and 
matrix interaction. 
 
In conclusion, we demonstrated that 3D cell-deposited ECM provides a proper 
microenvironment for in vitro expansion of MSCs and terminally differentiated cells, not only 
promoting self-renewal ability but also improving chondrogenic potential, and the novel 3D 
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